documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals health care related products acquisitions divestitures january company completed sale inventory trademark patent intellectual property rights related dovonex treatment psoriasis united states us warner chilcott company inc million cash addition company receive royalty based net sales dovonex end result transaction company recognized pretax gain approximately million million net tax first quarter bristolmyers squibb website companys internet website address wwwbmscom company makes available free charge website annual quarterly current reports including amendments reports soon reasonably practicable company electronically files material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including companys standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning companys executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available companys website wwwbmscom investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly companys website information relating stockholder services including companys dividend reinvestment plan direct deposit dividends available companys website wwwbmscom investorsstockholder services caption company incorporates reference certain information parts proxy statement annual meeting stockholders sec allows company disclose important information referring manner please refer information companys proxy statement annual meeting stockholders annual report available companys website wwwbmscom investorssec filings caption march business segments company three reportable segmentspharmaceuticals nutritionals health care pharmaceuticals segment made global pharmaceutical international consumer medicines business nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula childrens nutritionals business health care segment consists convatec medical imaging additional information segments see item financial statementsnote segment information pharmaceuticals segment pharmaceuticals segment competes worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession company manufactures products us puerto rico fourteen foreign countries pharmaceuticals net sales accounted companys net sales us pharmaceuticals net sales accounted total pharmaceuticals net sales respectively pharmaceuticals net sales europe middle east africa accounted total pharmaceuticals net sales respectively pharmaceuticals net sales japan accounted total pharmaceuticals net sales respectively companys pharmaceutical portfolio continued transition away products lost exclusivity towards growth drivers recently launched products resulted companys focus areas significant unmet medical need products company considers growth drivers include plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate abilify aripiprazole erbitux cetuximab recently launched products include sustiva franchise efavirenz sprycel dasatinib baraclude entecavir orencia abatacept company experienced substantial revenue losses last several years due expiration market exclusivity certain products company expects major new exclusivity losses accordingly expects reductions net sales moderate range billion billion levels products lost exclusivity previous years primarily pravachol pravastatin sodium us europe taxol paclitaxel europe japan compared net sales reduction billion levels timing amounts sales reductions exclusivity losses realization particular periods eventual levels remaining sales revenues uncertain dependent levels sales time exclusivity ends timing degree development generic competition speed approvals market entry impact factors composition matter patent plavix expires currently subject patent litigation us apotex inc apotex corp apotex generic companies well less significant jurisdictions august apotex launched generic clopidogrel bisulfate product competes plavix august court patent litigation apotex granted motion company product partner sanofi aventis sanofi enjoin sales apotexs generic clopidogrel bisulfate product order apotex recall product customers courts grant preliminary injunction affirmed appeal trial underlying patent litigation ended february court expected rule following posttrial briefing generic launch significant adverse impact plavix sales results operations full impact generic launch apotex august estimated certainty time depend number factors including amount generic product apotex sold distribution channels prior grant preliminary injunction halting sales possible time reasonably assess outcome patent litigation apotex andor timing renewed generic competition apotex additional generic competition generic pharmaceutical companies however apotex prevail patent litigation company would expect renewed generic competition promptly thereafter company expects generic clopidogrel bisulfate inventory market continued residual impact plavix net sales company expect plavix net sales earnings growth assuming absence renewed additional generic competition company expects increased prescription demand plavix well growth drivers recently launched products compared companys gross margin expected improve due growth higher margin products lower margin erosion related exclusivity losses improved manufacturing efficiencies marketing selling administrative expense expected remain relatively unchanged efficiency savings largely offset inflationary cost increases company continues focus high value primary care specialist physicians implements various productivity initiatives company expects continue increase investments develop additional new compounds support introduction new products company subsidiaries subject number significant pending lawsuits claims proceedings investigations including pending plavix litigation possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed aggregate impact beyond current reserves pending plavix patent litigation litigations investigations legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity companys expectations described reflect potential impact either pending plavix patent litigation litigations investigation impact legal matters companys results operations beyond current reserves ongoing matters information matters see products competition research development item managements discussion analysis financial condition results operationsplavix outlook item financial statementsnote legal proceedings contingencies products companys pharmaceutical revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv oncology affective psychiatric disorders immunoscience pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity market exclusivity based upon patent rights andor certain regulatory forms exclusivity us countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product companys business focused innovative pharmaceutical products company relies patent rights forms protection maintain market exclusivity products discussion patents rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition companys business see generic competition chart shows net sales key products pharmaceuticals segment together year basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us european union eu japan company also sells pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity company estimates market exclusivity period products casebycase basis purposes business planning length market exclusivity companys products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation although company provides estimates business planning purposes intended indication companys patents might fare particular patent litigation brought potential infringers assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate past currently past currently past currently estimated estimated estimated year year year us basic eu basic japanese basic pharmaceutical products exclusivity loss exclusivity loss exclusivity loss dollars millions cardiovascular plavix pravachol avaproavalide coumadin b monopril virology reyataz sustiva franchise total revenue c c zerit baraclude infectious diseases cefzil oncology erbitux e taxol paclitaxel sprycel affective psychiatric disorders abilify total revenue f emsam immunoscience orencia e pharmaceuticals efferalgan na note currently estimated year basic exclusivity loss includes statutory extensions exclusivity earned speculative instances may laterexpiring patents cover particular forms compositions drug well methods manufacture methods using drug patents may sometimes result favorable market position companys product product exclusivity predicted assured note also products filed biologics license application bla us year exclusivity listed year patent expiration even though currently regulatory pathway approval followon biologic products described detail intellectual property product exclusivity indicates brand names products registered trademarks owned company subsidiaries specific trademark ownership information found company currently market product jurisdiction indicated references eu throughout include following current member states austria belgium bulgaria cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg malta netherlands poland portugal romania slovakia slovenia spain sweden united kingdom uk basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states instances earliest latest dates basic exclusivity loss listed eu countries basic patent obtained may data protection available b eu basic exclusivity expired bms acquired product c exclusivity period relates sustiva brand pending application eu patent application filed cyprus estonia latvia lithuania malta netherlands slovakia slovenia e biologic product approved bla us currently regulatory approval path generic biologics f companys rights commercialize aripiprazole us terminate summary indication intellectual property position licensing arrangements thirdparty manufacturing arrangements products us applicable eu japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofi worldwide alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory composition matter patent us expires includes statutory patent term extension currently subject patent litigation us apotex generic companies well less significant jurisdictions possible time reasonably assess outcome litigation apotex andor timing renewed generic competition apotex potential additional generic competition generic pharmaceutical companies however apotex prevail patent litigation company would expect renewed generic competition promptly thereafter information litigation matters well generic launch apotex see item managements discussion analysis financial condition results operations executive summaryplavix outlook item financial statementsnote legal proceedings contingencies eu regulatory data exclusivity extends eu member countries key composition matter patent expires majority eu member countries company obtains bulk requirements clopidogrel bisulfate sanofi third party company sanofi finish product facilities information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments pravachol pravastatin sodium hmg coa reductase inhibitor indicated adjunct diet exercise patients primary hypercholesterolemia lowering risk first heart attack people without clinically evident coronary heart disease elevated cholesterol reducing risk heart attack stroke patients clinically evident coronary heart disease company licensed patent covering pravastatin marketed company us pravachol sankyo company ltd sankyo japan key provisions agreement expiring exclusivity expires marketbymarket basis exclusivity us patent including pediatric extension expired april company entered distribution agreement watson pharmaceutical watson november authorizing watson distribute generic pravastatin sodium tablets us eu composition matter patent expired countries except italy expiration occur january company obtains bulk requirements pravastatin sankyo finishes product facilities avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi worldwide alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory september company elected terminate copromotion product sanofi ireland sweden norway finland denmark basic composition matter patent us expires including pediatric extension eu data exclusivity eu expires august avapro october avalide irbesartan manufactured company sanofi company manufactures bulk requirements irbesartan finishes avaproavalide facilities avalide company purchases bulk requirements hydrochlorothiazide third party information companys arrangements sanofi see strategic alliances item financial statementsnote alliances investments coumadin warfarin sodium oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism market exclusivity expired us basic patent protection regulatory data protection expired company acquired coumadin company obtains bulk requirements warfarin third party produces majority finished goods facilities monopril fosinopril sodium secondgeneration angiotensin converting enzyme inhibitor onceaday dosing indicated treatment hypertension monopril discovered developed internally basic composition matter patent us expired june basic composition matter patent expired denmark greece portugal spain october composition matter patent obtained finland rest eu composition matter patent expires countrybycountry basis company manufactures bulk requirements fosinopril finishes product facilities virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launched us july company developed atazanavir worldwide license novartis ag novartis pays royalty based percentage net sales company entitled promote reyataz use combination ritonavir atazanavir nonexclusive license agreement abbott laboratories company dated july amended pays royalty based percentage net sales market exclusivity reyataz expected expire us major eu member countries japan company manufactures bulk requirements atazanavir finishes product facilities sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor nnrti treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla sold joint venture gilead sciences inc gilead company gilead share responsibility commercializing atripla us gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture third party customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand information companys arrangement gilead see strategic alliances item financial statementsnote alliances investments rights market efavirenz us canada uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales market exclusivity sustiva expected expire us countries eu company another company market efavirenz japan company obtains bulk requirements efavirenz third parties produces finished goods facilities zerit stavudine used treatment hiv company holds exclusive patent license zerit yale university yale pursuant pays royalty based product sales japan company exclusive license zerit yamasa corporation pursuant pays royalty based net sales japan use patent expires us december use patent series expires eu patent applications pending denmark finland japan december company manufactures bulk requirements stavudine finishes product facilities baraclude entecavir potent selective inhibitor hepatitis b virus approved us food drug administration fda march treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu company learned china two companies received clinical trial permission entecavir two companies seeking marketing approval formulations entecavir due uncertainty chinas exclusivity laws possible one companies could receive marketing authorization chinas health authority end company composition matter patent expires us application patent term extension filed us approved would extend patent expiration composition matter patent expires eu japan company manufactures bulk requirements entecavir finishes product facilities infectious diseases cefzil cefprozil semisynthetic broadspectrum cephalosporin antibiotic treatment mild moderately severe bacterial infections throat ear sinuses respiratory tract skin cefprozil discovered developed internally basic composition matter patent protecting cefprozil us including patent term extension expired december spain patent expired february certain european countries japan patent expired several european countries including austria finland italy switzerland uk composition matter patent expires including term extension company manufactures bulk requirements cefprozil finishes product facilities oncology erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan patients egfrexpressing metastatic colorectal cancer failed irinotecanbased regimen monotherapy patients intolerant irinotecan march fda approved erbitux use treatment squamous cell carcinoma head neck erbitux marketed north america company distribution copromotion agreement imclone systems incorporated imclone company imclone share distribution rights erbitux merck kgaa japan erbitux yet marketed japan although application submitted japanese pharmaceuticals medical devices agency pmda use erbitux treating patients advanced colorectal cancer description companys alliance imclone see strategic alliances item financial statementsnote alliances investments composition matter patent specifically claims erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires inventorship use patent challenged three researchers yeda research development company ltd yeda claim named coinventors september court granted yeda complete ownership patent imclone appealed courts decision imclone also filed declaratory judgment action alleging yeda researchers remain sole inventors patent patent invalid assurance financial consequences company result courts decision information litigation see item financial statementsnote legal proceedings contingencies european equivalent use patent opposed information biologics patents see intellectual property product exclusivity company obtains finished goods requirements cetuximab imclone imclone manufactures bulk requirements cetuximab facilities finishing performed third party imclone description companys supply agreement imclone see manufacturing quality assurance taxol paclitaxel paclitaxel used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin second line treatment acquired immunodeficiency syndrome aids related kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin active ingredient taxol paclitaxel patent protection us eu japan regulatory protection form data exclusivity data exclusivity us expired initial approval us generic version paclitaxel granted revoked fda reinstated data exclusivity eu expired data exclusivity taxol paclitaxel japan expired patent claiming approved dosing administration schedule expires japan nullity action filed japanese patent office invalidated patent company appealing decision meanwhile generic paclitaxel launched japan paclitaxel developed collaborative research development agreement us government agreement company obtained rights us governments taxol paclitaxel data company manufactures bulk requirements paclitaxel finishes product facilities sprycel dasatinib multitargeted tyrosine kinase inhibitor approved fda june treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including imatinib treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy dasatinib approved eu november sprycel discovered developed internally basic composition matter patent protecting dasatinib us due expire april patent term extension requested upon grant would extend patent term june several eu countries patent pending upon grant would expire april excluding term extensions eu patent application filed cyprus estonia latvia lithuania malta netherlands slovakia slovenia us new chemical entity protection expires orphan drug exclusivity expires protects product generic applications currently approved orphan indications company manufactures bulk requirements dasatinib finishes product facilities affective psychiatric disorders abilify aripiprazole atypical antipsychotic agent patients schizophrenia acute bipolar mania bipolar disorder abilify introduced us november approved marketing eu switzerland applications pending countries aripiprazole copromoted us company otsuka pharmaceutical co ltd otsuka companys rights commercialize aripiprazole us terminate thereafter otsuka sole right commercialize aripiprazole us company also right distribute andor copromote abilify several european countries uk france germany italy spain act exclusive distributor product rest eu company exclusive licensee product rest world excluding japan certain countries us spain germany company records alliance revenue contractual share net sales records expenses related product alliance revenue recorded company net sales based upon otsukas net sales copromotion countries company recognizes alliance revenue abilify shipped risks rewards ownership transferred otsukas customers uk france italy company currently records net sales related cost products sold countries company exclusive right sell abilify company also records net sales related cost products sold information companys arrangement otsuka see strategic alliances item financial statementsnote alliances investments basic us composition matter patent abilify expires including granted patent term extension otsuka filed us patent trademark office uspto request reexamination us composition matter patent us patent patent covering abilify aripiprazole uspto granted request reexamination otsuka determined original patent application mistakenly identified prior art reference wrong patent number addition otsuka took opportunity bring citations attention uspto reexamination allowed uspto consider patentability patent claims light correctly identified patent reference newly cited documents june uspto issued ex parte reexamination certificate patent confirming patentability original claims approving additional new claims otsuka received formal notices teva pharmaceuticals usa barr pharmaceuticals inc sandoz inc synthon laboratories inc sun pharmaceuticals ltd apotex stating filed abbreviated new drug application anda fda various dosage forms aripiprazole company otsuka comarket us abilify notices states anda contains piv certification directed patent covers aripiprazole expires october addition notices purports provide otsuka respective piv certification certifications contain various allegations regarding enforceability patent andor validity andor infringement claims therein otsuka sole rights enforce patent composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplemental protection certificate countries except romania denmark data exclusivity eu expires composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania bulgaria estonia company obtains bulk requirements aripiprazole otsuka otsuka company finish product facilities emsam emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adults approved fda february made commercially available us april emsam developed somerset pharmaceuticals inc somerset joint venture mylan laboratories inc mylan watson company obtained exclusive distribution rights commercialize emsam us canada markets emsam us new drug formulation emsam received three years hatchwaxman data exclusivity expires us two us patents cover different aspects selegiline transdermal patch technology issued mylan technologies inc affiliate mylan expire data exclusivity covering new dosage form expires us third quarter company recorded impairment charge million representing unamortized balance regulatory approval milestone paid first quarter resulting lower expected sales emsam emsam manufactured behalf somerset mylan technologies inc us third party somerset obtains finished goods mylan technologies inc finished product supplied company somerset immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept approved fda december made commercially available us february orencia discovered developed internally company series patents covering abatacept method use latest composition matter patents expires us company submitted request extending composition matter patent time lost regulatory review period per hatchwaxman act january repligen regents university michigan filed complaint company us district court eastern district texas marshall division alleging companys anticipated sales orencia infringe us patent august zymogenetics inc filed complaint company us district court district delaware complaint alleges companys manufacture sales orencia infringe us patents information litigations see item financial statements note legal proceedings contingencies company obtains bulk abatacept third party manufacturing facilities company finishes product facilities efferalgan efferalgan formulation acetaminophen first introduced distributed effervescent tablet indicated treatment fever mild moderate pain adults children marketed exclusively europe composition matter patent europe efferalgan addition products discussed companys pharmaceuticals segment also includes companys wholly owned upsa consumer medicines business europe includes efferlagan described well aspirine upsa dafalgan fervex europe overseas markets strategic alliances arrangements company enters strategic alliances arrangements third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties company also enters strategic alliances arrangements third parties give third parties rights develop manufacture market andor sell pharmaceutical products rights owned company alliances arrangements take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances arrangements reduce risk incurring research development expenses lead revenuegenerating products however gross margins alliance products generally lower sometimes substantially gross margins companys products partnered profits alliance products shared companys alliance partners assurance new alliances formed company actively pursues arrangements views alliances important complement discovery development activities companys significant current alliances arrangements companys products sanofi plavix avaproavalide otsuka abilify imclone erbitux gilead atripla somerset emsam sankyo pravachol companys significant alliances arrangements investigational compounds development pierre fabre medicament sa pierre fabre vinflunine novel investigational anticancer agent rights owned pierre fabre medarex inc medarex ipilimumab monoclonal antibody investigated anticancer treatment rights owned medarex astrazeneca plc astrazeneca saxagliptin oral compound potential treatment diabetes dapagliflozin sodiumglucose cotransporter sglt inhibitor significant alliances arrangements discussed detail additionally company licensing arrangements yale zerit novartis reyataz helmholtz zentrum fr infektionsforschung helmholtz centre infection research ixabepilone novel microtubulestabilizing agent multiple tumor types general companys strategic alliances arrangements periods coextensive periods market exclusivity protection countrybycountry basis based companys current expectations respect expiration market exclusivity companys significant markets licensing arrangements yale zerit expected expire us eu japan novartis reyataz expected expire us eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan see products intellectual property product exclusivity companys strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured early termination due product safety concerns typically arises product determined create significant risk harm patients due concerns regarding products efficacy level toxicity companys strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general party companys strategic alliance arrangement continue exclusivity protection upon expiration termination alliance company retain rights product partys intellectual property loss rights one products marketed sold company pursuant strategic alliance arrangements third parties one countries territories could material companys results operations cash flows case plavix could material financial condition liquidity customary pharmaceutical industry terms companys strategic alliances arrangements generally coextensive exclusivity period discussed may vary countrybycountry basis discussed companys strategic alliance otsuka expires november us puerto rico may prior expiration market exclusivity protection abilify expected expire us including granted patent term extension current marketed products sanofi company agreements codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us company tradename karveakarvezide plavix platelet aggregation inhibitor copromoted certain countries outside us tradename plavix comarketed certain countries outside us company tradename iscover worldwide alliance operates framework two geographic regions one covering certain european asian countries defined territory one covering us puerto rico canada australia certain latin american countries defined territory b region covering us puerto rico canada australia certain latin american countries managed two separate territory agreements one us puerto rico avaproavalide second agreement us puerto rico plavix plus canada australia mexico brazil colombia argentina products within territory b territory partnership exists supply product countries within territory manage certain central expenses marketing research development royalties countries within territory b structured companys local affiliate sanofi either comarket whereby affiliate operates independently sells competing brand copromote single brand within territory comarketing countries include germany spain italy irbesartan greece china company sells iscover karveakarvezide sanofi sells plavix aprovelcoaprovel countries except china company retains right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export countries sanofi acts operating partner territory owns majority financial controlling interest territory companys ownership interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million within territory b company sanofi copromote plavix us canada puerto rico avaproavalide canada territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries company sanofi modified previous exclusive license company avaproavalide us puerto rico form copromotion joint venture part company contributed avaproavalide intellectual property sanofi agreed pay company million million company accounts payments sale interest license defers amortizes total amount million income expected useful life license approximately years date formation copromotion joint venture company acts operating partner territory b uspuerto rico avaproavalide territory owns majority controlling interest territories company consolidates partnership results territories records sanofis share results minority interest expense net taxes million million million company recorded sales territory b uspuerto rico avaproavalide territory comarketing countries germany italy spain greece million million million september company optedout copromotion rights sanofi aprovelcoaprovel ireland sweden denmark finland norway company also opted comarketing copromotion arrangements number countries prior company receives royalty payment sanofi based percentage sanofis net sales optout countries territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees senior committees final decision making authority respect territory enumerated functions powers responsibilities within jurisdiction agreements sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory alliance arrangements may terminated company sanofi either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory case avaproavalide us respect advertising promotion spending levels amount sales force commitment iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements include provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events company could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach company defaulting party discussion companys strategic alliance sanofi see item financial statementsnote alliances investments otsuka company entered worldwide commercialization agreement otsuka codevelop copromote abilify treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company began copromoting product otsuka us puerto rico november june company received marketing approval european commission product currently copromoted otsuka uk germany france spain us germany spain product sold otsuka affiliate distributor company records alliance revenue contractual share otsukas net sales company recognizes alliance revenue abilify shipped risks rewards ownership transferred otsukas customers uk france italy company presently exclusive distributor product company records net sales related cost products sold company also exclusive right sell abilify number countries europe americas asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company agreement expires november us puerto rico eu agreement expires june later tenth anniversary first commercial sale country expiration applicable patent country early termination available based partys voluntary involuntary bankruptcy failure make minimum payments failure commence first commercial sale within three months receipt necessary approvals material breach amount notice required early termination strategic alliance immediately upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event company challenge otsukas patent rights marketbymarket basis company market product direct competition abilify upon termination expiration alliance company retain rights abilify company recorded total revenue abilify million million million total milestone payments made otsuka million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging years company amortized cost products sold million million unamortized capitalized payment balance million million december respectively discussion companys strategic alliance otsuka see item financial statementsnote alliances investments imclone company purchased million shares imclone per share million represented approximately imclone shares outstanding prior companys commencement public tender offer imclone shares imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also included arrangement expiring september codevelop copromote cancer drug erbitux series payments originally totaling billion company paid imclone milestone payment million million expensed acquired inprocess research development million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone agreement imclone revised reduce total payments million billion accordance agreement company paid imclone million million million million first quarter payment made upon approval fda bla erbitux use combination irinotecan treatment patients egfr expressing metastatic colorectal cancer refractory irinotecan based chemotherapy use single agent treatment patients egfr expressing metastatic colorectal cancer intolerant irinotecan based chemotherapy fda also approved imclones chemistry manufacturing controls supplemental biologics license application sbla licensure bb manufacturing facility milestone payment made upon fda approval erbitux use treatment squamous cell carcinoma head neck company also codevelopment copromotion rights canada japan extent product commercialized countries japan company imclone share distribution rights erbitux merck kgaa february company imclone submitted application japanese pmda use erbitux treating patients advanced colorectal cancer agreement imclone receives distribution fee based flat rate product revenues north america company purchases commercial requirements bulk erbitux imclone price equal imclones manufacturing cost plus company accounts million total approval milestones paid license acquisitions amortizes payments cost products sold term remaining term agreement ends company amortized cost products sold million million million respectively unamortized capitalized payment balance recorded intangible assets net consolidated balance sheet million million december respectively company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognized pre approval milestone payments recorded company additional equity investment company recorded net income million net loss million net income million share imclones net incomelosses company records share results equity net income affiliates consolidated statement earnings company recorded net sales erbitux million million million companys recorded investment market value holdings imclone common stock million approximately million december respectively million approximately million december respectively company holds million shares imclone stock representing approximately imclones shares outstanding december per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice company exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance company retain rights erbitux may mckesson corporation mckesson one companys wholesalers provided warehousing packing shipping services erbitux mckesson held erbitux inventory consignment companys revenue recognition policy company recognized revenue inventory shipped mckesson endusers mckesson also held inventories erbitux account upon divestiture oncology therapeutics network otn may company discontinued consignment arrangement mckesson mckesson longer held inventories account thereafter company sold erbitux intermediaries wholesalers specialty oncology distributors shipped erbitux directly endusers product customers intermediaries beginning third quarter company expanded distribution model include one companys wholesalers held erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy discussion companys strategic alliance imclone see item financial statementsnote alliances investments sankyo company licensed patent covering pravastatin marketed company us pravachol sankyo key provisions agreement expiring exclusivity expires marketbymarket basis exclusivity expired every market except italy exclusivity expire january early termination available based partys voluntary involuntary bankruptcy material breach amount notice required early termination strategic alliance immediately upon notice case either voluntary involuntary bankruptcy days notice case material breach occurred cured commencement cure occurred upon termination expiration alliance company retain patent exclusivity rights relation pravastatin gilead company gilead entered joint venture develop commercialize fixeddose combination companys sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate us july fda approved treatment atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers guidelines issued us department health human services list combination emtricitabine tenofovir disoproxil fumarate efavirenz one preferred nonnnrtibased treatments use appropriate patients never taken antihiv medicines company gilead share responsibility commercializing atripla us provide funding fieldbased sales representatives support promotional efforts atripla gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture third party customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand september companies amended agreements commercialize atripla canada subject approval product health canada us companies share responsibility commercializing atripla canada gilead recording atripla revenues company recording revenue bulk efavirenz component atripla joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions sustiva appear market us gilead right terminate joint venture thereby acquire rights combination product us canada however company continue three years receive percentage net sales based contribution bulk efavirenz atripla otherwise retains rights sustiva discussion companys strategic alliance gilead see item financial statementsnote alliances investments somerset company somerset joint venture mylan watson entered agreement commercialization supply distribution somersets emsam selegiline transdermal system monoamine oxidase inhibitor administered transdermal patch treatment patients major depressive disorder somerset received approval fda emsam february use without dietary restriction recommended dose mg hours emsam first transdermal treatment major depressive disorder terms agreement company received exclusive distribution rights commercialize emsam approved us canada company made expensed million upfront payment december made million payment following regulatory approval us first quarter capitalized amortized cost products sold remaining term agreement third quarter company recorded impairment charge unamortized balance million resulting lower expected sales emsam charge recorded cost products sold companys consolidated statement earnings addition payments somerset may receive milestone payments based achievement certain sales levels well reimbursement certain development costs incurred term agreement somerset supply products company receive royalties companys sales emsam unless earlier terminated extended accordance terms agreement terminate fifth anniversary date first commercial sale emsam agreement may earlier terminated either party event material breach agreement bankruptcy party addition general rights termination company right terminate agreement time following launch generic product occurrence material safety issue relating emsam date months date first commercial sale emsam upon days prior notice somerset right terminate agreement time following occurrence material safety issue relating emsam failure company meet specified detailing requirements upon termination somerset retains product rights emsam investigational compounds development medarex company entered worldwide collaboration share purchase agreement medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma agreement became effective january companies received certain governmental clearances approvals receipt consent us public health service sublicense company medarexs rights mdx gp vaccine developed combination ipilimumab fda granted fast track status ipilimumab combination mdx treatment patients late stage unresectable metastatic melanoma failed intolerant first line therapy january terms agreement company made cash payment million medarex expensed research development additional million equity investment medarex milestone payments expected made upon successful achievement various regulatory sales related stages company medarex also share future development commercialization costs medarex could receive million regulatory milestones met million salesrelated milestones medarex option copromote receive profits company us company receive exclusive license outside us pay royalties medarex agreement medarex expire unless one following events occurs company voluntarily terminates agreement entirety countrybycountry basis providing medarex six months prior written notice company voluntarily terminates agreement productbyproduct basis second product glp toxicology studies later countrybycountry basis providing medarex six months prior written notice depending circumstances company terminates medarexs co promotion option rights us sixty days written notice end second calendar year event medarex provides less sixty percent certain performance obligations two three consecutive calendar years termination right exercised respect indications medarex failed meet performance obligation upon termination company via scenarios medarex longer right share profits losses product terminated indications instead company pay medarex royalties net sales product medarex terminates agreement respect products sixty days written notice company provides less sixty percent certain performance obligations two three consecutive calendar years generally upon termination company assign rights product medarex receive royalty thereafter intellectual property licensed company medarex medarex may also elect copromote product one indications us event receive royalty sales product indication material breach manufacturing party party shall limited termination partys manufacturing rights pierre fabre company pierre fabre entered three related agreements patent knowhow license agreement trademark license agreement supply agreement develop commercialize vinflunine novel investigational anticancer agent vinflunine phase iii clinical trials metastatic bladder cancer phase iii trials lung breast cancer terms agreement company receives exclusive license vinflunine us canada japan korea select southeast asian markets pierre fabre responsible development marketing vinflunine countries including europe supply companys requirements product terms agreement company made expensed upfront milestone payments million million million potential additional million milestone payments time patent knowhow license agreement company licensed right market vinflunine expires countrybycountry product formbyproduct form basis date latter expiration applicable patent data exclusivity given product form country ii tenth anniversary commercial sale product form country time company may exercise royaltyfree nonexclusive right market product agreement may terminated sooner follows party may terminate agreement voluntary involuntary bankruptcy insolvency party dismissed within certain period time party may terminate material breach cured specified period termination shall relate countries product forms relating material breach unless product form iv form case forms terminated unless breach pertains us case countries terminated pierre fabre pierre fabre terminates supply agreement material breach company either party upon days notice justifiable demonstrable safety efficacy technical regulatory reasons preclude development iv form indication determined joint steering committee pierre fabre company fails file process registrational filing required filed agreement without justifiable demonstrable safety efficacy technical regulatory reasons b company launch iv product form country within time period required agreement generally ninety days following receipt regulatory applicable pricing approval c company challenge contest pierre fabre patent rights company makes improper contract assignment e company fails meet certain minimum sales levels agreement company without cause countrybycountry basis giving pierre fabre least ninety days prior written notice notice given prior regulatory approval first approved indication us ii one hundred eighty days prior written notice regulatory approval first approved indication us generally termination made pierre fabre termination company without cause company shall retain rights product rights shall revert pierre fabre astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca one codevelopment cocommercialization saxagliptin dppiv inhibitor phase iii clinical trials saxagliptin agreement one codevelopment cocommercialization dapagliflozin sglt inhibitor phase iib clinical trials sglt agreement compounds studied treatment diabetes discovered company terms agreements company received upfront payments million january capitalized amortized life agreement income milestone payments expected received company upon successful achievement various regulatory sales related stages agreement company astrazeneca also share future development commercialization costs saxagliptin agreement company could receive million regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million regulatory milestones met additional million salesbased milestones met majority development costs initial development plans paid astrazeneca additional development costs generally shared equally agreement two companies share commercialization expenses profitslosses equally global basis excluding japan company manufacture products certain limited exceptions record net sales agreement additional compounds dppiv sglt classes may developed either party must proposed inclusion collaboration predesignated trigger points end phase ii iii lead compound fails either party actively conducting clinical development compound class accepted party inclusion collaboration upfront payment regulatory sales based milestones may paid nondeveloping party additional compound amount timing depend nature triggering event whether additional compound replacing developed addition lead compound event astrazeneca party developed compound controls intellectual property rights astrazeneca assume rights obligations company collaboration respect compound company rights astrazeneca respect compound certain limited exceptions company party developed compound controls intellectual property rights respect initial two compounds agreement expires productbyproduct countrycountry basis upon latest expiration lasttoexpire patent controlled parties covering product country expiration statutory exclusivity product country permanent cessation sale product country agreement may sooner terminated entirety productbyproduct regionbyregion countrybycountry basis case may mutual written agreement party accordance terms agreement follows astrazeneca without cause regionby region productbyproduct basis six months notice given sooner finalization clinical database database lock last completed pivotal phase iii clinical trial later date company may elect opt sale force efforts obligations us ii astrazeneca without cause regionbyregion productbyproduct basis twelve months notice termination may effective earlier two years launch product region iii either party respect agreement entirety upon written notice given following permanent cessation development product long products developed commercialized iv party upon days notice party materially breaches agreement engages gross negligence willful misconduct willful misrepresentation fundamentally frustrates transactions contemplated agreement v party event insolvency bankruptcy party vi party given product country party fails provide least required sales force effort two three consecutive years vii party party becomes incapable consecutive months performing material obligations force majeure viii either party productbyproduct basis event material safety issues ix either party development commercialization given compound enjoined sglt agreement astrazeneca may also exercise termination right lead compound meet specified end phase ii success criteria event termination astrazeneca company event development commercialization collaboration compounds enjoined party must offer collaboration compounds actively conducting clinical development accepted party inclusion collaboration upfront payment regulatory salesbased milestones may paid nondeveloping party additional compound event astrazeneca party developed compound controls intellectual property rights astrazeneca assume rights obligations company collaboration respect compound company rights astrazeneca respect compound certain limited exceptions additional compounds offered additional compound offered accepted collaboration agreement terminate event change control either party whether result merger consolidation sale substantially assets similar transaction agreements would assigned assumed successor company agreement terminated astrazeneca described clause iv v vi preceding paragraph prior change control company company retain rights product pay astrazeneca royalty net sales thereafter agreement terminated astrazeneca described clause iv v vi preceding paragraph following change control company astrazeneca may elect receive royalty net sales thereafter elect product rights assigned pay company royalty net sales thereafter agreement terminated company described clause iv v vi preceding paragraph company retain rights product pay astrazeneca royalty net sales thereafter information alliances relating products development drug discovery see research development health care group health care group consists two segments nutritionals health care health care segments currently consists convatec medical imaging prior also included consumer medicines health care group sales accounted companys sales companys sales companys sales us health care group sales accounted total health care group sales respectively international health care group sales accounted total health care group sales respectively nutritionals segment nutritionals segment mead johnson manufactures markets distributes sells infant formulas nutritional products including entire line enfamil products enfamil lipil product first infant formula us contain nutrients docosahexaenoic acid dha arachidonic acid ara also naturally found breast milk dha ara believed support infant brain eye development company obtains nutrients sole provider pursuant nonexclusive worldwide license supply agreement supply agreement force least provides firm guaranty supply pricing subject change pursuant pricing formula license expires beginning countrybycountry basis years company commenced sales country companys nutritionals products generally sold wholesalers retailers promoted primarily health care professionals company also promotes nutritionals products directly consumers worldwide advertising company manufactures products us five foreign countries nutritionals sales accounted companys sales companys sales companys sales us nutritionals sales accounted total nutritionals sales respectively international nutritionals sales accounted total nutritionals sales respectively approximately onehalf us gross sales infant formula subject rebates issued women infants children wic program sales subject wic rebates much lower margins nonwic program sales net sales selected products product categories nutritionals segment follows dollars millions infant formulas enfamil toddlerchildrens nutritionals enfagrow february company completed divestiture adult nutritional business novartis million including million payment contingent achievement contractual requirements satisfied million upfront payment tenyear supply agreement health care segment health care segment currently consists convatec medical imaging prior also included consumer medicines health care sales accounted companys sales respectively us health care sales accounted total health care sales respectively international health care sales accounted total health care sales respectively convatec convatec manufactures distributes sells ostomy modern wound skin care products principal brands convatec include natura surfit esteem aquacel duoderm flexiseal products marketed worldwide primarily hospitals medical profession medical suppliers company mainly relies internal sales force sales made various distributors around world company manufactures products us uk dominican republic convatec sales accounted approximately companys sales companys sales us convatec sales accounted total convatec sales respectively international convatec sales accounted total convatec sales respectively medical imaging medical imaging manufactures distributes sells medical imaging products principal brands include cardiolite kit preparation technetium tcm sestamibi injection cardiac perfusion imaging agent definity vial perflutren lipid microsphere injectable suspension ultrasound contrast agent products manufactured company puerto rico third party us marketed internal sales force us cardiolite radiopharmaceutical products primarily sold distributed via thirdparty radiopharmacies endcustomers eg healthcare providers us definity distributed directly enduser customers definity called luminity eu approved eu us company currently one two suppliers technetium tcm generators widely used radioisotope required compound unitdose cardiolite injections company relies single source supply key ingredient molybdenum connection companys international business medical imaging owns certain radiopharmacies outside us cardiolite covered series patents claim components patent coverage differs somewhat countrybycountry basis us cardiolite patent exclusivity expires january cardiolite entitled sixmonth extension exclusivity july company submits fda january certain pediatric clinical data accordance written request issued fda guarantee company able fulfill requirements written request eu patent expiry timeline spans december japan patent expiry timeline spans august medical imaging sales accounted approximately companys sales approximately companys sales us medical imaging sales accounted total medical imaging sales international medical imaging sales accounted total medical imaging sales company maintains license supply agreements radiopharmacies including cardinal health nuclear pharmacy services independent radiopharmacies provide right sell cardiolite us sources availability raw materials general company purchases raw materials medical devices supplies required production companys products open market products company purchases raw materials medical devices supplies single source certain circumstances specified companys product registrations thereby requiring company obtain raw materials supplies particular source company attempts possible mitigate raw material supply risks company inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance company seeks design operate manufacturing facilities manage thirdparty manufacturers maintain inventory way allow meet expected product demand maintaining flexibility reallocate manufacturing capacity improve efficiency respond changes supply demand pharmaceutical production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals discussion regulatory impact companys manufacturing see government regulation price constraints pharmaceutical manufacturing facilities require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition company adds product line realigns focus next several years company expects modify existing manufacturing networks devote substantial resources excess historical levels meet heightened processing standards may required sterile newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations although company capacity manufacture biologics clinical trials commercial launch capacity manufacture larger commercial volumes limited biologics become important companys product portfolio company may continue make arrangements thirdparty manufacturers addition expects make substantial investments increase internal capacity produce biologics commercial scale board directors approved capital expenditures approximately million bulk biologics manufacturing facility us february company completed land purchase acre site locate large scale multiproduct bulk biologics manufacturing facility devens massachusetts construction facility expected begin early facility projected operationally complete company expects submit site regulatory approval commercial production biologic compounds anticipated begin company relies third parties manufacture supply active ingredients necessary manufacture certain products including plavix abilify erbitux sustiva franchise orencia pravachol coumadin taxol paclitaxel maintain stable supply products company takes variety actions designed provide reasonable level ingredients held thirdparty supplier company companys manufacturing operations interrupted additional protection cases company takes steps maintain approved backup source available company received approval fda manufacture orencia companys syracuse ny manufacturing facility given companys current limited capacity commercial volumes biologics products company also received approval fda manufacture orencia lonza biologic plcs lonza manufacturing facility also expects rely celltrion incs celltrion existing facility celltrions new largescale facility provide additional capacity orencia commercial scale production pending submission approval sbla fda company rely initially third party manufacturers manufacture belatacept ipilimumab commercial scale products commercialized belatacept ipilimumab investigational biologics compounds late stage development company made filings fda seeking approval celltrion manufacture orencia ii lonza celltrion manufacture belatacept ipilimumab company sought approval fda market sell belatacept ipilimumab assurance regulatory approval either products obtained regulatory approval manufacturing facilities obtained company entered agreements lonza celltrion among things reserve portions respective biologics manufacturing capacity companys future requirements orencia ii contain certain rights negotiate lonza celltrion additional biologics manufacturing capacity biologics products company commenced certain discussions thirdparty manufacturers relating biologics manufacturing capacity belatacept ipilimumab regulatory approval obtained information orencia see products additional information belatacept ipilimumab see research development company thirdparty manufacturer company relies existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet heightened processing requirements biologics companys business performance prospects could negatively impacted additionally company thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons company could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain companys products certain circumstances company entered agreements company agreed supply products third parties addition liabilities could arise companys failure supply products agreements arrangements could require company invest facilities production non strategic products result additional regulatory filings obligations cause interruption manufacturing products companys success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts companys operations including research development purchasing facilities planning manufacturing distribution company maintains qualityassurance procedures relating quality integrity scientific information production processes control production processes involves rigid specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling company performs tests various stages production processes final product assure product meets regulatory requirements companys standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used company subsidiaries thirdparty suppliers intellectual property product exclusivity company owns licenses number patents us foreign countries primarily covering pharmaceutical products company also developed many brand names trademarks products areas company considers overall protection patent trademark license intellectual property rights material value acts protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity us countries market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category discussion generic versions product impact products sales see generic competition products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy regulatory intellectual property rights also available certain markets incentives research new indications orphan drugs medicines useful treating pediatric patients regulatory intellectual property rights independent patent rights company may possess particularly important drug lacks broad patent protection however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator company estimates likely market exclusivity period products casebycase basis possible predict length market exclusivity companys products certainty complex interaction patent regulatory forms exclusivity inherent uncertainties concerning patent litigation assurance particular product enjoy market exclusivity full period time company currently estimates exclusivity limited estimate discussion market exclusivity see pharmaceuticals segment addition patents regulatory forms exclusivity company also holds intellectual property form trademarks products enfamil trademarks effect market exclusivity product considered marketing value worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely specific aspects law governing market exclusivity pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant company sales united states company seeking market innovative pharmaceutical us must file complete set safety efficacy data fda type application filed depends whether drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company files new drug application nda medicine biological product bla filed type application filed affects regulatory exclusivity rights competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda medicines approved nda receive several types regulatory data protection innovative chemical pharmaceutical also known new chemical entity entitled five years regulatory data protection us anda filed fda innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation new indication basis new clinical trials receives three years data protection finally nda designated orphan drug drug gains indication treatment condition occurs rarely us receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use significant portion patent life lost time takes obtain regulatory approval innovator extend one patent compensate innovator lost patent term least part specifically innovator may identify one patent claims product approved method use depending number factors may extend expiration date patent two limits extensions first maximum term patent extended years second extension cause patent effect years date nda approval company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity sixmonth period extends forms exclusivity patent regulatory listed fda time studies completed submitted fda products already finally approved currently generic versions biological products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations many innovative drugs also covered patents held nda sponsor beyond minimum period regulatory exclusivity provided us law innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer one ndalisted patents successfully challenged innovator chooses sue first filer paragraph iv certification first filers one generic qualifies may entitled day period market exclusivity generic manufacturers time time andas including paragraph iv certifications filed respect certain companys products company evaluates andas casebycase basis warranted files suit generic manufacturer protect patent rights us increased likelihood generic challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products discussion one litigation related patent challenges generic companies see item financial statementsnote legal proceedings contingenciesplavix litigation intellectual property litigation second statutory regulatory provisions us limit ability innovator company prevent generic drugs approved launched patent litigation ongoing third fda actively considering ways expand use regulatory mechanism allows regulatory approval drugs similar generic copies innovative drugs basis less extensive data required full nda result developments possible predict length market exclusivity particular company product certainty based solely expiration relevant patents current forms regulatory exclusivity information new legislation see government regulation price constraints european union eu innovative pharmaceuticals entitled ten years regulatory data protection marketing approval obtained via centralized procedure product receives approval centralized procedure automatically receives approval every member state eu however company must obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure take months sometimes years obtain consequently regardless whether innovative medicine covered patents generic copies relying innovators data usually approved minimum ten years approval additional one year protection available certain circumstances innovator drug receives substantial new indication approval innovative pharmaceuticals gain marketing approval using noncentralized mutual recognition procedure period six ten years depending individual eu member state however regardless regulatory exclusivity competitors may obtain approval identical product basis safety efficacy data time recent pharmaceutical legislation eu impact procedures authorization pharmaceutical products eu centralized mutual recognition procedures particular legislation contains new data protection provisions products regardless whether approved centralized mutual recognition procedures subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities however generic company may commercialize product either ten eleven years elapsed initial marketing authorization granted innovator possible one year extension available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments transitional provision new data protection requirements provisions apply new marketing authorization applications submitted new legislation patents pharmaceutical products generally enforceable eu however contrast us patents listed regulatory authorities generic copies approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant us patents eu may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis general eu law treats chemically synthesized drugs biologically derived drugs respect intellectual property market exclusivity european medicines evaluation agency emea issued guideline outlines additional information provided biosimilar products also known generic biologics order emea review application marketing approval japan japan medicines new chemical entities nces generally afforded six years data exclusivity approved indications dosage japans ministry health expected extend pharmaceutical data exclusivity period nces eight years patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemically synthesized biologically derived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eg canada eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto obligations long process assurance outcome thus assessing likely future market exclusivity companys innovative drugs developing countries company takes account formal legal rights political factors well marketing distribution customers company promotes products medical journals directly health care providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos government agencies company also markets directly consumers us directtoconsumer print radio television advertising addition company sponsors general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints companys sales marketing organizations company explains approved uses advantages products medical professionals company works gain access health authority pbm mco formularies lists recommended approved medicines products including medicare part plans reimbursement lists demonstrating qualities treatment benefits products marketing prescription pharmaceuticals limited approved uses particular product company continues develop information products provides information response unsolicited inquiries doctors medical professionals drugs must complete clinical trials required regulatory authorities show safe effective treating one medical problems manufacturer may choose however undertake additional studies including comparative clinical trials competitive products demonstrate additional advantages compound studies costly take years complete results uncertain balancing considerations makes difficult decide whether undertake additional studies successful studies major impact approved marketing claims strategies companys operations include several pharmaceutical marketing sales organizations organization markets distinct group products supported sales force typically based particular therapeutic areas physician groups sales forces often focus selling new products introduced promotion physicians increasingly targeted specialists high value primary care physicians companys prescription pharmaceutical products sold principally wholesalers company also sells directly retailers hospitals clinics government agencies pharmacies sales three pharmaceutical wholesalers us mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen accounted approximately respectively companys total net sales sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total net sales sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total net sales sales us wholesalers concentrated pharmaceuticals segment companys us pharmaceuticals business inventory management agreements imas arrangements substantially direct wholesaler customers allow company monitor us wholesaler inventory levels require wholesalers maintain inventory levels one month demand agreements twoyear term december subject certain termination provisions may mckesson one companys wholesalers provided warehousing packing shipping services erbitux mckesson held erbitux inventory consignment companys revenue recognition policy company recognized revenue inventory shipped mckesson endusers mckesson also held inventories erbitux account upon divestiture otn may company discontinued consignment arrangement mckesson mckesson longer held inventories account thereafter company sold erbitux intermediaries wholesalers specialty oncology distributors shipped erbitux directly endusers product customers intermediaries beginning third quarter company expanded distribution model include one companys wholesalers held erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy information sales marketing nutritionals health care products see nutritionals segment health care segment competition markets company competes generally broadbased highly competitive principal means competition vary among product categories business groups companys pharmaceuticals segment competes worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated cost effectiveness marketing effectiveness product labeling service research development new products processes sales companys products impacted new studies indicate competitors product greater efficacy treating disease particular form disease one companys products companys sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages companys products subject progressive price reductions decreased volume sales successfully compete business managed care pharmacy benefits management organizations company must often demonstrate products offer medical benefits also cost advantages compared forms care new products company introduces must compete products already market products later developed competitors manufacturers generic pharmaceuticals typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product certain countries outside us patent protection weak nonexistent company must compete generic versions shortly launches innovative product addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation discussion generic launch clopidogrel bisulfate product competes plavix see item financial statementsnote legal proceedings contingenciesplavix litigation many companies large small manufacture sell one products similar marketed companys nutritionals health care segments sources competitive advantage include product quality efficacy brand identity advertising promotion product innovation broad distribution capabilities customer satisfaction price significant expenditures advertising promotion marketing generally required achieve consumer trade acceptance products company believes longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical need together ability manufacture products efficiently market effectively highly competitive environment assurance companys research development efforts result commercially successful products products processes become outmoded time time result products processes developed competitors managed care organizations growth mcos us major factor competitive makeup health care marketplace half us population participates version managed care size patient population covered mcos marketing prescription drugs pbms serve many organizations become important companys business mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part formularies alliances hospitals physicians physician organizations organizations consolidating fewer even larger entities enhancing purchasing strength importance company major objective mcos contain possible reduce health care expenditures typically use formularies volume purchases longterm contracts negotiate discounts pharmaceutical providers mcos pbms typically develop formularies reduce cost medications formularies based prices therapeutic benefits available products due generally lower cost generic medicines often favored breadth products covered formularies vary considerably one mco another many formularies include alternative competitive products treatment particular medical problems mcos use variety means encourage patients use products listed formularies exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price company generally although universally successful major products included mco formularies generic competition one biggest competitive challenges company faces us lesser extent internationally generic pharmaceutical manufacturers upon expiration loss market exclusivity product company lose major portion sales product short period time us fda approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allows generic manufacturers rely safety efficacy innovator product therefore generic competitors operate without companys large research development expenses costs conveying medical information product medical community information market exclusivity see intellectual property product exclusivity rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture noted mcos focus primarily immediate cost drugs often favor generics brandname drugs many governments also encourage use generics alternatives brandname drugs health care programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures therapeutically equivalent brandname drug substitution must made unless prescribing physician expressly forbids laws policies provide added incentive generic manufacturers seek marketing approval automatic substitution removes need generic manufacturers incur many sales marketing costs innovators must incur research development company invests heavily research development believes critical longterm competitiveness pharmaceutical research development carried bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick nj wallingford ct pharmaceutical research development also carried various facilities us belgium canada uk management continues emphasize leadership innovation productivity quality strategies success pharmaceutical research institute company spent million million million company sponsored research development activities company sponsored pharmaceutical research development spending includes certain payments thirdparty collaborations contracts end company employed approximately people research development throughout company including pharmaceutical research institute including substantial number physicians scientists holding graduate postgraduate degrees higher skilled technical personnel company concentrates pharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders alzheimersdementia atherosclerosisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant however company continues analyze may selectively pursue promising leads areas addition discovering developing new molecular entities company looks ways expand value existing products new uses formulations provide additional benefits patients supplement companys internal efforts company collaborates independent research organizations including educational institutions researchbased pharmaceutical biotechnology companies contracts others performance research facilities companys drug discovery program includes many alliances collaborative agreements agreements bring new products pipeline help company remain cutting edge technology search novel medicines drug development company engages services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products drug development timeconsuming expensive risky development human health products industry practice government regulations us foreign countries provide determination effectiveness safety new molecular entities preclinical tests controlled clinical evaluation new drug may marketed us recorded data preclinical clinical experience included nda bla fda required approval development certain products also subject government regulations covering safety efficacy us many foreign countries assurance compound developed result program obtain regulatory approvals necessary marketed particular disease indication average one ten thousand chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine process discovery regulatory approval typically takes ten years longer drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval company believes investments research internally collaboration others rewarded number new pharmaceutical compounds indications stages development listed several investigational compounds company later stages development compounds phase iii clinical trials whether investigational compounds ultimately becomes one companys marketed products depends results preclinical clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance company seek regulatory approval compounds approval sought obtained stage development company determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted include potential patent term extensions apixaban apixaban oral factor xa inhibitor developed internally recently entered phase iii clinical trials prevention thromboembolic disorders company owns issued us patent covering composition matter method use apixaban expires september extended february via patent term adjustment saxagliptin saxagliptin oral compound potential treatment diabetes discovered internally currently phase iii clinical trials january company entered worldwide except japan agreement astrazeneca codevelopment cocommercialization saxagliptin patent application covering composition matter issued expire us ixabepilone ixabepilone epothilone b analog novel microtubulestabilizing agent multiple tumor types phase iii clinical trials treatment metastatic breast cancer phase ii clinical trials treatment prostate cancer company composition matter patent us expires company acquired rights develop ixabepilone compounds class epothilones analogs helmholtz centre infection research ipilimumab ipilimumab codeveloped medarex currently phase iii clinical trials monoclonal antibody investigated anticancer treatment novel class agents intended potentiate elements immunologic response company owns composition matter patent expires us rights method use patents owned medarex expire us company also rights medarex composition matter patent expires extended via patent term adjustment pending medarex patent applications covering composition matter method use ipilimumab belatacept belatacept biological product developed internally phase iii clinical trials fusion protein novel immunosuppressive activity targeted prevention solid organ transplant rejection company composition matter patent expires us vinflunine vinflunine codeveloped pierre fabre currently phase iii clinical trials metastatic bladder cancer novel investigational anticancer agent pierre fabre composition matter patent expires us company sometimes enters agreements respect investigational compounds order share costs risks development cases facilitate commercialization agreements take many forms including codevelopment comarketing copromotion andor joint venture arrangements companys competitors also devote substantial funds resources research development addition consolidation occurred pharmaceutical industry created companies substantial research development resources extent companys competitors successful research could result erosion sales products unanticipated product obsolescence government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion companys products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition companys operations subject complex federal state local foreign environmental occupational safety laws regulations company anticipates laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense significant capital investment particular importance fda us jurisdiction virtually companys businesses imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance companys pharmaceutical products fda also regulates companys nutritionals health care products many cases fdas requirements increased amount time money necessary develop new products bring market us companys pharmaceutical products well medical device products sells convatec business subject premarket approval requirements us new drugs approved subject fdc act related regulations biological drugs subject fdc act public health service act phs act related regulations biological drugs licensed phs act medical devices subject fdc act including medical device amendments nutritional products regulated fda primarily infant formula act amendments fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production record keeping quality control ensure product meets applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy product occur following approval federal government extensive enforcement powers activities pharmaceutical medical device manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed company could materially adversely affect business financial condition results operations cash flows federal government similar powers respect manufacturing operations nutritionals business marketing authorization companys products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel record keeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples diversions discussion recent settlement certain investigations drug pricing sales marketing activities see item financial statementsnote legal proceedings contingencies marketing practices us pharmaceutical manufacturers subject federal state health care laws used protect integrity government health care programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal anti kickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government health care program oig issued series guidances segments health care industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices company subscribes phrma code implemented compliance program address requirements set forth oig guidance companys compliance health care laws failure comply health care laws could subject company administrative legal proceedings including actions state federal government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect companys business financial condition results operations cash flows company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us company also licensed us drug enforcement agency procure produce controlled substances company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies various federal state agencies regulatory authority regarding manufacture storage transportation disposal many medical imaging products radioactive nature companys activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing companys products regulatory requirements vary country country eu two ways company obtain marketing authorization pharmaceutical product first route centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products second route obtain marketing authorization eu mutual recognition procedure applications made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states set forth pricing reimbursement product continues subject member state law whether fda approval approval emea obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control european countries provide market pricing new medicines except uk germany pricing freedom limited uk operation profit control plan germany operation reference price system companies also face significant delays mainly france spain italy belgium market access new products two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within europe due different national pricing reimbursement laws leads significant parallel trade flows recent years congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others similar cost containment issues exist many foreign countries company business federal state governments also pursued direct methods reduce cost drugs pay company participates state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities rebates medicaid related state programs reduced revenues million million million decrease compared primarily due exclusivity loss pravachol lower plavix sales shift patient enrollment medicaid medicare medicare part also resulted decrease medicaid rebates partially offset corresponding increase companys managed health care rebates company also participates prime vendor programs government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases prime vendor programs company participates provide discounts outpatient medicines purchased certain public health service entities hospitals meeting certain criteria company recorded discounts related prime vendor programs million million million us governmental cost containment efforts extended federally funded special supplemental nutrition program wic states participate wic program sought obtained rebates manufacturers infant formula whose products used program states conducted competitive bidding infant formula contracts require use specific infant formula products state wic program unless physician requests noncontract formula wic customer states participating wic program required engage competitive bidding use cost containment measures yield savings equal greater savings generated competitive bidding system mead johnson participates program approximately half gross us sales subject rebates wic program rebates wic program reduced revenues million million million discussion rebates programs see item managements discussion analysis financial condition results operations results operations environmental regulation companys facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many companys operations permits subject modification renewal revocation issuing authorities environment health safety group within company monitors operations around world providing company overview regulatory requirements overseeing implementation company standards compliance company also incurs operating capital costs matters ongoing basis company expended approximately million million million capital environmental projects undertaken specifically meet environmental requirements respectively expects spend approximately million although company believes substantial compliance applicable environmental health safety requirements permits required operations company nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many companys current former facilities operation many years time company operators facilities generated used stored disposed substances wastes considered hazardous federal state foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated company may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently company involved investigation remediation approximately current former company facilities company also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing company may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites company bears remediation responsibility pursuant contract obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees company employed approximately people december foreign operations company significant operations outside us conducted companys subsidiaries distributors involve three business segments companys us operations pharmaceuticals nutritionals health care revenues operations outside us billion accounted companys total revenues revenues exceeded million france japan canada spain italy mexico revenues exceeded million france japan spain canada italy germany revenues exceeded million france japan germany spain italy canada uk single country outside us contributed companys total revenues geographic breakdown net sales see table captioned geographic item financial statementsnote segment information discussion companys sales geographic area see item managements discussion analysis financial condition results operationsgeographic areas international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit limitations foreign participation local enterprises restrictive governmental actions companys international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase reduce reported dollar value companys net assets results operations change foreign exchange rates net favorable impact growth rate revenues company predict certainty future changes foreign exchange rates effect company attempts mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known company risks company currently considers immaterial may also impair companys operations patent infringement lawsuit apotex involving plavix ongoing risk generic competition apotex generic pharmaceutical companies companys largest product ranked net sales plavix clopidogrel bisulfate net sales united states us billion billion billion composition matter patent plavix expires currently subject patent litigation us apotex inc apotex corp apotex generic companies well less significant jurisdictions august apotex launched generic clopidogrel bisulfate product competes plavix august us district court southern district new york court patent litigation apotex granted motion company product partner sanofiaventis sanofi enjoin sales apotexs generic clopidogrel bisulfate product order apotex recall product customers courts grant preliminary injunction affirmed appeal trial underlying patent litigation ended february court expected rule following posttrial briefing atrisk launch generic clopidogrel bisulfate significant adverse effect net sales plavix company estimates range billion billion particular launch significant adverse effect net sales third quarter company estimates range million million well fourth quarter company estimates range million million first second third fourth quarters us net sales plavix million million million million respectively estimated total us prescription demand clopidogrel bisulfate branded generic increased compared estimated total us prescription demand branded plavix decreased period company expects generic clopidogrel bisulfate sold distribution channels following apotex atrisk launch august residual impact plavix net sales companys overall financial results full impact apotexs launch generic clopidogrel bisulfate product company reasonably estimated time depend number factors including among others amount generic product sold apotex whether company sanofi companies prevail underlying patent litigation even companies prevail pending patent case extent launch apotex permanently adversely impact pricing prescription demand plavix amount damages would sought andor recovered companies apotexs ability pay damages loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related us patent trial date action dr reddys set patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation dr reddys teva filed abbreviated new drug application us food drug administration fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages company continues believe plavix patents valid infringed sanofi vigorously pursuing enforcement patent rights plavix possible time reasonably assess ultimate outcome ongoing patent litigation apotex plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail trial company would expect face renewed generic competition plavix apotex promptly thereafter previously disclosed prior generic launch apotex companies entered proposed settlement apotex pending plavix patent litigation failed receive required antitrust clearances antitrust division us department justice conducting criminal investigation regarding proposed settlement plavix patent litigation apotex company cooperating fully investigation possible time reasonably assess outcome investigation impact company also possible time reasonably assess impact investigation companys compliance deferred prosecution agreement us attorneys office district new jersey company recorded deferred tax assets related us foreign tax credit research tax credit carryforwards expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets additional information pending plavix patent litigation related legal matters included item managements discussion analysis executive summaryplavix outlook sec consent order deferred prosecution agreement item financial statementsnote legal proceedings contingencies company faces competition pharmaceutical manufacturers including lowerpriced generic products competition manufacturers competing products including lowerpriced generic versions companys products major challenge within us internationally competition may include new products developed competitors lower prices superior performance features otherwise competitive companys current products ii technological advances patents attained competitors iii results clinical studies related companys products competitors products iv problems licensors suppliers distributors v business combinations among companys competitors major customers manufacturers generic products also increasingly seeking challenge patents expire may cases launch generic product expiration applicable patents andor final resolution related patent litigation company may experience difficulties delays manufacturing sale products company may experience difficulties delays inherent manufacturing sale seizure recalls pharmaceutical products forced closings manufacturing plants ii failure obtain imposition limitations use loss patent intellectual property rights iii failure company vendors suppliers comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing iv construction delays related construction new facilities expansion existing facilities including intended support future demand companys biologics products v manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations could impact continuous supply company may experience difficulties delays development commercialization new products company may experience difficulties delays development commercialization new products including inherent risks uncertainties associated product development compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved additional indications number reasons including efficacy safety concerns delay denial necessary regulatory approvals difficulty excessive cost manufacture ii failure enter successfully implement optimal alliances appropriate discovery andor commercialization products otherwise maintain consistent scope variety promising latestage products iii failure one companys products achieve maintain commercial viability legal matters adverse outcomes could negatively affect companys business company continuing obligations deferred prosecution agreement dpa us securities exchange commission sec consent order relating wholesaler inventory various accounting matters pursuant company agreed implement certain remedial measures including recommendations made monitor dpa undertake corporate reforms include additional disclosure periodic reports filed sec annual report shareholders company currently involved various lawsuits claims proceedings government investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition including intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi product pricing promotion matters vii lawsuits claims asserting violations securities antitrust federal state pricing laws viii environmental health safety matters ix failure comply antibribery laws foreign corrupt practices act x tax liabilities assurance increase scope matters additional lawsuits claims proceedings investigations future assurance matters material adverse impact company us foreign regulations may negatively affect companys sales profit margins company could become subject new government laws regulations health care reform initiatives us state federal level countries ii changes fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available us certain foreign countries iv new laws regulations judicial decisions affecting pricing marketing within across jurisdictions v changes intellectual property law vi matters compulsory licenses could alter protections afforded one products company faces increased pricing pressure us abroad managed care organizations institutional purchasers government agencies programs could negatively affect companys sales profit margins pharmaceutical products subject increasing price pressures restrictions us worldwide including rules practices managed care groups institutional governmental purchasers ii judicial decisions governmental laws regulations related medicare medicaid healthcare reform including medicare prescription drug improvement modernization act iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers company relies third parties meet contractual regulatory obligations company relies vendors partners including alliances pharmaceutical companies development commercialization products third parties meet contractual regulatory obligations relation arrangements company failure parties meet obligations andor development significant disagreements factors materially disrupt ongoing commercial relationship prevent optimal alignment partners activities could material adverse impact company company may adversely impacted economic factors beyond control company significant operations outside us revenue operations outside us accounted companys revenues company exposed changes fluctuation foreign currency exchange rates information companys foreign currency exchange exposure see item quantitative qualitative disclosures market risk company also significant borrowings exposed changes interest rates december company shortterm borrowings longterm debt billion information companys interest rate exposure see item quantitative qualitative disclosures market risk company also exposed economic factors company control failure execute companys business strategy could adversely impact growth profitability company may able fully execute strategic transformation business attain new period sustainable revenue earnings growth company continues invest growth drivers pipeline part focus addressing areas significant unmet medical need failure realize additional cost savings achieve maintain competitive cost base successfully transition product portfolio however could materially adversely affect companys results operations addition companys failure hire retain personnel right expertise experience operations critical business functions could adversely impact execution business strategy changes companys structure operations revenues costs efficiency resulting acquisitions divestitures mergers alliances restructurings strategic initiatives could result greater expected costs difficulties including need regulatory approvals appropriate company increasingly dependent information technology company increasingly dependent information technology systems significant breakdown invasion destruction interruption systems could negatively impact operations although company believes prudent plans assumptions assurance given goal plan set forth forward looking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise item b unresolved staff comments none item properties companys world headquarters located park avenue new york ny leases approximately square feet floor space approximately square feet sublet others company manufactures products major worldwide locations aggregate floor space approximately million square feet facilities owned company following table illustrates geographic location companys significant manufacturing facilities business segment total company pharmaceuticals nutritionals health care united states europe middle east africa western hemisphere pacific total portions facilities facilities owned leased company us elsewhere used research administration storage distribution information companys facilities see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december part ia executive officers registrant listed information executive officers company february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti president europe worldwide medicines group division executive vice president president company worldwide pharmaceuticals senior vice president president international member management council worldwide medicines group division company executive committee present executive vice president president worldwide pharmaceuticals division company stephen e bear present senior vice president human resources corporate staff senior vice president human resources company corporate staff member management council executive committee andrew r j bonfield executive director finance bg group plc executive vice president chief financial officer present chief financial officer corporate staff company corporate staff member management council executive committee joseph c caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john e celentano vice president general manager northern europe president health care group international medicines division company member management council senior vice president operations planning worldwide executive committee medicines group division company president canada mexico puerto rico worldwide medicines group division company president latin america canada worldwide medicines group division company present president health care group division company james cornelius chief executive officer chairman board guidant interim chief executive officer corporation member management council interim chief executive officer chairman board executive committee guidant corporation present interim chief executive officer director company sandra leung corporate secretary corporate staff company senior vice president general counsel vice president corporate secretary corporate staff corporate staff company member management council vice president corporate secretary acting general executive committee counsel corporate staff company present senior vice president general counsel corporate staff company elliott sigal md phd senior vice president drug discovery exploratory executive vice president chief scientific officer development pharmaceutical research institute division company president pharmaceutical research institute senior vice president global clinical pharmaceutical member management council development pharmaceutical research institute division company executive committee present chief scientific officer president pharmaceutical research institute division company part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse traded nyse arca inc formerly pacific exchange inc symbols bmy bmypr december company voluntarily withdrew securities listing nyse arca inc quarterly summary high low market prices presented common high low high low first quarter second quarter third quarter fourth quarter preferred high low high low first quarter second quarter third quarter fourth quarter second quarter first second third quarters trades companys preferred stock preferred stock pays quarterly dividend per share holders common stock number record holders common stock december number record holders based upon actual number holders registered books company date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies voting securities principal holders reference made proxy statement filed march respect voting securities principal holders incorporated herein reference made part hereof response information required item dividends dividends declared per share common preferred first quarter second quarter third quarter fourth quarter december board directors company declared quarterly dividend per share common stock company paid february shareholders record january unregistered sales equity securities use proceeds following table summarizes surrenders companys equity securities connection stock option restricted stock programs twelvemonth period ended december total number approximate dollar total number shares purchased value shares average price part publicly may yet shares paid per announced plans purchased period purchaseda sharea programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december reflects following transactions twelve months ended december surrender company shares common stock pay exercise price satisfy tax withholding obligations connection exercise employee stock options ii surrender company shares common stock satisfy tax withholding obligations connection vesting restricted stock issued employees b june company announced board directors authorized purchase billion company common stock twelve months ended december shares repurchased pursuant program purchases shares program expected performance graph following performance graph compares performance bristolmyers squibb periods indicated performance standard poors stock index sp average performance group consisting peer corporations lineofbusiness basis corporations making peer companies group abbott laboratories astrazeneca plc eli lilly company glaxosmithkline plc johnson johnson merck co inc novartis ag pfizer inc sanofiaventis including performance aventis prior merger sanofi scheringplough corporation wyeth total return indices reflect reinvested dividends weighted using beginningperiod market capitalization reported time periods measured performance group proxy statement comparison year cumulative total return bristolmyers squibb sp index peer group assumes invested bristolmyers squibb common stock sp index peer companies group index values december specified year assuming dividends reinvested item selected financial data fiveyear financial summary amounts millions except per share data income statement data net sales earnings continuing operations minority interest income taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results discussion items years see item managements discussion analysis financial condition results operationsexpenses item financial statementsnote alliances investments note restructuring note acquisitions divestitures note discontinued operations note shortterm borrowings longterm debt note legal proceedings contingencies excludes discontinued operations oncology therapeutics network years clairol zimmer million weightedaverage shares issuable well million interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation dilutive includes impact adoption statement financial accounting standard sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r discussion sfas see item financial statementsnote pension postretirement benefits item managements discussion analysis financial condition results operations executive summary company bristolmyers squibb company bms company bristolmyers squibb worldwide pharmaceutical related health care products company whose mission extend enhance human life providing highest quality pharmaceutical related health care products company engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals related health care products company three reportable segmentspharmaceuticals nutritionals health care pharmaceuticals segment comprised global pharmaceutical international consumer medicines business accounted approximately companys net sales nutritionals segment consists mead johnson nutritionals mead johnson primarily infant formula childrens nutritionals business accounted approximately companys net sales health care segment consists convatec medical imaging businesses accounted approximately companys net sales financial highlights company made progress longrange strategy despite significant challenges occurred year including atrisk launch generic clopidogrel bisulfate product adversely impacted plavix sales loss exclusivity pravachol united states us certain european markets increase litigation reserves company launched several important products including orencia sprycel gilead sciences inc gilead atripla orencia sprycel continue gain market share along double digit sales growth abilify reyataz erbitux sustiva franchise baraclude key components strong product line longterm growth company continues invest late stage compounds development new products growing importance biologics february company completed land purchase major new biologics facility devens massachusetts along expansion existing facilities syracuse new york manati puerto rico construction devens facility scheduled begin early worldwide net sales continuing operations decreased billion compared worldwide net sales products company views growth drivers increased compared period excluding plavix worldwide net sales growth drivers increased compared period products company considers growth drivers plavix avaproavalide abilify reyataz erbitux net income billion compared billion results include million increase reserves pricing sales litigation settlement million early debt retirement costs results included million gain sale consumer medicines business plavix companys largest product ranked net sales plavix clopidogrel bisulfate us sales billion billion billion composition matter patent plavix expires currently subject patent litigation us apotex inc apotex corp apotex generic companies well less significant jurisdictions company previously disclosed certain developments pending plavix litigation apotex including atrisk launch generic product apotex august noted apotex launched generic clopidogrel bisulfate product competes plavix august august us district court southern district new york court granted motion company product partner sanofiaventis sanofi enjoin sales apotexs generic clopidogrel bisulfate product order apotex recall product customers courts grant preliminary injunction affirmed appeal trial underlying patent litigation ended february court expected rule following posttrial briefing atrisk launch generic clopidogrel bisulfate significant adverse effect net sales plavix company estimates range billion billion particular launch significant adverse effect sales third quarter company estimates range million million well fourth quarter company estimates range million million first second third fourth quarters us net sales plavix million million million million respectively estimated total us prescription demand clopidogrel bisulfate branded generic increased compared estimated total us prescription demand branded plavix decreased period company expects generic clopidogrel bisulfate sold distribution channels following apotex atrisk launch august residual impact plavix net sales companys overall financial results full impact apotexs launch generic clopidogrel bisulfate product company reasonably estimated time depend number factors including among others amount generic product sold apotex whether company sanofi companies prevail underlying patent litigation even companies prevail pending patent case extent launch apotex permanently adversely impact pricing prescription demand plavix amount damages would sought andor recovered companies apotexs ability pay damages loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related us patent patent trial date action dr reddys set patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation dr reddys teva filed abbreviated new drug application anda us food drug administration fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages company continues believe plavix patents valid infringed sanofi vigorously pursuing enforcement patent rights plavix possible time reasonably assess ultimate outcome ongoing patent litigation apotex plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail trial company would expect face renewed generic competition plavix apotex promptly thereafter previously disclosed antitrust division us department justice conducting criminal investigation regarding proposed settlement pending patent plavix litigation apotex company cooperating fully investigation possible time reasonably assess outcome investigation impact company also possible time reasonably assess impact investigation companys compliance deferred prosecution agreement dpa us attorneys office district new jersey usao also previously disclosed usao initiated investigation conducted monitor dpa monitor usao corporate governance issues relating companys negotiations proposed settlement apotex included review whether violation federal securities laws connection proposed settlement apotex terms previously disclosed consent order company entered us securities exchange commission august consent sec consent monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former chief executive officer ceo former general counsel board directors board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional discussion legal matters including plavix patent litigation antitrust division investigation related proposed settlement apotex terms dpa sec consent see item financial statementsnote legal proceedings contingencies outlook sec consent order deferred prosecution agreement business environment company conducts business primarily within pharmaceutical industry highly competitive subject numerous government regulations many competitive factors may significantly affect companys sales products including product efficacy safety price costeffectiveness marketing effectiveness product labeling quality control quality assurance manufacturing operations research development new products successfully compete business health care industry company must demonstrate products offer medical benefits well cost advantages currently companys new product introductions compete products already market therapeutic category addition potential future competition new products competitors may introduce future company manufactures branded products priced higher generic products generic competition one companys leading challenges globally pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent subject new competing products form generic brands upon exclusivity loss company lose major portion products sales short period time us internationally health care industry subject various governmentimposed regulations authorize prices price controls continue impact companys sales us congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others addition january medicare prescription drug improvement modernization act became effective provides outpatient prescription drug coverage senior citizens us company assessing impact legislation could business including potential negative impact us pharmaceuticals business due legislative andor regulatory changes could result additional pricing pressures controls many markets outside us company operates environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available national markets growth managed care organizations mcos us played large role competition surrounds health care industry mcos seek reduce health care expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part companys strategy companies compete inclusion mco formulary company generally successful major products included company believes developments managed care industry including continued consolidation continue generally downward pressure prices pharmaceutical production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become important companys product portfolio company continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale including building new stateoftheart manufacturing facility production biologics devens massachusetts construction commence early company maintained competitive position market strives uphold position dependent success discovering developing innovative costeffective products serve unmet medical need company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy company continues execute strategy longterm growth currently track strategic transition strategy consists increasing investments behind growth brands new specialty products focusing companys research development programs products pharmaceutical pipeline disease areas address significant unmet medical need aligning sales marketing emphasis specialists high value primary care prescribers implementing initiatives designed achieve maintain efficient cost base companys pharmaceutical portfolio continued transition away products lost exclusivity towards growth drivers recently launched products include plavix clopidogrel bisulfate abilify aripiprazole avaproavalide irbesartanirbesartan hydrochlorothiazide reyataz atazanavir sulfate sustiva efavirenz franchise erbitux cetuximab orencia abatacept baraclude entecavir sprycel dasatinib us net sales products accounted companys us pharmaceutical net sales compared worldwide net sales products accounted companys worldwide pharmaceutical net sales compared company experienced last series major anticipated exclusivity losses market exclusivity expiration pravachol us certain markets europe expect significant new exclusivity losses next several years order support production specialty products pharmaceutical portfolio including biologics board directors approved capital expenditures approximately million bulk biologics manufacturing facility us february company completed land purchase acre site locate new largescale expandable multiproduct bulk biologics manufacturing facility devens massachusetts construction expected begin early facility projected operationally complete company expects submit site regulatory approval commercial production biologic compounds anticipated begin addition company expand manati puerto rico facility targeted start expansion add new space renovate existing space filling finishing companys sterile products biologic compounds including orencia several investigational compounds given companys current limited capacity commercial volumes biologics products company also received approval fda may permits third party manufacture orencia additional facility facility together another third party facility pending submission approval fda support increased production capacity necessary meet expected longterm demand orencia initial requirements biologics products commercialized keeping strategy company invested billion research development representing growth rate research development dedicated pharmaceutical products including milestone payments inlicensing development programs billion compared billion part strategy company reexamining operating costs achieve maintain efficient cost base end company launched initiative identify realize productivity savings initiative company reexamined operating model focus resources high value priorities simplify streamline business processes improve governance decision making build capabilities sustain cost reductions long term company plan achieve goal realizing minimum million productivity savings incremental million well making company productive efficient effective new product pipeline developments january company astrazeneca plc astrazeneca announced collaboration develop commercialize two investigational compounds saxagliptin dapagliflozin studied treatment type diabetes company discovered compounds collaboration compounds worldwide except japan separately company also announced collaboration otsuka pharmaceutical co ltd otsuka develop saxagliptin japan november fda granted fast track designation ipilimumab used combination chemotherapy dacarbazine previously untreated metastatic melanoma patients fda also granted fast track designation ipilimumab used monotherapy previously treated metastatic melanoma patients october company moved investigational antithrombosis compound apixaban phase iii development apixaban oral direct factor xa inhibitor october company received fda approval new oncedaily mg single capsule formulation reyataz treatment human immunodeficiency virus hiv infection adults part combination therapy replace two reyataz mg capsules appropriate patients company onepill oncedaily hiv medicine options available three drug classes part combination therapy company otsuka received approval fda september european medicines evaluation agency emea october abilify injection first readytouse singledose vial atypical antipsychotic control agitation adults schizophrenia bipolar mania august company sanofi received approval fda emea additional indication plavix reduce rate death cause rate combined endpoint reinfarction stroke death patients acute stsegment elevation myocardial infarction july atripla firstever oncedaily single tablet threedrug regimen hiv intended standalone therapy combination antiretrovirals received approval fda product combines sustiva efavirenz manufactured company truvada emtricitabine tenofovir disoproxil fumarate manufactured gilead company gilead merck co inc submitted marketing authorization approval atripla emea october addition company gilead submitted atripla regulatory approval canada september june company received approval sprycel dasatinib fda treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia philadelphia chromosomepositive acute lymphoblastic leukemia phall resistance intolerance prior therapy including gleevec imatinib mesylate sprycel launched us july november company also received approval sprycel committee medicinal products human use emea product launched austria germany france finland sweden uk february company received approval sprycel without phall indication switzerland april company launched emsam selegiline transdermal system us emsam first transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adults emsam developed somerset pharmaceuticals inc joint venture mylan laboratories inc mylan watson pharmaceuticals inc watson company obtained exclusive distribution rights commercialize emsam us canada markets emsam existing neuroscience sales force march fda approved erbitux copromoted company imclone systems incorporated imclone use treatment squamous cell carcinoma head neck erbitux previously indicated treatment metastatic colorectal cancer february company launched baraclude treatment hepatitis b china company also launched baraclude several new markets third quarter including germany france uk japan baraclude approved countries worldwide february company launched orencia treatment signs symptoms rheumatoid arthritis us receiving approval fda december june company received approval orencia canada launched product august outlook company expects reductions net sales products lost exclusivity previous years range billion billion compared billion billion company expects generic clopidogrel bisulfate inventory market continued residual impact plavix net sales company expect plavix net sales earnings growth assuming absence renewed additional generic competition company expects increased prescription demand plavix well key brands newly launched products compared gross margin expected improve due growth higher margin products lower margin erosion related exclusivity losses improved manufacturing efficiencies marketing selling administrative expense expected remain relatively unchanged efficiency savings largely offset inflationary cost increases company continues focus high value primary care specialist physicians implements various productivity initiatives company expects continue increase investments develop additional new compounds support introduction new products company subsidiaries subject number significant pending lawsuits claims proceedings investigations including pending plavix litigation described assurance increase scope matters future lawsuits claims proceedings material company addition increasing trend foreign governments scrutinize sales marketing activities pharmaceutical companies assurance investigations investigations material possible time reasonably assess final outcome investigations litigations management continues believe previously disclosed next years aggregate impact beyond current reserves pending plavix patent litigation litigations investigations legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity companys expectations next several years described reflect potential impact litigation companys results operations previously disclosed composition matter patent plavix expires subject litigation us apotex trial underlying patent litigation ended february court expected rule following posttrial briefing apotex prevail trial patent litigation company would expect face renewed generic competition plavix promptly thereafter pending plavix patent litigations us less significant markets product us companys us territory partnership alliance sanofi plaintiff three additional pending patent infringement lawsuits dr reddys teva cobalt related patent dr reddys teva filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us although launch point time would risk adverse damages award companies prevail underlying patent litigation company continues believe plavix patents valid infringed sanofi vigorously pursuing cases possible time reasonably assess ultimate outcome patent litigation apotex plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix generic pharmaceutical companies loss market exclusivity plavix andor development sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity plavix companys largest product net sales us net sales plavix billion billion billion respectively previously disclosed antitrust division us department justice conducting criminal investigation regarding proposed settlement pending plavix patent litigation apotex company cooperating fully investigation possible time reasonably assess outcome investigation impact company also possible time reasonably assess impact investigation companys compliance dpa usao also previously disclosed usao initiated investigation conducted monitor dpa usao companys negotiations proposed settlement apotex included review corporate governance issues whether violation federal securities laws connection proposed settlement apotex terms previously disclosed consent company entered securities exchange commission sec monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional discussion legal matters including plavix patent litigation antitrust division investigation related proposed settlement apotex terms dpa sec consent see executive summaryplavix sec consent order deferred prosecution agreement item financial statements note legal proceedings contingencies results operations following discussions companys results continuing operations exclude results related oncology therapeutics network otn business previously presented separate segment prior divestiture segregated continuing operations reflected discontinued operations periods presented see discontinued operations change dollars millions vs vs net sales earnings continuing operations minority interest income taxes net sales provision income taxes effective tax rate earnings continuing operations net sales net sales net sales continuing operations decreased billion compared us net sales decreased billion compared international net sales decreased billion compared including favorable foreign exchange impact net sales continuing operations decreased billion compared us net sales decreased billion compared international net sales billion remained relatively constant compared including favorable foreign exchange impact composition change net sales follows analysis change total change volume price foreign exchange vs vs general companys business seasonal information us pharmaceutical prescriber demand reference made table within business segments pharmaceuticals section sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys top pharmaceutical products products company views current future growth drivers sold within us company operates three reportable segmentspharmaceuticals nutritionals health care may company completed sale otn previously presented separate segment results operations otn presented part companys results discontinued operations accordance statement financial standards sfas accounting impairment disposal longlived assets accordingly otn results operations prior periods reclassified discontinued operations conform current year presentations companys net sales segment follows net sales change dollars millions vs vs pharmaceuticals net sales nutritionals net sales health care net sales health care group total company recognizes revenue net various sales adjustments arrive net sales reported consolidated statement earnings adjustments referred grosstonet sales adjustments described critical accounting policies following table sets forth reconciliation companys gross sales net sales significant category grosstonet sales adjustments years ended december dollars millions gross sales grosstonet sales adjustments prime vendor chargebacks women infants children wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments total grosstonet sales adjustments net sales decrease grosstonet sales adjustments compared affected number factors including changes customer mix portfolio shift case towards products required lower rebates well changes contract status decrease prime vendor chargebacks primarily result lower plavix net sales volume erosion highly rebated paraplatin carboplatin taxol paclitaxel due generic competition well impact discontinued commercialization tequin gatifloxacin managed health care rebates contract discounts decreased primarily result reversal reserves related tricare retail pharmacy refund program well exclusivity loss pravachol also reduced medicaid rebates addition lower plavix net sales shift patient enrollment medicaid medicare medicare part resulted decrease medicaid rebates partially offset corresponding increase managed health care rebates decrease cash discounts primarily due exclusivity loss pravachol lower plavix sales volumes increase sales returns primarily due higher returns trends nonexclusive brands well discontinued commercialization tequin decrease prime vendor chargebacks managed health care rebates primarily due lower relative sales volume segment due product mix decrease sales returns primarily due lower returns certain products including tequin pravachol sustiva decrease adjustments due lower sales discounts government rebates international businesses following table sets forth activities ending balances significant category grosstonet sales adjustments managed health care women rebates infants prime vendor children contract medicaid cash dollars millions chargebacks wic rebates discounts rebates discounts sales returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million primarily related higher expected return trends certain nonexclusive products well discontinued commercialization tequin credits contract discounts million primarily due reversal reserves related tricare retail pharmacy refund program significant items included charges million medicaid rebates primarily result higher expected medicaid utilization various products credits million adjustments primarily result lower expected rebates foreign governments credits million sales returns resulting lower returns certain products including tequin avaproavalide plavix significant revisions made estimates grosstonet sales adjustments pharmaceuticals composition change pharmaceutical sales follows analysis change foreign total change volume price exchange vs vs worldwide pharmaceuticals sales decreased million us pharmaceuticals sales decreased million million primarily due lower sales plavix resulting atrisk launch generic clopidogrel bisulfate august loss exclusivity pravachol offset continued growth abilify erbitux reyataz sustiva franchise avaproavalide sales newer products including orencia baraclude sprycel aggregate estimated us wholesaler inventory levels companys key pharmaceutical products sold us pharmaceuticals business end approximately two half weeks international pharmaceuticals sales decreased million million primarily due decline pravachol taxol paclitaxel sales resulting increased generic competition europe partially offset increased sales newer products including reyataz abilify baraclude worldwide pharmaceuticals sales decreased million us pharmaceuticals sales decreased million compared million primarily due continued impact exclusivity losses paraplatin glucophage franchise increased competition pravachol partially offset increased sales growth drivers including plavix abilify erbitux reyataz aggregate estimated wholesaler inventory levels companys key pharmaceutical products sold us pharmaceuticals business end end approximately threetenths month approximately two half weeks decline inventory levels negatively impacted sales performance certain products international pharmaceutical sales decreased including favorable foreign exchange impact million primarily due increased generic competition pravachol taxol paclitaxel partially offset increased sales newer products including reyataz abilify well growth plavix key pharmaceutical products sales representing total pharmaceutical sales respectively follows change dollars millions vs vs cardiovascular plavix pravachol avaproavalide coumadin monopril virology reyataz sustiva franchise total revenue zerit baraclude infectious diseases cefzil oncology erbitux taxol paclitaxel sprycel affective psychiatric disorders abilify total revenue emsam immunoscience orencia pharmaceuticals efferalgan excess sales plavix platelet aggregation inhibitor part companys alliance sanofi decreased million sales plavix decreased us million primarily result launch generic clopidogrel bisulfate product august market exclusivity plavix expected expire us major european markets composition matter patent plavix subject litigation including litigation apotex noted trial underlying patent litigation ended february court rule following posttrial briefing apotex prevail trial underlying patent litigation additional competition plavix thirdparty generic pharmaceutical companies plavix would face renewed generic competition sales increased including favorable foreign exchange impact million million us sales increased million million primarily due increased demand additional information plavix litigations well generic launch apotex see executive summaryplavix item financial statementsnote legal proceedings contingencies sales pravachol hmg coa reductase inhibitor decreased including unfavorable foreign exchange impact million due market exclusivity expiration april resulting generic competition strengths us generic competition key european markets estimated total us prescription demand decreased approximately compared sales pravachol decreased million million primarily due lower demand resulting increased competition related reduction wholesaler inventory levels partially offset lower managed health care rebates market exclusivity european union eu ended exception sweden expiration occurred march italy expiration occur january france generic competition authorized company commenced july previously disclosed company authorized watson distribute pravastatin sodium tablets us sales avaproavalide angiotensin ii receptor blocker treatment hypertension also part sanofi alliance increased including favorable foreign exchange impact million us sales increased million compared primarily due higher average net selling prices higher volume estimated total us prescription demand increased approximately compared international sales increased including favorable foreign exchange impact million compared sales increased including favorable foreign exchange impact million million us sales increased million compared million international sales increased including favorable foreign exchange impact million million primarily due increased sales canada france germany market exclusivity avaproavalide known eu aprovelkarvea expected expire including pediatric extension us countries eu avaproavalide currently marketed japan sales coumadin warfarin sodium oral anticoagulant used predominantly patients atrial fibrillation deep venous thrombosispulmonary embolism increased million compared primarily due higher average net selling prices partially offset lower demand driven continued competition estimated total us prescription demand decreased approximately compared sales decreased million million due continued competition market exclusivity coumadin expired us sales monopril second generation angiotensin converting enzyme inhibitor treatment hypertension sold almost exclusively non us markets decreased million sales million decrease including favorable foreign exchange impact million sales declines years due product supply issues key european markets market exclusivity protection monopril expired us expired expected expire countries eu monopril currently marketed japan sales reyataz protease inhibitor treatment hiv increased including favorable foreign exchange impact million primarily due increased demand us europe latin america estimated total us prescription demand increased approximately compared us sales increased million million primarily due higher demand higher average net selling prices international sales increased including favorable foreign exchange impact million compared sales million compared million primarily due increased demand us europe reyataz launched second quarter market exclusivity reyataz expected expire us countries eu japan total revenue sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv increased including favorable foreign exchange impact million due higher demand launch atripla third quarter estimated total us prescription demand sustiva franchise increased approximately compared july company gilead launched atripla oncedaily single tablet threedrug regimen hiv intended standalone therapy combination antiretrovirals total revenue sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla company records revenue bulk efavirenz component atripla upon sales atripla gilead joint venture thirdparty customers sustiva sales increased million million primarily due increased demand higher average selling prices lower sales returns market exclusivity sustiva expected expire us countries eu company others market sustiva japan additional information revenue recognition sustiva franchise see item financial statementsnote alliances investments sales zerit stavudine antiretroviral agent used treatment hiv decreased million primarily result lower demand us europe estimated total us prescription demand decreased approximately compared zerit sales decreased including favorable foreign exchange impact million million primarily result decrease demand us market exclusivity protection zerit expected expire us countries eu japan sales baraclude oral antiviral agent treatment chronic hepatitis b increased million compared million baraclude launched us april china february uk germany july france japan september company composition matter patent expires us germany france uk sales cefzil antibiotic treatment mild moderately severe bacterial infections decreased million primarily due generic competition us estimated total us prescription demand decreased approximately compared cefzil sales decreased including favorable foreign exchange impact million million primarily due lower demand market exclusivity expired december us expected expire eu sales erbitux sold company almost exclusively us increased million million driven continued growth related usage treatment colorectal cancer treatment head neck cancer approved fda march sales increased million million erbitux marketed company distribution copromotion agreement imclone use patent relating combination therapy cytotoxic treatments expires patent covering monotherapy currently generic versions biological products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations companys right market erbitux north america japan agreement imclone expires september company others market erbitux countries eu previously disclosed imclone yeda research development company ltd yeda litigation ownership use patent combination therapy cytotoxic treatments relating erbitux september court granted yeda complete ownership patent imclone appealed courts decision information pertaining legal proceedings involving erbitux see item financial statementsnote legal proceedings contingencies note alliances investments sales taxol paclitaxel anticancer agent sold almost exclusively nonus markets million compared million sales taxol paclitaxel decreased including unfavorable foreign exchange impact primarily due increased generic competition europe generic entry japan third quarter taxol paclitaxel sales decreased including unfavorable foreign exchange impact million million primarily result increased generic competition europe market exclusivity protection taxol paclitaxel expired us countries eu two generic paclitaxel products received regulatory approval japan one generic product entered market sprycel oral inhibitor multiple tyrosine kinases treatment adults chronic accelerated myeloid lymphoid blast phase chronic myloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate launched us july certain european markets fourth quarter sales million market exclusivity sprycel expected expire us total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increased million us sales increased million million primarily due higher demand higher average net selling prices estimated total us prescription demand increased approximately compared total revenue abilify million compared million primarily due demand growth us continued growth europe achieved sales million total revenue abilify primarily consists alliance revenue representing companys share net sales countries copromotes otsuka product sold otsuka affiliate distributor otsukas market exclusivity protection abilify expected expire us including granted patent term extension otsuka received formal notices six generic pharmaceutical companies stating filed anda fda various dosage forms aripiprazole company otsuka comarket us abilify notices states anda contains piv certification directed us patent patent covers aripiprazole expires october addition notices purports provide otsuka respective piv certification certifications contain various allegations regarding enforceability patent andor validity andor infringement claims therein otsuka sole rights enforce patent additional information see item business business segments pharmaceuticals segment company also right copromote abilify several european countries uk france germany spain act exclusive distributor product rest eu composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplemental protection certificate countries except romania denmark data exclusivity eu expires companys contractual right market abilify expires november us puerto rico countries eu company exclusive right market abilify june additional information revenue recognition abilify see item financial statementsnote alliances investments emsam transdermal patch delivery monoamine oxidase inhibitor treatment major depressive disorder adults launched us april sales million third quarter result lower expected sales emsam company recorded million impairment charge emsam related assets emsam developed somerset joint venture mylan watson company obtained exclusive distribution rights commercialize emsam us canada markets emsam us existing neuroscience sales force new drug formulation emsam received three years hatchwaxman data exclusivity expires us orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy launched us february sales million substantially us company composition matter patent expires us patent may eligible patent term restoration could possibly extend term noted generic versions biological products approved us law law could change future sales efferalgan paracetamol formulation acetaminophen pain relief sold principally europe decreased million primarily due change government reimbursement sales increased including favorable foreign exchange impact million million primarily due increased sales italy spain result strong flu season estimated us prescription change data provided includes information retail mail order channels reflect information channels hospitals institutions longterm care among others estimated prescription prescription change data based national prescription audit npa data provided ims health ims supplier market research pharmaceutical industry described instances basic exclusivity loss date indicated expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date indicated expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval prior expiration data exclusivity period submitting clinical trial data obtain marketing approval company assesses market exclusivity period products case bycase basis length market exclusivity companys products difficult predict certainty complex interaction patent regulatory forms exclusivity factors assurance particular product enjoy market exclusivity full period time company currently anticipates estimates market exclusivities reported business planning purposes intended reflect companys legal opinion regarding strength weakness particular patent legal position estimated enduser demand us pharmaceuticals following tables set forth companys top pharmaceutical products based annual net sales products company views current future growth drivers sold us pharmaceuticals business years ended december changes reported us net sales period b estimated total us prescription growth retail mail order channels calculated company based npa data nextgeneration prescription services ngps version data provided ims months ended december estimated us therapeutic category share applicable product calculated company based npa data ngps data provided ims year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzili coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyatazi sprycel j sustiva franchise k total revenue tequin videxvidex ec zerit year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyatazi sprycelj sustiva tequin videxvidex ec zerit year ended december month ended december estimated trx change us change us total prescriptions therapeutic category share net sales npa data b ngps data c npa data b ngps data c abilify total revenue avaproavalide baraclude e cefzil coumadin erbitux f na na na na glucophage franchise kenalog g na na na na orencia h na na na na paraplatin f na na na na plavix pravachol reyataz sprycelj sustiva tequin videxvidex ec zerit reflects percentage change net sales dollar terms including change average selling prices wholesaler buying patterns b based simple average estimated number prescriptions retail mail order channels provided ims c based weightedaverage estimated number prescription units tablets milliliters retail mail order channels based data provided ims therapeutic categories determined company products considered direct competition companys products products listed compete following therapeutic categories abilify antipsychotics avaproavalide angiotensin receptor blockers baraclude oral antiviral agent cefzil branded oral solid liquid antibiotics coumadin warfarin erbitux oncology glucophage franchise oral antidiabetics kenalog intraarticularintramuscular steroid orencia fusion protein paraplatin carboplatin plavix antiplatelet agents pravachol hmg coa reductase inhibitors reyataz protease inhibitors excluding norvir sprycel tkis leukemia sustiva franchise antiretroviralsthird agents excluding norvir trizivir tequin branded oral solid antibiotics videxvidex ec zerit nucleoside reverse transcriptase inhibitors e baraclude launched us april f erbitux paraplatin specifically parenterally administered oncology products general prescriptionlevel data physicians write prescriptions products company believes therapeutic category share information provided third parties products may reliable accordingly none presented g company prescription level data kenalog product dispensed retail pharmacy company believes therapeutic category share information provided third parties product may reliable accordingly none presented h orencia launched us february company prescription level data product dispensed retail pharmacies prior year estimated trx therapeutic category share percentage recalculated conform current year presentation following cefzil recalculated percentage share based combined oral liquidsuspension markets reyataz recalculated percentage share protease inhibitors excluding norvir sustiva franchise recalculated percentage share third agents excluding norvir trizivir j sprycel launched us july k beginning third quarter sustiva franchise total revenue includes sales sustiva well revenue bulk efavirenz included combination therapy atripla therapeutic category share information change us total prescriptions growth sustiva franchise antiretrovirals third agents excluding norvir trizivir includes branded sustiva atripla prescription units excess company historically reported estimated total us prescription change estimated therapeutic category share based npa data ims makes available public subscription basis simple average estimated number prescriptions retail mail order channels third quarter company began disclosing estimated total us prescription change estimated therapeutic category share based npa ngps version data ngps version data collected ims new revised methodology released ims limited basis pilot program ims announced ngps version data available public subscription basis starting january legacy npa ngps version discontinued company believes ngps data provided ims provides superior estimate prescription data companys products retail mail order channels company calculated estimated total us prescription change estimated therapeutic category share based ngps data weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions company believes calculation estimated total us prescription change estimated therapeutic category share based ngps data weightedaverage approach respect retail mail order channels provides superior estimate total prescription demand company uses methodology internal demand forecasts estimated prescription change data estimated therapeutic category share reported throughout annual report include information retail mail order channels reflect information channels hospitals institutions longterm care among others data provided ims product ims recordkeeping processes estimates based sampling procedures subject inherent limitations estimates based sampling addition ngps version data part pilot program replaced ims incorporated ngps version released january company continuously seeks improve quality estimates prescription change amounts therapeutic category share percentages ultimate patientconsumer demand review methodologies processes calculation estimates review analysis third parties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze third parties data used calculations international pharmaceuticals nutritionals health care following table sets forth companys key pharmaceutical products growth drivers sold companys international pharmaceuticals business including top pharmaceutical products sold companys major nonus countries based net sales key products sold reporting segments listed percentage change companys estimated ultimate patientconsumer demand months december september compared period prior year company commenced collecting estimated ultimate patientconsumer demand reporting segments march period company believes yeartoyear comparison provides meaningful comparison changes sales quarter quartertoprior quarter comparisons previously provided change demand constant us dollar basis december september vs december vs september international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite excess estimated inventory months hand distribution channel us pharmaceuticals following tables set forth companys top pharmaceutical products based annual net sales products company views current future growth drivers sold companys us pharmaceuticals business us pharmaceuticals net sales estimated number months hand applicable product us wholesaler distribution channel quarters ended december september company believes estimated number months hand quarters ended december september three preceding years provide meaningful comparison estimated enduser demand us pharmaceuticals disclosed companys former practice providing six recent quarters december december december months months months dollars millions net sales hand net sales hand net sales hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit september september september months months months dollars millions net sales hand net sales hand net sales hand abilify total revenue avaproavalide baraclude cefzil coumadin erbitux glucophage franchise kenalog orencia paraplatin plavix pravachol reyataz sprycel sustiva franchise total revenue tequin videxvidex ec zerit beginning third quarter sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla estimated months hand product us wholesale distribution channel include branded sustiva inventory baraclude launched us april anticipation launch companys us wholesalers built inventories product meet expected demand september baraclude inventory us wholesaler distribution channel exceeded one month hand estimated value baraclude inventory us wholesaler distribution channel worked less one month hand subsequent quarters december september estimated value cefzil inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively demand cefzil decreased significantly due reduced wholesaler outmovements generic competition began us december december estimated value cefzil inventory exceeded one month hand approximately million company built higher inventories product meet expected higher demand typically experienced winter months us company continues monitor cefzil sales objective work wholesaler inventory levels one month hand less december estimated value glucophage franchise products inventory glucophage xr glucophage ir glucovance metaglip us wholesaler distribution channel exceeded one month hand approximately million products months hand estimate glucophage franchise products average months hand stockkeeping units skus product group increase months hand glucophage franchise products end fourth quarter one month hand resulted primarily purchase wholesalers certain skus giving effect purchases increased months hand skus less one month hand however increased months hand skus averaged skus glucophage franchise products aggregate estimated months hand exceeded one month march estimated value glucophage franchise products inventory us wholesaler distribution channel worked approximately one month hand worked remained less one month hand subsequent quarters december september estimated value kenalog inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively due high levels goodsintransit caused shipping delays subsequent quarters estimated value kenalog inventory us wholesaler distribution channel worked less one month hand october us pediatric exclusivity period paraplatin expired resulting entry multiple generic competitors paraplatin led significant decrease demand paraplatin turn led months hand product us wholesaler distribution channel exceeding one month hand december september september december september estimated value paraplatin inventory us wholesaler distribution channel one month hand approximately million december million september million september million december million september company longer produces paraplatin us market continue monitor paraplatin wholesaler inventory levels depleted september estimated value plavix inventory us wholesaler distribution channel exceeded one month hand approximately million due atrisk launch generic clopidogrel bisulfate august demand plavix decreased precipitously following atrisk launch generic clopidogrel bisulfate december plavix inventory us wholesaler distribution channel worked less one month hand sprycel launched us july consistent customary practice time new product launch companys us wholesalers built inventories product meet expected demand december september estimated value sprycel inventory us wholesaler distribution channel exceeded one month hand approximately million million respectively company continues monitor sprycel inventory sales objective work wholesaler inventory levels one month hand less first quarter company made decision discontinue commercialization tequin commercial reasons company stopped shipping product us wholesalers june established accrual estimated returns tequin inventory july company notified us wholesaler retail distribution channels would allow return product regardless expiry dates estimated value tequin inventory us wholesaler distribution channel exceeded one month hand de minimis september december company aware significant amounts tequin inventory remaining us wholesaler distribution channel company expects tequin inventory us channels reduced nominal levels first quarter estimated value videxvidex ec didanosine inventory us wholesaler distribution channel exceeded one month hand de minimis december approximately million september result generic competition us commencing fourth quarter demand videxvidex ec decreased significantly products erbitux orencia company determines months hand estimates dividing estimated amount product us wholesaler distribution channel estimated amount outmovement product us wholesaler distribution channel period days calculated described factors may influence companys estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data represent recordkeeping processes may also reflect estimates company maintains inventory management agreements imas us pharmaceuticals wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect inventory levels product hand amount outmovement products three wholesalers accounted approximately total gross sales us pharmaceutical products inventory information received wholesalers excludes inventory held intermediaries sell retailers hospitals excludes goods transit wholesalers company uses information provided three wholesalers friday closest quarter end calculate amount inventory hand wholesalers applicable quarter end amount increased companys estimate goods transit wholesalers applicable friday reflected weekly data provided wholesalers companys revenue recognition policy sales recorded substantially risks rewards ownership transferred us pharmaceuticals business generally product shipped cases goods transit wholesaler owned applicable wholesaler accordingly reflected calculation inventories wholesaler distribution channel company estimates amount goods transit using information provided wholesalers respect open orders applicable friday companys records sales wholesalers respect open orders company determines outmovement product wholesalers period days using recent four weeks outmovement product provided wholesalers extrapolating amount day basis company estimates inventory levels hand outmovements us pharmaceuticals business wholesaler customers three largest wholesalers product based assumption amounts bear relationship three largest wholesalers inventory levels movements product percentage aggregate sales products wholesalers applicable quarter bears aggregate sales products companys three largest wholesalers quarter finally company considers whether adjustments necessary extrapolated amounts based factors historical sales individual products made wholesalers thirdparty market research data related prescription trends patient demand addition company receives inventory information wholesalers selective basis certain key products companys us pharmaceuticals business imas discussed arrangements substantially direct wholesaler customers requires wholesalers maintain inventory levels one month demand response atrisk launch generic clopidogrel bisulfate august company offered certain us mcos incremental rebates wholesaler list price plavix certain conditions march small number mcos accepted offer offers rejected qualify terminated prior time issuance preliminary injunction august offers made company also provided temporary price reduction federal supply schedule plavix veterans administration limited period august september primarily result limited participation rebate offer company estimates impact two programs plavix net sales third fourth quarters de minimis orencia launched february launch second quarter company distributed orencia exclusive distribution arrangement single distributor following approval supplemental biologics license application sbla allows third party manufacture orencia additional site exclusive distribution arrangement terminated july company expanded distribution network orencia multiple distributors estimates months hand calculated dividing inventories orencia held distributors end quarter outmovement product last day period reported distributors inventory hand outmovements reported distributors product distributors recordkeeping processes may mckesson corporation mckesson one companys wholesalers provided warehousing packing shipping services erbitux mckesson held erbitux inventory consignment companys revenue recognition policy company recognized revenue inventory shipped mckesson endusers mckesson also held inventories erbitux account upon divestiture otn may company discontinued consignment arrangement mckesson mckesson longer held inventories account thereafter company sold erbitux intermediaries wholesalers specialty oncology distributors shipped erbitux directly end users product customers intermediaries beginning third quarter company expanded distribution model include one companys wholesalers held erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy estimate months hand calculated dividing inventories erbitux held wholesaler account reported wholesaler end quarter outmovements product reported wholesaler last day period inventory levels reported wholesaler product wholesalers recordkeeping process previously disclosed companys pharmaceuticals business outside us nutritionals health care business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate direct customer product level inventory calculate months hand business units estimated inventory months hand distribution channel following table sets forth companys key products sold businesses listed net sales applicable product quarters ended december september december september estimated number months hand applicable product direct customer distribution channel businesses end four quarters company believes estimated number months hand quarters ended december september two preceding years provide meaningful comparison estimated enduser demand international pharmaceuticals nutritionals health care disclosed companys former practice providing four recent quarters estimates months hand key products described international pharmaceuticals business based data collected companys significant business units outside us also described information nonkey products amount inventory hand direct customers approximately one month impact de minimis nonpharmaceuticals reporting segments estimates based data collected us significant business units outside us december september months months dollars millions net sales hand net sales hand international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva franchise total revenue taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite beginning third quarter sustiva franchise includes sales sustiva well revenue bulk efavirenz included combination therapy atripla estimated months hand product distribution channel include branded sustiva inventory december september months months dollars millions net sales hand net sales hand international pharmaceuticals abilify total revenue avaproavalide baraclude bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva taxol paclitaxel videxvidex ec nutritionals enfamilenfagrow nutramigen health care convatec ostomy wound therapeutics medical imaging cardiolite months hand information represents companys estimates aggregate product level inventory hand direct customers divided expected demand applicable product expected demand estimated ultimate patientconsumer demand calculated based estimated enduser consumption direct customer outmovement data recent day period reasonable period factors may affect companys estimates include generic competition seasonality products direct customer purchases light price increases new product product presentation launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations company relies variety methods calculate months hand businesses reporting segments available company relies information provided third parties determine estimates aggregate product level inventory hand direct customers expected demand businesses reporting segments listed however company limited information direct customer product level inventory enduser consumption direct customer outmovement data quality thirdparty information available varies widely circumstances case new products seasonal products historical enduser consumption outmovement information may available applicable cases company uses estimated prospective demand cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available company developed variety methodologies calculate estimates data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand september company entered exclusive distributorship arrangements certain products several eastern central european markets september december september dafalgan analgesic product sold principally europe approximately months inventory hand respectively direct customers level inventory hand due primarily private pharmacists purchasing dafalgan approximately every eight weeks seasonality product september efferalgan analgesic product sold principally europe approximately months inventory hand direct customers level inventory hand due primarily private pharmacists purchasing efferalgan approximately every eight weeks seasonality product september reyataz antiviral product approximately months inventory hand direct customers increased level inventory hand due primarily government purchasing patterns brazil december september videxvidex ec antiviral product approximately months inventory hand direct customers increased level inventory hand due primarily government purchasing patterns brazil company contractually obligated provide videxvidex ec brazilian government upon placement order product government terms contract company control inventory levels relating orders company however expects inventory levels videxvidex ec worked december september nutramigen infant nutritional product sold principally us approximately months inventory hand direct customers level inventory hand end quarter ended december due primarily holiday stocking retailers quarter ended september due primarily impact retailers holding higher levels inventory response hurricane katrina company continuously seeks improve quality estimates months hand inventories held direct customers including thorough review methodologies processes calculation estimates thorough review analysis third parties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze third parties data calculations company also continue take steps expedite receipt processing data nonus pharmaceuticals businesses health care group combined revenues health care group increased million compared period despite unfavorable impact divestiture us canadian consumer medicines consumer medicines business third quarter combined revenues health care group increased million compared period nutritionals composition change nutritionals sales follows analysis change total change volume price foreign exchange vs vs key nutritionals product lines sales representing total nutritional sales respectively follows change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals enfagrow worldwide nutritionals sales increased including favorable foreign exchange impact million worldwide nutritionals sales million increase including favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million first quarter company divested adult nutritional business international sales increased including favorable foreign exchange impact million primarily due increased sales childrens nutritional products international sales increased including favorable foreign exchange impact despite unfavorable impact divestiture adult nutritional business million million primarily due increased sales enfamil enfagrow us sales increased million primarily due increased sales enfamil us sales increased despite unfavorable impact divestiture adult nutritional business million million primarily due increased sales enfamil health care health care segment includes convatec medical imaging business well consumer medicines business third quarter company sold consumer medicines business related assets composition change health care segment sales follows analysis change total change volume price foreign exchange vs vs health care sales decreased million compared period included unfavorable impact divestiture consumer medicines business health care sales decreased million compared period included unfavorable impact divestiture consumer medicines business health care sales business key products years ended december follows change dollars millions vs vs convatec ostomy wound therapeutics medical imaging cardiolite consumer medicines worldwide convatec sales increased including favorable foreign exchange impact million ostomy sales increased million including favorable foreign exchange impact sales wound therapeutic products increased including favorable foreign exchange impact million million primarily due continued growth aquacel franchise worldwide convatec sales increased including favorable foreign exchange impact million million primarily due increase worldwide sales wound therapeutic products worldwide medical imaging sales increased million growth primarily due increase technelite technetium tcm generator sales resulting competitors market absence first quarter increase definity sales competitors continued absence market cardiolite sales decreased million million primarily due decreased price medical imaging sales increased million million primarily due increased demand cardiolite geographic areas general companys products available countries world largest markets us france japan canada spain italy mexico germany companys sales geographic areas follows change dollars millions vs vs united states total europe middle east africa total western hemisphere total pacific total total sales us decreased primarily result lower sales plavix loss exclusivity pravachol april decrease sales partially offset growth remaining pharmaceutical growth drivers recently launched products sales us decreased result lower sales paraplatin glucophage franchise due continuing impact earlier exclusivity losses pravachol due lower demand resulting increased competition decrease sales mostly offset increased sales growth drivers including plavix abilify erbitux reyataz well strong sales growth enfamil sales europe middle east africa decreased result sales decline pravachol taxol paclitaxel resulting increased generic competition decrease sales partially offset increased sales major european markets reyataz avaproavalide sales decreased including favorable foreign exchange impact result sales decline taxol paclitaxel due increased generic competition pravachol due exclusivity loss select markets including uk netherlands decrease sales partially offset increased sales major european markets reyataz abilify launched europe second quarter sales western hemisphere countries increased including favorable foreign exchange impact primarily due increased sales avaproavalide canada key nutritional products partially offset decreased sales tequin pharmaceutical products sales increased including favorable foreign exchange impact primarily due increased sales plavix canada mexico reyataz brazil canada avaproavalide canada sales pacific region remained consistent compared sales increased result increased sales taxol paclitaxel japan enfagrow enfamil china expenses change vs vs dollars millions cost products sold net sales marketing selling administrative net sales advertising product promotion net sales research development net sales acquired inprocess research development net sales provision restructuring net net sales litigation charges net net sales gain sale businesses net sales equity net income affiliates net sales expense net net sales total expenses net net sales excess cost products sold percentage sales increased compared company included million percentage sales certain costs cost products sold reported marketing selling administrative expenses prior year results addition reclassification increase primarily due unfavorable impact pharmaceutical net sales mix including lower sales plavix impairment charges tequin emsam related assets well manufacturing facility cost products sold percentage sales unfavorable impact gross margins resulting change us pharmaceuticals sales mix offset tequin impairment charges million net litigation charges recorded marketing selling administrative expenses decreased million compared including decrease resulting mentioned reclassification addition reclassification decrease primarily due lower sales force expenses resulting previously announced restructuring us primary care sales organization became effective march lower expenses pravachol partially offset impact adoption stock option expensing marketing selling administrative expenses increased million million primarily due higher legal costs higher pension expenses reflecting increased amortization unrecognized net losses well change actuarial assumptions partially offset lower sales force expenses resulting focus specialists high value primary care physicians marketing selling administrative expenses percentage sales included decrease reclassification compared respectively advertising product promotion expenditures decreased million compared primarily driven divestiture consumer medicines business lower spending mature brands partially offset increased investments new products including orencia sprycel advertising product promotion expenditures increased million compared million primarily due increased investments directtoconsumer marketing campaigns plavix abilify increased costs associated pre launch activities orencia launch baraclude partially offset lower spending mature products companys investment research development million increase investment research development million represented increase million increases reflect companys strategy continued investments latestage compounds developing pipeline disease areas address significant unmet medical need research development costs also included charges consisting primarily upfront milestone payments million primarily exelixis pharmaceuticals inc solvay global solvay million primarily medarex pierre fabre medicament sa pierre fabre million primarily pierre fabre solvay percentage sales research development expenses compared percentage sales impacted lower plavix sales acquired inprocess research development million related purchase acordis ukbased company additional information acquisition see item financial statementsnote acquisitions divestitures restructuring programs implemented realign streamline operations order increase productivity reduce operating expenses rationalize companys manufacturing network research facilities sales marketing organizations actions restructuring program expected substantially complete actions restructuring programs substantially completed december result actions company expects future annual benefit earnings continuing operations minority interest income taxes approximately million million million programs respectively additional information restructuring see item financial statementsnote restructuring litigation charges net settlement income insurance recoveries million million million million net charge consisted increase reserves million settlement principle certain pricing sales investigations partially offset insurance recoveries million unrelated matter million income settlement litigation matter million net charge consisted increases reserves million liabilities primarily related private litigations governmental investigations partially offset insurance recoveries million million charge consisted million related private litigation governmental investigations related wholesaler inventory issues accounting matters million related platinol litigation settlement million related pharmaceutical pricing sales practices additional information litigation see item financial statementsnote legal proceedings contingencies gain sale businesses million million net tax related sale inventory trademark patent intellectual property rights related dovonex gain sale businesses million million net tax related sale consumer medicines business related assets gain sale business million million net tax related sale adult nutritional business additional information transactions see item financial statementsnote acquisitions divestitures equity net income affiliates million compared million million respectively equity net income affiliates principally related companys joint venture sanofi investment imclone million increase equity net income affiliates primarily due increased net income joint venture sanofi income equity investment imclone compared loss million increase equity net income affiliates primarily reflects increase net income sanofi joint venture partially offset net loss investment imclone additional information equity net income affiliates see item financial statementsnote alliances investments expense net million million million respectively expense net includes net interest expense foreign exchange gains losses income thirdparty contract manufacturing royalty income expense debt retirement costs gains losses disposal property plant equipment gains losses sale marketable securities certain litigation matters million increase expense net primarily due higher debt retirement costs connection repurchase billion notes due compared repurchase billion notes due well million nonrecurring income resulting termination muraglitazar collaborative agreement partially offset lower net foreign exchange losses million decrease expense net primarily due deferred income recognized termination collaborative agreement muraglitazar partially offset debt retirement costs connection repurchase billion notes due higher net foreign exchange losses additional information see item financial statementsnote expense net stockbased compensation expense recognized statement financial accounting standard sfas revised sharebased payment sfas r year ended december million charges recorded cost product sold marketing selling administrative expenses research development expenses stockbased compensation expense recognized accounting principles board apb years ended december million million respectively expenses recorded marketing selling administrative expenses years ended december company recorded several expenseincome items affected comparability results periods presented herein set forth following table discussion items see item financial statementsnote alliances investments note restructuring items note acquisitions divestitures note income taxes note intangible assets note shortterm borrowings longterm debt note legal proceedings contingencies marketing litigation research selling provision settlement year ended december cost restructuring expense expense gain sale dollars millions products sold development admin net income income net product asset total litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments streamlining worldwide operations gain sale product asset income taxes items change estimate taxes prior year items reduction net earnings continuing operations litigation research provision gain settlement year ended december cost sale expense expense dollars millions products sold development restructuring business income income net total litigation matters private litigation governmental investigations erisa liability matters pharmaceutical pricing sales litigation insurance recoveries accelerated depreciation asset impairment debt retirement costs streamlining worldwide operations upfront milestone payments loss sale fixed assets gain sale equity investment termination muraglitazar agreement gain sale consumer medicines businesses income taxes items adjustment taxes repatriation foreign earnings increase net earnings continuing operations acquired litigation expense cost research inprocess gain provision settlement year ended december products research sale restructuring expense income dollars millions sold development development business net income net total litigation matters private litigation governmental investigations product liability antitrust litigation pharmaceutical pricing sales litigation commercial litigation product liability insurance recovery accelerated depreciation streamlining worldwide operations acordis iprd writeoff upfront milestone payments gain sale adult nutritional business income taxes items deferred taxes anticipation repatriation foreign earnings tax adjustments reduction net earnings continuing operations earnings minority interest income taxes earnings continuing operations minority interest income taxes change dollars millions vs vs pharmaceuticals nutritionals health care health care group total segments corporateother total excess earnings continuing operations minority interest income taxes decreased million million decrease primarily driven net impact items affected comparability results discussed lower net sales pharmaceutical products resulting lower plavix net sales loss exclusivity pravachol increased spending research development partially offset increase equity net income affiliates lower advertising promotion expenses earnings continuing operations minority interest income taxes increased million million increase primarily result growth nutritionals segment net impact items affected comparability results discussed partially offset lower sales gross margin pharmaceutical products primarily due exclusivity losses increased spending research development primarily latestage pharmaceutical compounds pharmaceuticals earnings minority interest income taxes million decrease primarily due lower net sales result lower plavix sales loss exclusivity pravachol investment research development continued investment key growth drivers new products earnings minority interest income taxes million decreased million primarily due lower net sales gross margin primarily related exclusivity losses higher advertising product promotion investments behind growth drivers increased spending research development health care group nutritionals earnings minority interest income taxes million increase primarily due sales growth childrens nutritional products partially offset increased investments advertising expense research development programs earnings minority interest income taxes million increased million primarily due increased worldwide sales infant formula products international sales toddler childrens nutritional products partially offset increased investments advertising product promotion research development programs health care earnings minority interest income taxes million increase primarily driven increased sales convatec medical imaging businesses earnings minority interest income taxes million decreased million primarily due sale consumer medicines business third quarter higher spending research development partially offset sales growth convatec medical imaging businesses corporateother loss minority interest income taxes million increase primarily due higher debt retirement costs compared lower gain sale product asset compared consumer medicines business million income resulting termination muraglitazar collaborative agreement well lower insurance recoveries compared partially offset lower litigation charges compared loss minority interest income taxes million decreased million primarily due increase gain sales businessesproduct lines deferred income recognized termination collaborative agreement muraglitazar reduction litigation charges net income taxes effective income tax rate earnings continuing operations minority interest income taxes compared increase effective tax rate compared resulted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement internal revenue service irs examination favorable adjustment taxes special dividends american jobs creation act ajca partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions decrease effective tax rate due primarily charge approximately million taxes special dividends ajca charge related establishment valuation allowance certain charitable contributions tax benefits discussed partially offset lower estimated foreign tax credits company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see item financial statementsnote legal proceedings contingencies companys us federal income tax returns currently examination irs irs proposed significant disallowance certain litigation settlement expenses significant reduction us foreign tax credits claimed following companys previously disclosed international restructuring irs position latter matter also affects us foreign tax credits claimed company although year currently examination company believes strong positions respect issues intends contest irs positions possible predict outcome issues company established tax contingency reserves reflect best estimate probable tax liability matters company prevail final nonappealable determination matters amount loss excess established reserves could material adverse effect companys results operations however company believe determination would material adverse effect cash flows minority interest minority interest net taxes decreased million million primarily due lower earnings companys partnership sanofi territory covering americas resulting impact august atrisk launch generic clopidogrel bisulfate discontinued operations may company completed sale otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment discussions otn see item financial statementsnote discontinued operations following amounts related otn business segregated continuing operations reflected discontinued operations periods presented year ended december dollars millions net sales loss income taxes loss net taxes financial position liquidity capital resources cash cash equivalents marketable securities approximately billion december compared billion december company continues maintain sufficient level working capital approximately billion december decreasing billion december noted recent developments pending patent litigation involving plavix including generic launch apotex august currently subject preliminary injunction halted sales apotex trial underlying patent litigation ended february court expected rule following posttrial briefing apotex prevail trial company would expect plavix would face renewed generic competition promptly thereafter subject risks company currently believes absence renewed additional generic competition plavix generic pharmaceutical companies future periods cash generated us operations together existing cash borrowings capital markets sufficient cover cash needs working capital capital expenditures company expects include substantial investments facilities increase maintain companys capacity provide biologics commercial scale milestone payments dividends paid us cash cash equivalents marketable securities conversion workingcapital items borrowings expected fund nearterm operations circumstances renewed additional generic competition plavix would material companys sales plavix results operations cash flows could material companys financial condition liquidity additional information pending plavix patent litigation recent adverse developments included item financial statementsnote legal proceedings contingenciesintellectual property plavix litigation executive summaryplavix fourth quarter company disclosed anticipated repatriating approximately billion special dividends recorded million provision deferred income taxes pursuant ajca enacted pending matters company repatriated approximately billion foreign subsidiaries first quarter repatriated remaining balance approximately billion fourth quarter company used expects continue use special dividends accordance requirements established ajca us treasury department second quarter us treasury department issued ajca related guidance clarifying grossup foreign taxes associated special dividends also qualifies tax rate established ajca result guidance company reduced million provision recording benefit approximately million tax provision except earnings associated special dividends discussed us income taxes provided balance unremitted earnings nonus subsidiaries since company invested expects invest earnings permanently offshore december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided cash cash equivalents december primarily consisted us dollar denominated bank deposits original maturity three months less marketable securities december primarily consisted us dollar denominated floating rate instruments aaaaaa credit rating due nature instruments company considers reasonable expect fair market values significantly impacted change interest rates liquidated cash short notice average interest yield invested cash cash equivalents december respectively interest yields marketable securities averaged respectively september company sanofi posted million towards million bond court collateral support preliminary injunction company pledged issuer bond collateral million bond consisting shortterm high quality securities collateral reported marketable securities companys consolidated balance sheet december terms pledge agreement company entitled receive income generated marketable securities make certain investment strategy decisions restricted using million pledged securities purpose time bond cancelled december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million deferred reduce future lease rental costs lease periods ranging years shortterm borrowings end million million respectively company maintains cash balances shortterm investments excess shortterm borrowings longterm debt billion december compared billion december fourth quarter company restructured longterm debt retiring outstanding billion principal amount notes due cash tender offer subsequent redemption issuing million aggregate principal notes due million aggregate principal notes due well billion aggregate principal notes due company incurred aggregate pretax expense approximately million connection early redemption notes termination related interest rate swaps included writeoff related unamortized discount issuance costs deferred loss interest rate lock longterm debt december also included japanese yen debt billion yen december company replaced prior billion revolving credit facility new billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december august whollyowned subsidiary company entered new billion term loan facility syndicate lenders borrowings facility guaranteed company subsidiaries borrower certain european subsidiaries company facility contains fiveyear tranche billion twoyear tranche million fully drawn december fourth quarter company repaid entire million twoyear tranche million fiveyear tranche company subject substantially covenants included december revolving credit facility company also subject restrictions including certain financial covenants prior borrowing proceeds facility company obtained waiver lenders covenant default facility due onetime intercompany distribution december company full compliance covenants second quarter company repurchased outstanding billion aggregate principal amount notes due incurred aggregate pretax loss approximately million connection early redemption notes termination related interest rate swaps majority companys debt fixed rate company however entered fixed floating interest rate swaps billion longterm debt including billion euro interest expense net interest swap gains million million million respectively increase interest expense primarily due higher interest rates moodys investors service moodys longterm shortterm credit ratings company currently prime respectively following downgrade longterm credit rating third quarter moodys longterm credit rating amended negative outlook stable outlook third quarter standard poors sp longterm shortterm credit ratings company currently respectively sps longterm credit rating remains negative outlook fitch ratings fitch longterm shortterm credit ratings company currently f respectively fitch placed company rating watch negative following discussion working capital december dollars millions working capital decrease working capital million december december impacted decrease cash marketable securities primarily due repayment longtem debt lower receivables primarily due lower plavix sales loss exclusivity pravachol mostly offset higher receivables due alliance partners increase inventories support growth drivers recently launched products mostly offset reduction pravachol inventory resulting loss exclusivity reduction deferred tax assets primarily due litigation settlement payments lower accounts payable due lower purchases pravachol raw materials increase deferred income resulting higher deferred alliance revenue lower accrued rebates returns primarily due exclusivity loss pravachol volume erosion highly rebated paraplatin taxol paclitaxel lower plavix volumes partially offset higher sales returns following discussion cash flow activities year ended december dollars millions cash flow provided byused operating activities investing activities financing activities net cash provided operating activities billion billion million increase compared mainly attributable significant changes adjustments net earnings million net changes operating assets liabilities million offset lower net earnings million significant positive changes adjustments net earnings compared million mainly included million positive cash flow variance deferred income tax expensebenefit due lower level increase deferred tax benefit compared increase deferred tax benefits associated us research development foreign tax credits increase litigation reserves increase deferred tax benefits associated reversal tax liability related repatriation special dividends ajca million positive cash flow variance due lower gain sale product asset compared sale business million positive cash flow variance deferred income recognized related termination muraglitazar collaborative agreement net positive changes operating assets liabilities compared million mainly included million negative cash flow variance receivables increase cash flow driven increases receivables due alliance partners partially offset lower trade receivable volume increase cash flow driven collection foreign withholding taxes alliance partners million positive cash flow variance inventories primarily due increase inventories resulting growth newer products anticipation new product launches reduction inventories resulting pravachol exclusivity loss million negative cash flow variance litigation primarily due settlement payments million dpa vanlev litigation partially offset unrelated insurance recoveries million million positive cash flow variance income taxes payable primarily related payments settlement examinations irs years repatriation special dividends ajca net cash provided investing activities million compared net cash provided million million negative cash flow variance primarily attributable million negative cash flow variance mainly sale marketable securities million negative cash flow variance lower proceeds sale product asset compared sale consumer medicines otn businesses million negative cash flow variance milestone payments primarily related imclone million positive cash flow variance proceeds disposal properties connection sale lease back transaction net cash used financing activities million compared million million positive cash flow variance mainly attributable million positive cash flow variance repayment shortterm borrowings negative cash flow variance retirement longterm debt company repaid debt million retired notes due million company retired notes due million net cash provided operating activities billion billion million decrease compared mainly attributable significant changes adjustments net earnings million net changes operating assets liabilities million offset higher net earnings million significant negative changes adjustments net earnings compared million mainly included million negative cash flow variance due primarily reversal million ajca deferred tax provision recorded million negative cash flow variance due lower litigation settlement expenses million negative cash flow variance due higher gain sale businesses compared net changes operating assets liabilities compared million mainly included million positive cash flow variance receivables increase cash flow receivables driven lower sales volume increase foreign withholding taxes receivable million positive cash flow variance primarily due lower litigation settlement payments well insurance recoveries million negative cash flow variance accounts payable accrued expenses primarily due vendor payments prior sale otn business lower accrued rebates returns compared million negative cash flow variance income taxes payable primarily related payments settlement examinations irs years repatriation special dividends ajca net cash provided investing activities million compared net cash used million million positive cash flow variance primarily attributable million positive cash flow variance mainly sale marketable securities compared purchases million positive cash flow variance higher proceeds sale consumer medicines otn businesses compared sale adult nutritionals business million positive cash flow variance due milestone payment imclone million positive cash flow variance due purchase acordis specialty fibres net cash used financing activities million compared million million negative cash flow variance mainly attributable million negative cash flow variance retirement commercial paper compared purchases million negative cash flow variance due repurchase billion notes due million positive cash flow variance proceeds borrowings new term loan facility cash provided operations borrowings primarily used past three years pay dividends approximately billion company also invested approximately billion past three years capital expansion improve plant efficiency maintain superior research facilities past three years company repurchase common stock total shares acquired since share repurchase programs inception million shares share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit program intended reduce increase shares outstanding option exercises obtain shares general corporate purposes dividends declared per common share december company declared quarterly dividend per common share indicated dividend full year per share dividend decisions made quarterly basis companys board directors companys financial condition liquidity could affected obligations make milestone onetime payments outcome pending litigations investigations including challenge plavix patent andor potential renewed additional generic competition plavix information see item financial statementsnote alliances investments note legal proceedings contingencies contractual obligations payments due period companys contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt operating leases purchase obligations standby letters creditperformance guarantees pension liabilities total current portion longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values contractual obligations table excludes interest payment obligations companys convertible debenture included due payment contains put call feature addition company committed make potential future milestone payments thirdparties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheet discussion contractual obligations see item financial statementsnote shortterm borrowings longterm debt note financial instruments note leases note pension postretirement benefit plans sec consent order deferred prosecution agreement previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september terms consent company agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice company also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer companys accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring companys budget process gives appropriate weight inputs come bottom top come top bottom adequately documenting process company agreed consent retain independent advisor date companys year ended filed sec independent advisor continues serve monitor dpa discussed previously disclosed june company entered dpa usao district new jersey resolving investigation usao company relating wholesaler inventory various accounting matters covered companys settlement sec pursuant dpa usao filed criminal complaint company alleging conspiracy commit securities fraud defer prosecution company dismiss complaint two years company satisfies requirements dpa copy dpa filed exhibit form k filed company june incorporated reference hereto exhibit w fiscal year ended december dpa among things company agreed include forms q k filed sec annual report shareholders following information estimated wholesalerdirect customer inventory levels top fifteen products sold us pharmaceuticals business b major nonus countries estimated aggregate wholesalerdirectcustomer inventory levels top fifteen pharmaceutical products sold countries taken whole measured aggregate annual sales countries c arrangements policies concerning wholesalerdirect customers distributors products including efforts company control monitor wholesalerdistributor inventory levels data concerning prescriptions measures enduser demand products pursuant dpa company also agreed include filings reports information acquisition divestiture restructuring reserve policies activity rebate accrual policies activity company also agreed implement remedial measures already undertaken mandated consent settlements derivative litigation federal securities class action relating wholesaler inventory various accounting matters addition company agreed undertake additional remedial actions corporate reforms actions including appointing additional nonexecutive director acceptable usao b establishing maintaining training education program topics include corporate citizenship financial reporting obligations c making additional million payment shareholder compensation fund established connection consent engaging attempting engage criminal conduct term defined dpa e continuing cooperate usao including respect ongoing investigation regarding individual current former employees company f retaining monitor also part dpa board separated roles chairman chief executive officer ceo company june elected nonexecutive chairman noted dpa company agreed engage attempt engage criminal conduct criminal conduct defined dpa crime related companys business activities committed one executive officers directors b securities fraud accounting fraud financial fraud business fraud materially affecting books records publicly filed reports company c obstruction justice usao discretion may prosecute company federal crimes usao knowledge including matters subject criminal complaint referenced usao determine company committed criminal conduct monitor defined powers responsibilities dpa including responsibility least april oversee companys compliance terms dpa consent settlements derivative action federal securities class action monitor authority require company take steps believes necessary comply terms dpa company required adopt recommendations made monitor unless company objects recommendation usao agrees adoption recommendation required addition monitor reports usao least quarterly basis companys compliance dpa implementation effectiveness internal controls financial reporting disclosure processes related compliance functions company september board announced companys current ceo general counsel would leaving respective positions effective immediately announcement took place board received considered reports companys outside counsel issues relating plavix patent litigation apotex preliminary recommendation monitor terminate employment individuals monitors recommendation followed investigation initiated usao conducted monitor usao corporate governance issues relating companys negotiations proposed settlement apotex company advised monitor usao investigation involve matters subject ongoing investigation antitrust division department justice plavix settlement agreement time monitor made preliminary recommendation monitor usao also advised company found violation dpa unlawful conduct company employees investigation included review whether violation federal securities laws connection proposed settlement apotex terms sec consent monitor completed investigation submitted report investigation usao monitors report find violation consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report additional information pending plavix patent litigation antitrust division investigation see item financial statements note legal proceedings contingencies company established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis company maintains imas us pharmaceutical wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect months hand product level inventories amount outmovement products three wholesalers currently account total gross sales us pharmaceutical products inventory information received wholesalers together companys internal information used estimate months hand product level inventories wholesalers company estimates months hand product inventory levels us pharmaceutical businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers company considers whether adjustments necessary extrapolated amounts based factors historical sales individual products made wholesalers thirdparty market research data related prescription trends patient demand contrast companys pharmaceutical business outside us nutritionals health care business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate months hand product level inventories business units company discloses top fifteen pharmaceutical products based net sales pharmaceutical products company views current future growth drivers sold us pharmaceuticals business amount net sales estimated number months hand us wholesaler distribution channel end immediately preceding quarter end applicable quarter well corresponding information prior year quarterly annual reports forms q k company discloses corresponding information top fifteen pharmaceutical products pharmaceutical products company views current future growth drivers sold within major nonus countries described business units company discloses quarterly basis key product level inventories information required estimate months hand product level inventories direct customer distribution nonus pharmaceuticals businesses available prior filing quarterly report form q applicable quarter accordingly company discloses information website approximately days end applicable quarter furnishes form k companys form q following quarter addition foregoing quarterly disclosure company include foregoing information business units immediately preceding quarter applicable quarter well corresponding information prior year annual report products described inventory direct customers exceeds approximately one month hand company disclose estimated months hand products except impact company de minimis company enhanced continue seek enhance methods estimate months hand product inventory levels us pharmaceuticals business nonus pharmaceuticals businesses around world taking account complexities described company also taken continue take steps expedite receipt processing data nonus pharmaceuticals businesses company believes abovedescribed procedures provide reasonable basis ensure compliance consent dpa provides sufficient information comply disclosure requirements recently issued accounting standards company adopted sfas r sharedbased payment requires measurement recognition compensation expense stock based payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march sec issued staff accounting bulletin sab sharebased payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fasb staff position fsp r transition election related accounting tax effects share based payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r february financial accounting standards board fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal years beginning november company evaluating pronouncement september fasb issued sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november adoption accounting pronouncement expected material effect companys consolidated financial statements september sec issued staff accounting bulletin sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staffs views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxesan interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits accordance fin company report difference net amount assets liabilities recognized statement financial position prior application fin cumulative effect adjustment opening balance retained earnings adoption accounting pronouncement expected material effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assetsan amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement expected material effect companys consolidated financial statements february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement expected material effect companys consolidated financial statements may fasb issued sfas accounting changes error corrections replaces apb opinion accounting changes sfas reporting accounting changes interim financial statements pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate affected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligations fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation adoption accounting pronouncement material effect companys consolidated financial statements december fasb issued fsp application sfas accounting income taxes tax deduction qualified production activities provided american jobs creation act fsp provides deduction qualified production activities treated special deduction described sfas accounting income taxes accordingly tax effect deduction reported component companys tax provision effect deferred tax assets liabilities may irs issued final tax regulations ftr respect deduction qualified production activities section internal revenue code final regulations effective taxable years beginning june adoption ftr fsp material impact companys consolidated financial statements december fasb issued sfas exchanges nonmonetary assets provisions statement effective nonmonetary asset exchanges occurring fiscal periods beginning june provisions statement applied prospectively eliminates exception fair value measurement nonmonetary exchanges similar productive assets paragraph b apb accounting nonmonetary transactions replaces exception exchanges commercial substance adoption accounting pronouncement material effect companys consolidated financial statements november fasb issued sfas inventory costsan amendment arb chapter pronouncement requires abnormal amounts idle facility related expenses recognized current period charges also requires allocation fixed production overheads costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years beginning june adoption accounting pronouncement material effect companys consolidated financial statements critical accounting policies company prepares financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following discussion represents critical accounting policies management discussed companys critical accounting policies audit committee board directors revenue recognition company recognizes revenue accordance sab revenue recognition financial statements amended sab revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue substantially risks rewards ownership transferred customer generally occurs date shipment exceptions described previous years certain transactions companys us pharmaceutical wholesalers accounted using consignment model case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue net gross net sales adjustments discussed involve significant estimates judgments consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout basis fifo case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns discussions revenue recognition see item financial statementsnote accounting policiesrevenue recognition sales rebate return accruals grosstonet sales adjustments company following significant categories grosstonet sales adjustments prime vendor chargebacks wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require company use information external sources company accounts grosstonet sales adjustments accordance emerging issues task force issue accounting consideration given vendor customer including reseller vendors products sfas revenue recognition right return exists applicable see net sales section reconciliation companys gross sales net sales significant category grosstonet sales adjustment prime vendor chargebacks companys us businesses participate prime vendor programs government entities significant us department defense us department veterans affairs parties whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower prime vendor price wholesalers charge difference acquisition cost lower prime vendor price back company company accounts prime vendor chargebacks reducing accounts receivable amount equal companys estimate chargeback claims attributable sale company determines estimate prime vendor chargebacks primarily based historical experience regarding prime vendor chargebacks current contract prices prime vendor programs company considers prime vendor payments levels inventory distribution channel companys claim processing time lag adjusts reduction accounts receivable periodically throughout quarter reflect actual experience wic rebates companys us nutritionals business participates competitive bidding basis nutrition programs sponsored states tribal governments commonwealth puerto rico us territories wic programs company reimburses entities difference wholesaler list price contract price eligible products company accounts wic rebates establishing accrual amount equal companys estimate wic rebate claims attributable sale company determines estimate wic rebate accrual primarily based historical experience regarding wic rebates current contract prices wic programs company considers levels inventory distribution channel new wic contracts terminated wic contracts changes existing wic contracts wic participation adjusts accrual periodically throughout quarter reflect actual experience managed health care rebates contract discounts company offers rebates discounts managed health care organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations company accounts managed health care rebates contract discounts establishing accrual amount equal companys estimate managed health care rebates contract discounts attributable sale company determines estimate managed health care rebates contract discounts accrual primarily based historical experience regarding rebates discounts current contract prices company considers sales performance products subject managed health care rebates contract discounts levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience medicaid rebates companys us businesses participate state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included companys medicaid rebate accrual considered medicaid rebates purposes discussion company accounts medicaid rebates establishing accrual amount equal companys estimate medicaid rebate claims attributable sale company determines estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates company considers outstanding medicaid claims medicaid payments levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience cash discounts us certain countries company offers cash discounts approximating sales price incentive prompt payment company accounts cash discounts reducing accounts receivable full amount discounts company considers payment performance adjusts accrual reflect actual experience sales returns company accounts sales returns accordance sfas revenue recognition right return exists establishing accrual amount equal companys estimate sales recorded related products expected returned provision sales returns million million million respectively gross sales three years returns established products company determines estimate sales return accrual primarily based historical experience regarding sales returns also considers factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products company considers factors adjusts accrual periodically throughout quarter reflect actual experience company considers level inventory distribution channel determines whether believes adjustment sales return accrual appropriate company adjusts sales return accrual based historical experience companys returned goods policy shelf life companys products life cycle product levels inventory distribution channel company considers introductions generic products factors impact sales returns calculation based historical experience companys returned goods policy event product recall product discontinuance company considers reasons impact actions adjusts sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product company historical experience products similar therapeutic category company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns company also considers shelf life new products determines whether believes adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products company may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases company assesses reduced shelf life together estimated levels inventory distribution channel projected demand determines whether believes adjustment sales return accrual appropriate adjustments addition grosstonet sales adjustments described company makes grosstonet sales adjustments example company offers sales discounts significantly nonus businesses also offers consumer coupons rebates significantly us nutritionals pharmaceuticals business addition number countries outside us including major european countries company provides rebates government entities company generally accounts grosstonet adjustments establishing accrual amount equal companys estimate adjustments attributable sale company generally determines estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjusts accruals periodically throughout quarter reflect actual experience use information external sources company uses information external sources estimate grosstonet sales adjustments companys estimates inventory wholesalers deferred revenue consigned inventory based projected prescription demandbased sales products historical inventory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data companys internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals company receives information ims supplier market research pharmaceutical industry uses project prescription demandbased sales many us pharmaceutical products company historically reported estimated total us prescription growth estimated therapeutic category share based npa data ims made available public subscription basis simple average estimated number prescriptions retail mail order channels third quarter company began disclosing estimated total us prescription growth estimated therapeutic category share based npa ngps version data ngps version data collected ims new revised methodology released ims limited basis pilot program ims announced ngps version data available public subscription basis starting january legacy npa ngps version discontinued company believes ngps data provided ims provides superior estimate prescription data companys products retail mail order channels company calculated estimated total us prescription growth estimated therapeutic category share based ngps data weighted average basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions company believes calculation estimated total us prescription growth estimated therapeutic category share based ngps data weighted average approach respect retail mail order channels provide superior estimate total prescription demand company uses methodology internal demand forecasts company also uses information external sources identify prescription trends patient demand average selling prices companys estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date company receives thirdparty information retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers accounting pensions sfas employers accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows plan description company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular full time employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans ie us plans together international plans benefits companys defined benefit pension plans based primarily years credited service participants compensation assets companys defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets companys defined benefit plans increased million million december us plans assets allocated equity securities compared end fixed income securities compared end private equity investments compared end bristolmyers squibb common stock represented less assets us plans end company provides comprehensive medical group life benefits substantially us retirees elect participate companys comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent requirements sfas company accounts pension benefits using accrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate company uses yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup median yield curve used determining discount rate us plans assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense companys defined benefit pension plans included earnings minority interest income taxes million compared million us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed rate compensation increase assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining accumulated benefit obligation december reduced accumulated benefit obligation would increased million us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million actual rates return earned us plan assets last years follows year return year return december company increased assumed discount rate us plans maintained assumed rate compensation increase compensation assumed increase scale different rates different ages rate disclosed december single rate used age would produce present value benefit obligations company maintained expected rate return us plan assets company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million lower million reflecting primarily positive delayed impact favorable investment returns company used assumed discount rates expected longterm rates return plan assets calculating cost pension benefits cost postretirement benefits us plans except case discount rates december rates respectively used pension benefits versus respectively postretirement benefits reflect shorter duration postretirement liabilities december respectively us health care costs retiree population assumed increase trend expected increase per year actual costs higher assumed likely put significant upward pressure companys expense retiree health care effects medicare prescription drug improvement modernization act reflected net periodic postretirement benefit cost reduction million accumulated postretirement benefit obligation january reduction million recognition actuarial gains losses sfas requires recognition actuarial gains losses component stockholders equity accumulated comprehensive income sfas provides delayed recognition years prior amounts arise changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial loss gain exceeds greater projected benefit obligation marketrelated value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years unrecognized net actuarial loss reflects large part steady reduction weightedaverage discount rate years unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization unrecognized loss expected increase pension expense million progressively lower amounts following nine years plan funding companys funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed million million defined benefit plans respectively discussions retirement benefits see item financial statementsnote pension postretirement benefit plans acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combination used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred discussions acquired inprocess research development see item financial statementsnote accounting policiesacquired inprocess research development impairment longlived assets accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value accordance sfas goodwill intangible assets goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds estimated fair value intangible assets evaluated impairment accordance sfas described estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge discussions impairment longlived assets see item financial statementsnote accounting policiesimpairment longlived assets goodwill intangible assets equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys investment imclone subject accounting discussion companys investment imclone see item financial statementsnote alliances investments discussions equity investments see item financial statementsnote accounting policiesinvestments note alliances investments restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates adjustments million million million recorded respectively reflect changes estimates restructuring actions taken prior periods discussions restructuring see item financial statementsnote accounting policiesrestructuring note restructuring items contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussions contingencies see item financial statementsnote accounting policiesincome taxes contingencies note income taxes note legal proceedings contingencies income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively increase net deferred tax assets primarily resulted adoption sfas see item financial statementsnote income taxes note pension postretirement benefit plans company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see item financial statementsnote legal proceedings contingencies company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes stockbased compensation expense company adopted sfas r sharebased payment requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values company uses modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity comparatively pro forma basis stockbased compensation expense million million million million net tax respectively recognized years ended december respectively apb additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r company estimates fair value stockbased payment awards date grant using optionpricing model value portion award ultimately expected vest recognized expense requisite service periods companys consolidated statement earnings prior adoption sfas r company accounted stockbased awards employees directors using intrinsic value method related stock options accordance apb allowed sfas accounting stockbased compensation intrinsic value method stockbased compensation expense recognized companys consolidated statement earnings exercise price companys stock options granted employees directors equaled fair market value underlying stock date grant stockbased compensation expense recognized period based value portion stockbased payment awards ultimately expected vest period stockbased compensation expense recognized companys consolidated statement earnings year ended december included compensation expense stockbased payment awards granted prior yet vested january based grant date fair value estimated accordance pro forma provisions sfas r compensation expense stockbased payment awards granted subsequent january based grant date fair value estimated accordance provisions sfas r conjunction adoption sfas r company changed method attributing value stockbased compensation expense accelerated multipleoption approach straightline single option method compensation expense stockbased payment awards granted prior continue recognized using accelerated multipleoption approach compensation expense stockbased payment awards service condition granted subsequent january recognized using straightline singleoption method stockbased payment awards granted subsequent january service market condition recognized using accelerated multipleoption approach required sfas r prior company applied apb opinion recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date however grants restricted stock company recognized compensation expense straightline basis period restrictions expire fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model following assumptions expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company determines fair value certain stockbased payment awards date grant using optionpricing model model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors respect accounting treatment retirement eligibility provisions employee stockbased compensation awards company historically followed nominal vesting period approach upon adoption sfas r company follows nonsubstantive vesting period approach recognizes compensation cost oneyear period awards granted retirement eligible employees period grant date date retirement eligibility achieved one year less vesting period impact applying nonsubstantive vesting period approach material companys consolidated financial statements stockbased compensation expense recognized consolidated statement earnings year ended december based awards ultimately expected vest reduced estimated forfeitures company estimates forfeitures time grant revised necessary subsequent periods actual forfeitures differ estimates companys pro forma information required sfas periods prior company accounted forfeitures occurred special note regarding forwardlooking statements annual report written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years company included important factors cautionary statements included annual report company believes could cause actual results differ materially forwardlooking statement although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes gains losses hedging transactions offset gains losses underlying exposures hedged ineffective portion hedges reported earnings occurs companys primary net foreign currency translation exposures euro japanese yen mexican peso chinese renminbi canadian dollar company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate table summarizes companys outstanding foreign exchange forward contracts december fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average fair value dollars millions except currency rates strike price notional amount assetliability maturity foreign exchange forwards australian dollar british pound canadian dollar euro japanese yen mexican peso swedish krona swiss franc total contracts december company held foreign exchange forward contracts maturity dates december company hold foreign exchange option contracts notional amounts fair values foreign exchange forward contract maturity dates expressed table dollars millions year maturity notional amount fair value december fair value companys foreign exchange forward contracts net liability million million recorded noncurrent asset million recorded current liability company estimates appreciation depreciation underlying currencies hedged levels dollar december variables held constant would decrease increase respectively million fair value foreign exchange forward contracts held december company obligated settle foreign exchange forward contracts based specified contract rates december balance deferred net aftertax losses foreign exchange forward contracts included accumulated comprehensive income million net aftertax loss million estimated reclassified earnings within next months december company held foreign exchange forward contracts aggregate notional amount million fair value foreign exchange forward contracts net asset million million recorded noncurrent asset million recorded current liability contracts primarily related exposures euro canadian dollar australian dollar company estimates appreciation depreciation underlying currencies hedged levels dollar december variables held constant would decrease increase respectively million fair value foreign exchange forward contracts held december years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges loss million gain million gain million respectively furthermore company uses foreign exchange forward contracts offset exposure certain currency assets liabilities foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur amounts recognized earnings related foreign exchange forward contracts qualify hedge accounting treatment significant company also uses foreign exchange forward contracts hedge foreign currency denominated monetary assets liabilities primary objective foreign exchange forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro foreign exchange forward contracts designated hedges marked market incomeexpense notional fair value amounts purchased foreign exchange forward contracts million million asset respectively december million million liability respectively december notional fair value amounts sold foreign exchange forward contracts million million liability respectively december million million asset respectively december addition foreign exchange forward contracts noted company uses non us dollar borrowings lesser extent foreign exchange forward contracts hedge foreign currency exposures companys net investment certain foreign affiliates non us dollar borrowings foreign exchange forward contracts designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component comprehensive income december million tax losses million tax gains respectively recorded foreign currency translation component accumulated comprehensive income company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion euro billion companys newly issued fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt total notional amount outstanding interest rate swaps billion billion euros billion december billion december respectively accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million net reduction interest expense million million respectively impact interest rate swaps sfas requires revaluation fair value swap contracts well underlying debt hedged swap contracts underlying debt revalued resulting increase noncurrent assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated comprehensive income amortized earnings remaining life debt following tables summarize interest rate swaps outstanding december terminated interest rate swaps notional amount underlying variable rate year fair interest rate contracts debt received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million eur notes due month eur euribor million eur notes due month eur euribor notes due month us libor notes due month us libor terminated swap contracts total pretax pretax pretax year notional amount deferred incomeexpense incomeexpense interest rate contracts termination underlying debt gainloss recognized recognized dollars millions interest rate swap lock associated notes due interest rate swap lock associated notes due swaps associated notes due swaps associated notes due swaps associated notes due swaps associated notes due underlying notes extinguished respectively december company held interest rate swap contracts notional value billion billion euro billion fair value net liability million estimated increase decrease basis points shortterm longterm interest rates would material impact companys consolidated financial position results operations cash flows company million million longterm debt outstanding december respectively additional information see item financial statementsnote shortterm borrowings longterm debt see note financial instruments company maintains cash cash equivalents marketable securities various financial institutions order limit exposure one financial institution financial institutions headquartered primarily north america europe bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation charges net gain sale product asset businesses equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations earningsloss net taxes gain disposal net taxes net earnings earnings per common share basic earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share diluted earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements bristolmyers squibb company consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation tax effect net tax liability tax benefit deferred gainslosses derivatives qualifying hedges net tax benefit net tax liability minimum pension liability adjustment net tax liability net tax benefit available sale securities net tax liability net tax benefit tax effect total comprehensive incomeloss comprehensive income retained earnings retained earnings january net earnings cash dividends declared retained earnings december accompanying notes integral part financial statements bristolmyers squibb company consolidated balance sheets dollars millions except per share data december assets current assets cash cash equivalents marketable securities receivables net allowances inventories net deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances prepaid pension assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns deferred income us foreign income taxes payable dividends payable accrued litigation liabilities total current liabilities pension postretirement liabilities deferred income liabilities longterm debt total liabilities commitments contingencies note stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax benefitsexpense litigation settlement expense net recoveries stockbased compensation expense provision restructuring gain sale product asset businesses deferred income recognized acquired inprocess research development impairment charges asset writeoffs loss disposal property plant equipment investment companies deferred expenses extinguishment longterm debt underover distribution earnings affiliates unfunded pension expense changes operating assets liabilities receivables inventories prepaid expenses assets litigation settlement payments net insurance recoveries accounts payable accrued expenses deferred income product liability us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities purchases proceeds marketable securities net additions property plant equipment capitalized software proceeds disposal property plant equipment investment companies proceeds sale product assets businesses proceeds sale leaseback properties upfront milestone payments purchase acordis speciality fibres purchases trademarks patents licenses businesses investments companies divestiture acquisition costs net cash provided byused investing activities cash flows financing activities shortterm borrowingsrepayments longterm debt borrowings longterm debt repayments charges extinguishment longterm debt issuances common stock stock plans excess tax benefits sharebased payment arrangements dividends paid net cash used financing activities effect exchange rates cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period accompanying notes integral part financial statements note accounting policies basis consolidation consolidated financial statements include accounts bristolmyers squibb company bms company bristolmyers squibb controlled majorityowned subsidiaries intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity united states us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting stockbased compensation costs retirement postretirement benefits including actuarial assumptions actual results may may differ estimated results revenue recognition company recognizes revenue accordance staff accounting bulletin sab revenue recognition financial statements amended sab revenue recognition substantially risks rewards ownership transferred customer generally revenue recognized time shipment however case certain sales made nutritionals health care segments certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser revenues reduced time recognition reflect expected returns estimated based historical experience business trends additionally provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case sales made wholesalers result incentives excess wholesalers ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesalers cost carrying inventory excess wholesalers ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory companys cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers customers firstin firstout basis fifo case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns sales rebate return accruals medicaid rebate accruals million million december respectively women infants children wic rebate accruals million million december respectively sales return accruals million million december respectively managed health care rebate contractual discount accruals million million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals established similar manner recorded reduction accounts receivable million million december respectively note accounting policies continued income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made december company net deferred tax assets million million respectively net valuation allowances million million respectively company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known cash cash equivalents cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value marketable securities company accounts marketable securities accordance statement financial accounting standard sfas accounting certain investments debt equity securities company determined appropriate classification marketable securities availableforsale time purchase december companys investments marketable securities reported fair value unrealized gains losses reported component accumulated comprehensive income loss stockholders equity company follows investment managers method determining cost basis computing realized gains losses sale availableforsale securities average cost method realized gains losses included income expense note accounting policies continued inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included intangible assets million million december respectively amortization expense million million million years ended december respectively investments company accounts less owned companies ability exercise significant influence using equity method accounting otherwise cost method used companys share net income losses equity investments included equity net income affiliates consolidated statement earnings losses recognized income expense decline market value deemed temporary company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers accounting principles board apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment goodwill intangible assets goodwill tested impairment annually using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value company completed goodwill impairment assessment indicated impairment goodwill intangible assets consisting patents trademarks technology licenses capitalized software amortized straightline basis useful lives ranging years indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset intangible assets deemed impaired net carrying value exceeds estimated fair value intangible assets evaluated impairment described impairment longlived assets note accounting policies continued restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results may may vary estimates product liability accruals product liability including associated legal costs recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation charges consolidated statement earnings contingencies normal course business company subject loss contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters accordance sfas accounting contingencies company records accruals loss contingencies probable liability incurred amount loss reasonably estimated company accordance sfas recognize gain contingencies realized discussion contingencies see note income taxes note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statement earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss subsequently recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statement earnings shipping handling costs company typically charge customers shipping handling costs therefore shipping handling costs included marketing selling administrative expenses million million advertising costs advertising costs expensed incurred advertising expense million million million respectively research development research development costs expensed incurred company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners connection research development contingent upon achievement certain predetermined criteria milestones achieved prior regulatory approval product payments expensed research development milestone note accounting policies continued payments made connection regulatory approvals including nonus regulatory approvals additional indications capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable acquired inprocess research development fair value inprocess research development acquired business combination determined independent appraisal based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weighted average cost capital acquired process research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation statements earnings companys foreign subsidiaries translated us dollars using average exchange rates net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included accumulated comprehensive income oci recently issued accounting standards company adopted sfas revised sharebased payment sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb accounting stock issued employees periods beginning january march us securities exchange commission sec issued sab sharebased payment relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fasb staff position fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r february financial accounting standards board fasb issued sfas fair value option financial assets financial liabilities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet statement effective fiscal year beginning november company evaluating pronouncement september fasb issued statement sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r pronouncement requires employer recognize overfunded underfunded status defined benefit postretirement plan multiemployer plan asset liability statement financial position recognize changes funded status year changes occur comprehensive income business entity pronouncement also requires employer measure funded status plan date yearend statement financial position limited exceptions pronouncement require prior periods restated reflect impact sfas company adopted sfas fiscal year ended december adoption accounting pronouncement resulted million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows note accounting policies continued september fasb issued sfas fair value measurements pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements statement effective fiscal years beginning november adoption accounting pronouncement expected material effect companys consolidated financial statements september sec issued sab considering effects prior year misstatements quantifying misstatements current year financial statements expresses staffs views regarding process quantifying financial statement misstatements bulletin effective interim period first fiscal year ending november sab requires companies utilize dual approach assess quantitative effects financial statement misstatements dual approach includes income statement focus balance sheet focus assessment adoption bulletin effect companys consolidated financial statements july fasb issued fasb interpretation number fin accounting uncertainty income taxesan interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits accordance fin company report difference net amount assets liabilities recognized statement financial position prior application fin cumulative effect adjustment opening balance retained earnings adoption accounting pronouncement expected material effect companys consolidated financial statements march fasb issued sfas accounting servicing financial assetsan amendment fasb statement pronouncement relates accounting separately recognized servicing assets servicing liabilities statement effective fiscal years beginning september adoption accounting pronouncement expected material effect companys consolidated financial statements february fasb issued sfas accounting certain hybrid financial instruments amendment fasb statements pronouncement primarily resolves certain issues addressed implementation sfas accounting derivative instruments hedging activities concerning beneficial interests securitized financial assets statement effective financial instruments acquired issued subject remeasurement event occurring beginning fiscal year adoption accounting pronouncement expected material effect companys consolidated financial statements may fasb issued sfas accounting changes error corrections replaces apb opinion accounting changes sfas reporting accounting changes interim financial statements pronouncement applies voluntary changes accounting principle revises requirements accounting reporting change accounting principle sfas requires retrospective application prior periods financial statements voluntary change accounting principle unless impracticable pronouncement also requires change method depreciation amortization depletion longlived nonfinancial assets accounted change accounting estimate affected change accounting principle sfas effective accounting changes corrections errors made fiscal years beginning december statement change transition provisions existing accounting pronouncements including transition phase effective date sfas adoption accounting pronouncement material effect companys consolidated financial statements march fasb issued fin accounting conditional asset retirement obligations fin clarifies entity must record liability conditional asset retirement obligation fair value obligation reasonably estimated asset retirement obligations covered fin entity legal obligation perform asset retirement activity even timing method settling obligation conditional future event may may within control entity fin also clarifies entity would sufficient information reasonably estimate fair value asset retirement obligation company adopted provisions fin fiscal year ended december adoption accounting pronouncement material effect companys consolidated financial statements note accounting policies continued december fasb issued fsp application sfas accounting income taxes tax deduction qualified production activities provided american jobs creation act fsp provides deduction qualified production activities treated special deduction described sfas accounting income taxes accordingly tax effect deduction reported component companys tax provision effect deferred tax assets liabilities may internal revenue service irs issued final tax regulations ftr respect deduction qualified production activities section internal revenue code final regulations effective taxable years beginning june taxable years beginning prior effective date final regulations taxpayer may apply either final regulations provided taxpayer applies provisions final regulations subject certain limitations rules provided notice well proposed regulations issuance ftr adoption fsp material impact companys consolidated financial statements december fasb issued sfas exchanges nonmonetary assets provisions statement effective nonmonetary asset exchanges occurring fiscal periods beginning june provisions statement applied prospectively eliminates exception fair value measurement nonmonetary exchanges similar productive assets paragraph b apb accounting nonmonetary transactions replaces exception exchanges commercial substance adoption accounting pronouncement material effect companys consolidated financial statements november fasb issued sfas inventory costsan amendment arb chapter standard requires abnormal amounts idle facility related expenses recognized current period charges also requires allocation fixed production overheads costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years beginning june adoption accounting pronouncement material effect companys consolidated financial statements note alliances investments sanofiaventis company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix clopidogrel platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded sales territory comarketing countries outside territory germany italy spain greece million million million cash flows operating activities partnerships territory covering americas australia recorded operating activities within companys consolidated statement cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recorded within operating activities companys consolidated statement cash flows sanofi acts operating partner territory covering europe asia owns majority financial controlling interest within territory companys ownership interest partnerships within territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statement earnings companys share net income partnership entities taxes million million million note alliances investments continued company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia transactions recorded operating activities within companys consolidated statement cash flows company sanofi companies formed alliance copromotion irbesartan part company contributed irbesartan distribution rights us sanofi paid company total million two years ended december company accounted transaction sale interest license deferred amortizing million income expected useful life license approximately years formation irbesartan copromotion alliance company recognized income million million million respectively unamortized portion deferred income recorded liabilities section consolidated balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt product currently copromoted otsuka united kingdom uk germany france spain us germany spain product sold otsuka affiliate distributor company records alliance revenue contractual share otsukas net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred otsukas customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company customers agreement expires november us puerto rico entire european union eu agreement expires june country company exclusive right sell abilify agreement expires later tenth anniversary first commercial sale country expiration applicable patent country company recorded total revenue abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets amortized cost products sold remaining life agreement us ranging years company amortized cost products sold million million million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone systems incorporated imclone biopharmaceutical company focused developing targeted cancer treatments codevelopment copromotion erbitux us us food drug administration fda approved biologics license application bla erbitux use combination irinotecan treatment patients epidermal growth factor receptor egfrexpressing metastatic colorectal cancer refractory irinotecanbased chemotherapy use single agent treatment patients egfrexpressing metastatic colorectal cancer intolerant irinotecanbased chemotherapy also fda approved imclones chemistry manufacturing controls supplemental bla licensure bb manufacturing facility march fda approved erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company paid million milestone payment imclone fda approvals agreement imclone receives distribution fee based flat rate net sales north america addition company coexclusive right commercialize erbitux japan imclone previously granted coexclusive right merck kgaa japan december company japanese affiliate bmkk merck kgaa merck ltd imclone executed joint development agreement erbitux japan erbitux yet marketed japan although application submitted japanese pharmaceuticals medical devices agency use erbitux treating patients advanced colorectal cancer note alliances investments continued company accounts million approval milestones paid license acquisitions capitalized amortized cost products sold remaining term agreement ends company amortized cost products sold million million million respectively unamortized portion approval payments recorded intangible assets million million december respectively company accounts investment imclone equity method records share results equity net income affiliates consolidated statement earnings companys recorded investment market value holdings imclone common stock million approximately million december respectively million approximately million december respectively company holds million shares imclone stock representing approximately imclones shares outstanding december per share basis carrying value imclone investment closing market price imclone shares december respectively compared respectively december company determines equity share imclones net income loss eliminating imclones results milestone revenue imclone recognizes million preapproval milestone payments made company company recorded million preapproval milestone payments equity investment expensed remaining million acquired inprocess research development period milestone revenue recognized imclone excess million eliminated company determining equity share imclones results share imclones results operations company recorded net income million net loss million net income million company recorded net sales erbitux million million million gilead company gilead sciences inc gilead entered joint venture develop commercialize fixeddose combination companys sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate us canada july fda granted approval atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg treatment human immunodeficiency virus hiv infection adults atripla firstever oncedaily single tablet regimen hiv intended standalone therapy combination antiretrovirals gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture third party customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand company recorded efavirenz revenues million related atripla sales company accounts participation joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statement earnings company recorded equity loss joint venture gilead million million year ended december respectively summary financial information following summarized financial information companys equity investments joint venture sanofi europe asia dollars millions revenues gross profit net income current assets current liabilities note restructuring activities company recorded pretax charges million related termination benefits related costs workforce reductions approximately selling operating administrative personnel charges decreased million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company expects substantially complete activities termination dollars millions benefits exit costs total pharmaceuticals nutritionals health care subtotal changes estimates restructuring reflected statement earnings activities company recorded pretax charges million related termination benefits related costs workforce reductions streamlining worldwide operations charges million related employee termination benefits related expenses approximately selling administrative personnel includes restructuring us cardiovascularmetabolics primary care sales organization workforce headcount reduction million related retention bonuses million related asset impairments charges decreased million adjustments reflecting changes estimates restructuring actions taken prior periods following table presents detail charges segment type company substantially completed restructuring activities late termination relocation asset dollars millions benefits exit costs retention writedowns total pharmaceuticals nutritionals health care subtotal changes estimates restructuring reflected statement earnings activities company recorded pretax charges million relating termination benefits related costs workforce reduction streamlining worldwide operations charges million primarily related employee termination benefits related expenses approximately selling administrative manufacturing personnel million related primarily asset impairments million related consolidation certain research facilities million retention bonuses charges partially offset million adjustment reflecting changes estimates restructuring actions taken prior periods million gain sale research facility previously written restructuring following table presents detail charges segment type company substantially completed restructuring activities termination relocation asset dollars millions benefits exit costs retention write downs total pharmaceuticals health care corporateother subtotal changes estimates gain sale research facility restructuring reflected statement earnings note restructuring continued rollforward restructuring charges spending liabilities associated prior current actions follows employee termination exit cost dollars millions liability liability total balance january charges spending changes estimate balance december charges spending changes estimate balance december charges spending changes estimate balance december liabilities million million december respectively included accrued expenses consolidated balance sheet longterm liability million included liabilities december note acquisitions divestitures january company completed sale inventory trademark patent intellectual property rights us related dovonex treatment psoriasis warner chilcott company inc million cash addition company receive royalty based net sales dovonex end result transaction company recognized pretax gain million million net tax first quarter third quarter company completed sale us canadian consumer medicines consumer medicines business related assets novartis ag novartis terms agreement novartis acquired trademarks patents intellectual property rights consumer medicines million cash including impact working capital adjustment million attributable postclosing supply arrangement company novartis related assets include rights us consumer medicines brands latin america europe middle east africa results operations consumer medicines included companys consolidated statement earnings date disposal result transaction company recorded pretax gain million million net tax third quarter april company completed acquisition acordis speciality fibres acordis company purchased stock acordis million incurred million acquisition costs connection transaction december company accrued million liability based achievement production volumes recorded additional goodwill purchase price acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date million million allocated process research development immediately expensed million assigned identifiable intangible assets predominantly patents excess purchase price estimated fair values net assets acquired recorded goodwill acquisition accounted purchase method accordingly results operations included accompanying consolidated financial statements date acquisition february company completed divestiture adult nutritional business novartis million including million contingent achievement contractual requirements satisfied million upfront payment supply agreement company recorded total pretax gain million million net tax included million contingent payment million reduction company goodwill associated mead johnson product lines note discontinued operations may company completed sale oncology therapeutics network otn one equity partners llc cash proceeds million including impact preliminary working capital adjustment company recorded pretax gain million million net tax presented gain sale discontinued operations consolidated statement earnings otn previously presented separate segment following amounts related otn business segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided otn company costs allocated company otn services included legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december dollars millions net sales lossearnings incomes taxes net lossearnings discontinued operations consolidated statement cash flows includes otn business date disposition company uses centralized approach cash management financing operations accordingly debt allocated business cash flows operating activities discontinued operations consist outflows million year ended december cash inflows million year ended december cash flows used investing activities discontinued operations million year ended december investing activities year ended december note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common stock denominator basic earnings per share weighted average number common stock outstanding period denominator diluted earnings per share weighted average shares outstanding adjusted effect dilutive stock options assumed conversion convertible debt common stock computations basic diluted earnings per common share follows year ended december amounts millions except per share data basic earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings basic earnings per share average common shares outstanding earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share diluted earnings continuing operations interest expense conversion convertible debt net taxes discontinued operations loss net taxes gain disposal net taxes net earnings diluted earnings per share average common shares outstanding conversion convertible debt incremental shares outstanding assuming exercisevesting dilutive stock optionsrestricted stock earnings continuing operations discontinued operations loss net taxes gain disposal net taxes net earnings per common share weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million respectively million weightedaverage shares issuable well million interest expense net tax assumed conversion convertible debt included diluted earnings per share calculation dilutive note expense net components expense net year ended december dollars millions interest expense interest income foreign exchange transaction losses net expense net interest expense increased net interest swap losses million interest expense reduced net interest swap gains million million respectively interest income relates primarily cash cash equivalents investments marketable securities net includes income thirdparty contract manufacturing royalty income expenses debt retirement costs certain litigation matters gains losses disposal property plant equipment gains losses sale marketable securities deferred income recognized change net compared primarily due debt retirement costs deferred income recognized note income taxes components earnings loss continuing operations minority interest income taxes year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus note income taxes continued effective tax rate companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes dollars millions earnings continuing operations minority interest income taxes us statutory rate foreign tax effect operations ireland puerto rico switzerland state local taxes net valuation allowance us federal foreign contingent tax matters dividend repatriation ajca us federal research tax credit us federal foreign valuation allowance foreign effective income tax rate earnings continuing operations minority interest income taxes compared increase effective tax rate compared resulted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible tax benefits associated settlement irs examination favorable adjustment taxes special dividends american jobs creation act ajca partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions decrease effective tax rate due primarily charge approximately million taxes special dividends ajca charge related establishment valuation allowance certain charitable contributions tax benefits discussed partially offset lower estimated foreign tax credits note income taxes continued deferred taxes valuation allowance components current noncurrent deferred income tax assets liabilities december dollars millions acquired inprocess research development intercompany profit inventory items us federal foreign tax credit carryforward deferred income us federal research development tax credit carryforward us federal charitable contribution carryforward state net operating loss carryforwards foreign net operating loss carryforwards foreign deferred tax assets pension postretirement benefits depreciation share based compensation legal settlements net valuation allowance deferred tax assets net recognized deferred income taxescurrent deferred income taxesnoncurrent us foreign income taxes payable liabilitiesnoncurrent total includes impact million increase deferred tax benefits adoption sfas see note pension postretirement benefit plans valuation allowance million december relates million state deferred tax assets million foreign net operating loss tax credit carryforwards million state net operating loss tax credit carryforwards company currently believes likely realized company recorded significant deferred tax assets related us foreign tax credit carryforwards approximately million us research tax credit carryforwards approximately million expire varying amounts beginning realization foreign tax credit research tax credit carryforwards dependent generating sufficient domestic taxable income prior expiration although realization assured management believes likely deferred tax assets realized company anticipates increasing level domestic profitability time undertaking actions increasing biologics manufacturing capacity us implementing tax planning strategies increasing domestic profitability likely cause companys effective tax rate increase also enhance companys ability utilize foreign tax credit research tax credit carryforwards amount foreign tax credit research tax credit carryforwards considered realizable however could reduced near term plavix subject either renewed additional generic competition events occur company may need record significant valuation allowances us federal deferred tax assets discussion plavix related matters see note legal proceedings contingencies income taxes paid year million million million respectively current tax benefit realized upon exercise stock options charged capital excess par value stock amounted million million million respectively note income taxes continued december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation company recognized income tax benefit approximately million due settlement companys us federal income tax returns years companys us federal income tax returns currently examination irs irs proposed significant disallowance certain litigation settlement expenses significant reduction us foreign tax credits claimed following companys previously disclosed international restructuring irs position latter matter also affects us foreign tax credits claimed company although year currently examination company believes strong positions respect issues intends contest irs positions possible predict outcome issues company established tax contingency reserves reflect best estimate probable tax liability matters company prevail final nonappealable determination matters amount loss excess established reserves could material adverse effect companys results operations however company believe determination would material adverse effect cash flows note receivables major categories receivables follow december dollars millions trade receivables miscellaneous receivables less allowances receivables net miscellaneous receivables includes million net allowances million million net allowances million respectively related receivables alliance partners additional information companys alliance partners see note alliances investments note inventories major categories inventories follow december dollars millions finished goods work process raw packaging materials inventories net note property plant equipment major categories property plant equipment follow december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest million million million years ended december respectively included categories property plant equipment shown note goodwill changes carrying amount goodwill years ended december follows pharmaceuticals nutritionals health care discontinued dollars millions segment segment segment operations total balance january adjustments reduction due sale otn reduction due sale consumer medicines purchase price allocation adjustment balance december adjustments reduction due sale business purchase price allocation adjustments balance december note intangible assets december intangible assets consisted following december dollars millions patentstrademarks less accumulated amortization patentstrademarks net licenses less accumulated amortization licenses net technology less accumulated amortization technology net capitalized software less accumulated amortization capitalized software net total intangible assets net note intangible assets continued first quarter year company recorded impairment charges licenses million million respectively resulting actual estimated future sales declines tequin charges recorded cost products sold companys consolidated statement earnings march result fda approval erbitux use treatment head neck cancer company made million milestone payment imclone capitalized licenses third quarter company recorded impairment charge licenses million resulting lower expected sales emsam charge recorded cost products sold companys consolidated statement earnings amortization expense intangible assets years ended december million million million respectively expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years note shortterm borrowings longterm debt shortterm borrowings end million million respectively longterm debt billion december compared billion december fourth quarter company restructured longterm debt retiring outstanding billion notes due cash tender offer subsequent redemption issuing million million aggregate principal amount notes due million million aggregate principal amount notes due well billion aggregate principal amount notes due resulted million pretax expense comprised items discussed premium paid debt tender make whole million million respectively addition company recognized earnings million unamortized discount debt issuance costs associated debt incurred pretax loss million related termination remaining billion notional amount fixedtofloating interest rate swap agreements recognized earnings pretax unamortized portion million aforementioned loss incurred termination million notional amount fixedtofloating interest rate swaps occurred june furthermore november company recognized earnings accumulated comprehensive income pretax unamortized portion million loss incurred settlement interest rate lock contracts used manage exposure changes interest rates anticipated issuance longterm fixed rate debt december company replaced prior billion revolving credit facility new billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions substantially similar prior facility including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december company unused shortterm lines credit available trade finance facilities foreign banks million million december respectively august whollyowned subsidiary company entered billion term facility syndicate bank lenders borrowings facility guaranteed company subsidiaries borrower certain european subsidiaries company facility contained fiveyear tranche billion twoyear tranche million fully drawn december interest paid periodic basis agreed lenders annual rate equal applicable london interbank offered rate libor plus company subject substantially covenants included december revolving credit facility company also subject restrictions including certain financial covenants prior borrowing proceeds facility company obtained waiver lenders covenant default facility due one time intercompany distribution december company fully repaid twoyear tranche billion outstanding fiveyear tranche full compliance covenants note shortterm borrowings longterm debt continued second quarter company retired outstanding billion notes due incurred aggregate pretax expense approximately million connection early redemption notes termination related interest rate swaps components longterm debt follows december dollars millions notes due floating rate bank term facility due notes due floating rate convertible debentures due euro notes due euro notes due notes due floating rate bank term facility due notes due debentures due debentures due debentures due yen notes due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due companys outstanding billion convertible debentures pay interest quarterly annual rate equal month libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership company occurs bond initial conversion price conversion rate shares adjustable depending average closing prices applicable period maximum conversion rate shares company entered fixed floating interest rate swaps billion longterm debt conjunction new issuance billion notes due billion euro notes billion company executed several fixed floating interest rate swaps convert new fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt year ended december company realized net increase interest expense million result higher floating rates obtained swap agreements year ended december company recognized net reduction interest expense million reflects benefit lower floating rates obtained swap agreements november connection early retirement outstanding billion notes due company terminated remaining billion notional amount fixed floating interest rate swap agreements incurred pretax loss million april connection early redemption billion notes due company terminated billion notional amount fixedtofloating interest rate swap agreements incurred pretax loss million june company terminated million notional amount fixedtofloating interest rate swap agreements related billion notes due incurred pretax loss million loss amortized interest expense million million recognized respectively remaining loss million together million loss incurred unwind billion swap fully recognized september company terminated million notional amount fixedtofloating interest rate swap agreements related million debentures due gain million gain recognized interest expense remaining life debentures due approximately million recognized note shortterm borrowings longterm debt continued cash payments interest including payments due interest rate swaps million million million respectively companys cash receipts interest rate swaps million million million respectively excluded cash payments interest payments due period later dollars millions total years longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values companys convertible debenture included due payment contains put call feature described december company provided total million financial guarantees form standby letters credit performance bonds standby letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale company products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority companys outstanding financial guarantees expire within year expected funded note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock capital excess common shares treasury cost treasury par value restricted dollars shares millions issued shares stock stock stock balance january issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december issued pursuant stock plans options amortization restricted stock lapses forfeitures restricted stock balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share note stockholders equity continued accumulated balances related component comprehensive incomeloss net taxes follows deferred charges minimum pension accumulated foreign deferred pension currency incomeloss liability postretirement available comprehensive dollars millions translation effective hedges adjustment benefits sale securities incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss adjustments adoption sfas balance december note employee stock benefit plans employee stock plans companys stock incentive plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years generally company issues shares stock option exercise treasury stock additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price terms stock incentive plan authorized shares include outstanding shares per year well number shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year granted year shares cancelled forfeited expired also available future grant stock incentive plan provides granting common stock key employees subject restrictions continuous employment restrictions generally expire fouryear period date grant compensation expense recognized restricted period december million million shares restricted stock restricted stock units outstanding plan respectively years ended december approximately million million million shares respectively restricted stock restricted stock units granted weighted average fair value per common share respectively stock incentive plan also incorporates companys longterm performance awards awards delivered form target number performance shares threeyear cycle awards based cumulative earnings per share cumulative sales ultimate payout modified companys total stockholder return versus companies proxy peer group threshold targets met performance period payment made longterm performance award plan maximum performance three measures result maximum payout target december million million performance shares outstanding plan respectively million million million performance shares granted respectively fair value per common share respectively teamshare stock option plan terminated january fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally became exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december note employee stock benefit plans continued companys results operations year ended december reflect impact sfas r includes impact expensing stock options company elected alternative method provided fsp r determining companys pool excess tax benefits results operations years ended december restated reflect impact expensing stock options prepared accordance apb following table summarizes stockbased compensation expense net tax related employee stock options restricted stock longterm performance awards years ended december years ended december dollars millions cost products sold marketing selling administrative research development total stockbased compensation expense deferred tax benefit stockbased compensation net tax table reflects pro forma net income diluted net income per share years ended december year ended december dollars millions except per share data net earnings reported total stockbased employee compensation expense included reported net earnings net related tax effects total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma basic earnings per share reported pro forma diluted earnings per share reported pro forma costs related stockbased compensation capitalized period summary option activity follows shares common stock available issued weightedaverage shares millions option award plan exercise price shares balance january authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december note employee stock benefit plans continued weightedaverage grantdate fair value options granted company twelve months ended december respectively total intrinsic value options exercised twelve month periods ended december million million million respectively twelve months ended december company received million million million cash proceeds exercise stock options december million total unrecognized compensation cost related stock options expected recognized weightedaverage period years following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities remaining available future number securities issued weightedaverage exercise issuance equity upon exercise outstanding price outstanding compensation plans excluding options rights options rights securities reflected column shares millions b c plan category equity compensation plans approved security holders equity compensation plans approved security holders shares plan longer issued following table summarizes significant ranges outstanding exercisable options december shares millions options outstanding options exercisable weighted weighted average weighted aggregate average weighted aggregate remaining average intrinsic remaining average intrinsic range number contractual exercise price value number contractual exercise price value exercise prices outstanding life years per share millions exercisable life years per share millions total aggregate intrinsic value preceding table represents total pretax intrinsic value based companys average stock price december would received option holders option holders exercised options date total number inthe money options exercisable december million december million outstanding options exercisable weighted average exercise price december million shares common stock reserved issuance pursuant stock plans options conversions preferred stock stock option valuation fair value employee stock options granted estimated date grant prior january estimated using weighted average estimated per option value granted using blackscholes option pricing model following assumptions expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs note employee stock benefit plans continued company derived expected volatility assumption required blackscholes model calculating year historical volatility weighting equally derived implied volatility consistent sfas r sab prior company used historical stock price volatility accordance sfas purposes pro forma information selection blended historical implied volatility approach based companys assessment calculation expected volatility representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect time grant dividend yield assumption based companys history expectation dividend payouts expected life employee stock options represents weightedaverage period stock options expected remain outstanding derived output latticebinomial model expected life employee stock options impacted underlying assumptions calibration companys model latticebinomial model assumes employees exercise behavior function options remaining vested life extent option inthemoney latticebinomial model estimates probability exercise function two variables based entire history exercises cancellations past option grants made company prior company used optionpricing model indirectly estimate expected life stock options expected life expected volatility stock options based upon historical economic data trended future forfeitures employee stock options accounted incurred basis stockbased compensation expense recognized consolidated statement earnings twelve months ended december based awards ultimately expected vest reduced estimated forfeitures sfas r requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates forfeitures estimated based historical experience companys pro forma information required sfas periods prior company accounted forfeitures occurred restricted stock fair value nonvested shares companys common stock determined based average trading price companys common stock grant date summary restricted share activity follows weighted average grant date shares thousands number shares fair value nonvested shares january granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december december million million respectively total unrecognized compensation cost related nonvested restricted stock restricted stock units cost expected recognized weightedaverage period years balance december years balance december total fair value shares share units vested twelve months ended december million million million respectively note employee stock benefit plans continued longterm performance awards prior adoption sfas r compensation expense related longterm performance awards determined based market price companys stock time award applied expected number shares contingently issuable amortized threeyear performance cycle upon adoption sfas r fair value longterm performance award estimated date grant using monte carlo simulation model instead grant date market price used previously company changed valuation technique based clarification provided sfas r fact longterm performance awards contain market condition performance conditions affect factors vesting ie variable number shares awarded reflected grant date fair value award monte carlo simulation model utilizes multiple input variables determine probability satisfying market condition stipulated award grant calculates fair market value longterm performance awards valuation model used following assumptions weightedaverage expected expected dividend risk free grant year grant date volatility yield interest rate weightedaverage expected volatility based three year historical volatility levels companys common stock expected dividend yield based historical dividend payments risk free interest rate reflects yield year zero coupon us treasury bonds based performance shares contractual term fair value longterm performance awards amortized performance period award longterm performance shares thousands shares outstanding performance cycle weightedaverage grant date measurement date grant date fair value december december million million respectively total unrecognized compensation cost related performance share plan expected recognized weightedaverage period years years respectively accuracy fair value estimates companys determination fair value stockbased payment awards date grant using optionpricing model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors optionpricing models developed use estimating value traded options vesting hedging restrictions fully transferable companys employee stock options certain characteristics significantly different traded options changes subjective assumptions materially affect estimated value managements opinion existing valuation models may provide accurate measure fair value companys employee stock options although fair value employee stock options determined accordance sfas r sab using optionpricing model value may indicative fair value observed willing buyerwilling seller market transaction company adopted sfas r requires measurement recognition compensation expense stockbased payment awards made employees directors based estimated fair values sfas r supersedes companys previous accounting apb periods beginning january march sec issued sab relating sfas r company applied provisions sab adoption sfas r company adopted sfas r using modified prospective transition method requires application accounting standard january elected alternative method provided fsp r determining companys pool excess tax benefits companys consolidated financial statements year ended december reflect impact sfas r accordance modified prospective transition method note employee stock benefit plans continued companys consolidated financial statements prior periods restated reflect include impact sfas r stockbased compensation expense recognized sfas r year ended december million million net tax per share corresponding amount recorded additional paidin capital within stockholders equity additionally million related performance awards reclassified liabilities stockholders equity connection adoption sfas r note financial instruments company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used speculative purposes companys primary net foreign currency translation exposures euro japanese yen mexican peso chinese renminbi canadian dollar company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings company reclassified deferred losses million million million respectively accumulated oci earnings majority classified cost products sold december balance deferred net aftertax losses foreign exchange forward contracts included accumulated oci million net aftertax loss million estimated reclassified earnings within next months sfas requires company perform periodic assessments hedge effectiveness assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred accumulated oci included current period earnings years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges loss million gain million respectively furthermore company uses foreign exchange forward contracts offset exposure certain currency assets liabilities foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings occur amounts recognized earnings related foreign exchange forward contracts qualify hedge accounting treatment significant fair value forward contracts net liability million december million recorded noncurrent asset million recorded current liability fair value forward contracts net asset million december million recorded noncurrent asset million recorded current liability fair value foreign exchange contracts based yearend currency rates blackscholes model case option contracts company exposures net foreign currency denominated assets liabilities approximately billion billion december respectively primarily mexico japan uk china australia canada reduction net exposure primarily due issuance billion euro billion notes additional information see note shortterm borrowing longterm debt addition foreign exchange hedge contracts noted company utilizes forward contracts hedge foreign currency denominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currency denominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated euro forward contracts designated hedges marked market incomeexpense notional fair value amount purchased foreign exchange forward contracts million million asset respectively december million million liability respectively december notional fair value amount sold foreign exchange forward contracts million million liability respectively december million million asset respectively december note financial instruments continued company also uses non us dollar borrowings lesser extent forward contracts hedge foreign currency exposures companys net investment certain foreign affiliates non us dollar borrowings forward contracts designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component oci december million tax losses million tax gains respectively recorded foreign currency translation component oci company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixed floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixed floating interest rate swaps convert billion billion euro billion companys newly issued fixed rate debt paid variable rate debt company executed several fixed floating interest rate swaps convert million companys fixed rate debt paid variable rate debt total notional amount outstanding interest rate swaps billion billion euro billion december billion december accordance sfas accounting derivative instruments hedging activities company recognized net increase interest expense million net reduction interest expense million million respectively impact interest rate swaps swap contracts well underlying debt hedged recorded fair value resulted increase noncurrent assets million current liabilities million reduction longterm debt million december increase noncurrent assets million current liabilities million reduction longterm debt million december swap contracts generally held maturity intended create appropriate balance fixed floating rate debt company swap contracts qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swap contracts qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt following tables summarize new terminated interest rate swaps year notional amount dollarseuros millions transaction underlying debt interest rate contracts swaps associated eur notes due swaps associated eur notes due swaps associated notes due terminated swap contracts total notional pretax pretax pretax year amount deferred incomeexpense incomeexpense interest rate contracts termination underlying debt gainloss recognized recognized dollars millions interest rate swap lock associated notes due interest rate swap lock associated notes due swaps associated notes due swaps associated notes due swaps associated notes due swaps associated notes due underlying notes extinguished respectively carrying amount companys financial instruments includes cash cash equivalents marketable securities accounts receivable accounts payable approximates fair value december longterm debt difference fair value carrying value material note segment information company organized three reportable segmentspharmaceuticals nutritionals health care pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business childrens nutritional business health care segment consists convatec medical imaging consumer medicines businesses third quarter company completed sale consumer medicines business additional information sale consumer medicines see note acquisitions divestitures companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession three wholesalers accounted approximately respectively companys total net sales sales wholesalers accounted respectively companys total net sales three wholesalers accounted approximately respectively companys total net sales sales concentrated pharmaceuticals segment earnings minority net sales interest income taxes yearend assets dollars millions pharmaceuticals nutritionals health care health care group total segments corporateother total corporateother consists principally interest income interest expense certain administrative expenses allocations business segments certain corporate programs litigation expense debt retirement costs gain sale businesses product asset deferred income recognized collaboration agreement restructuring charges corporateother assets include cash cash equivalents marketable securities goodwill assets otn held available sale december sold certain assets capital expenditures depreciation dollars millions pharmaceuticals nutritionals health care health care group total segments corporateother total note segment information continued geographic areas net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total change yearend assets us primarily due decrease cash cash equivalents marketable securities resulting reinvestment foreign dividends received pursuant repatriation earnings us ajca note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million deferred reduce future lease rental costs lease periods ranging years note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular full time employees principal pension plan bristolmyers squibb retirement income plan us funding policy contribute amounts provide current service fund past service liability plan benefits based primarily participants years credited service compensation plan assets consist principally equity fixedincome securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us note pension postretirement benefit plans continued company adopted sfas fiscal year ended december resulting million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities impact adoption summarized follows sfas adjustments dollars millions pre sfas pretax tax net post sfas current assets deferred income taxes noncurrent assets deferred income taxes prepaid pension assets current liabilities accrued expenses us foreign income taxes payable noncurrent liabilities liabilities stockholders equity accumulated comprehensive loss cost companys deferred benefits postretirement benefit plans included following components pension benefits benefitsa dollars millions service costbenefits earned year interest cost projected benefit obligation expected return plan assets net amortization deferral net periodic benefit cost curtailments settlements total net periodic benefit cost company recognized impact medicare prescription drug improvement modernization act accordance fsp recorded million million million respectively reduction net periodic benefit costs estimated net actuarial loss prior service cost amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service cost note pension postretirement benefit plans continued changes benefit obligations plan assets funded status amounts recognized balance sheet years ended december companys defined benefit postretirement benefit plans pension benefits benefits dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial lossesgains plan amendments retiree drug subsidy received benefits paid exchange rate gainslosses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements retiree drug subsidy received benefits paid exchange rate lossesgains fair value plan assets end year funded status unamortized net obligation adoption unrecognized prior service cost unrecognized net actuarial loss net amount recognized amounts recognized balance sheet consist prepaid pension prepaid benefit cost assets accrued expenses pension postretirement liabilities accrued benefit cost accumulated comprehensive loss net amount recognized amounts recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service cost several plans underfunded accrued benefit obligations exceeded accrued benefit liabilities december additional minimum liabilities established increase accrued benefit liabilities values underfunded accrued benefit obligations additional minimum liabilities totaled million december prior adoption sfas us unfunded benefit equalization plan several international plans liabilities reversed upon adoption sfas additional minimum liabilities totaled million december offset intangible assets million charges accumulated oci included stockholders equity million accumulated benefit obligation defined benefit pension plans million million december respectively note pension postretirement benefit plans continued information pension plans accumulated benefit obligations excess plan assets december dollars millions projected benefit obligation accumulated benefit obligation fair value plan assets attributable primarily unfunded us benefit equalization plan several plans international markets unfunded us benefit equalization plan provides pension benefits employees compensation irs limits funded taxadvantaged manner additional information pertaining companys pension postretirement plans pension benefits benefits dollars millions decreaseincrease minimum liability including impact foreign currency fluctuations included comprehensive income weightedaverage assumptions used determine benefit obligations december pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december pension benefits benefits discount rate expected longterm return plan assets rate compensation increase december companys expected longterm rate return us pension plan assets target asset allocation public equity us international private equity fixed income approximated applying expected returns public equity private equity fixed income target allocation actual historical returns also relevant annualized returns periods ended december years years years us pension plan assets represented approximately total company pension plan assets december disclosed total company expected return assets us pension plans due impact international pension plans typically employ less aggressive asset allocation expected return disclosed benefits relevant assets invested manner us pension plan assets international plan assets assumed health care cost trend rates december health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate note pension postretirement benefit plans continued assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation companys asset allocation pension postretirement benefits december pension benefits benefits public equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company common stock represents less plan assets december assets postretirement benefits commingled us pension plan assets therefore investment strategy identical described us pension plans contributions although minimum contributions required company made cash contributions us pension plans million million million respectively company also plans make cash contribution us pension plans contributions made us pension plans company may make taxdeductible contributions h account retiree medical benefits equal portion pension normal cost contributions international pension plans million million million respectively contributions international plans expected million estimated future benefit payments following benefit payments mainly us pension plans reflect expected future service appropriate expected paid benefits medicare dollars millions pension benefits gross subsidy net years note pension postretirement benefit plans continued savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million termination indemnity plans company operates certain jurisdictions primarily europe require recording statutory termination obligations obligations assessed accordance emerging issues task force issue determination vested benefit obligation defined benefit pension plan total pension liability recorded obligations million december million december note legal proceedings contingencies various lawsuits claims proceedings investigations pending involving company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement pricing sales marketing practices environmental health safety matters consumer fraud product liability insurance coverage significant matters described assurance increase scope matters future lawsuits claims proceedings investigations material management continues believe previously disclosed next years aggregate impact beyond current reserves legal matters affecting company reasonably likely material companys results operations cash flows may material financial condition liquidity intellectual property plavix litigation plavix currently companys largest product ranked net sales net sales plavix approximately billion year ended december billion year ended december billion us net sales plavix billion billion billion plavix patents subject number challenges us less significant markets product possible reasonably estimate impact lawsuits company however loss market exclusivity plavix sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity company sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation united states patent infringement litigation companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted us district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp apotex suit filed march based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix plaintiffs infringement position based defendants filing abbreviated new drug applications anda fda seeking approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendants responded alleging patent invalid andor unenforceable march companies announced executed proposed settlement agreement march agreement apotex settle patent infringement lawsuit pending parties us district court southern district new york response concerns expressed federal trade commission state attorneys general parties modified march agreement modified agreement july companies announced modified agreement failed receive required antitrust clearance state attorneys general august apotex launched generic version clopidogrel bisulfate august companies filed motion preliminary injunction august trial court issued preliminary injunction ordered apotex halt sales generic clopidogrel bisulfate court order apotex recall product customers companies also required post bond amount million provide security apotex court conclude end patent litigation injunction wrongly imposed september companies posted million bond satisfy requirement company pledged issuer bond collateral million bond consisting shortterm high quality securities collateral reported marketable securities consolidated balance sheet december terms pledge agreement company entitled receive income generated marketable securities make certain investment decisions restricted using million pledged securities purpose time bond cancelled note legal proceedings contingencies continued september court denied apotexs motion stay preliminary injunction apotex filed appeal preliminary injunction us court appeals federal circuit september filed motion stay injunction pending appeal september federal circuit denied september december federal circuit affirmed trial courts issuance injunction apotex subsequently filed motion reconsideration andor rehearing denied january september apotex filed motion supplement answer counterclaims add claims breach contract antitrust counterclaims additional equitable defenses trial court permitted apotex add additional antitrust counterclaims stayed pending outcome trial court permit apotex add breach contract claim trial commenced january ended february court ordered posttrial briefing expected rule thereafter companys us territory partnership alliance sanofi also plaintiff three additional pending patent infringement lawsuits instituted us district court southern district new york dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt related patent trial date action dr reddys set patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation dr reddys teva filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired exception month stay applies teva expires february accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages companys us territory partnership alliance sanofi plaintiff another pending patent infringement lawsuit instituted us district court district new jersey entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v watson pharmaceuticals inc watson laboratories inc suit filed october based us patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix case discovery phase december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter possible time reasonably assess patent litigation apotex plavix patent litigation timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail patent litigation company would expect face renewed generic competition plavix apotex promptly thereafter noted loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity full impact apotexs launch generic clopidogrel bisulfate product company reasonably estimated time depend number factors including among others amount generic product sold apotex whether companies prevail underlying patent litigation even companies prevail pending patent case extent launch apotex permanently adversely impact pricing prescription demand plavix amount damages would sought andor recovered companies apotexs ability pay damages loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity launch generic clopidogrel bisulfate product apotex august significant adverse effect sales company estimates range billion billion particular launch adverse impact sales third fourth quarters company estimates range million million third quarter million fourth quarter first second third fourth quarters us net sales plavix million million million million respectively sales generic clopidogrel note legal proceedings contingencies continued bisulfate expected residual impact plavix sales company certainty estimate impact point time also previously disclosed antitrust division us department justice doj conducting criminal investigation regarding proposed settlement company cooperating fully investigation possible time reasonably assess outcome investigation impact company previously disclosed company entered deferred prosecution agreement dpa us attorneys office district new jersey usao june pursuant dpa usao filed criminal complaint company alleging conspiracy commit securities fraud deferred prosecution company dismiss complaint two years company satisfies requirements dpa terms dpa usao discretion may prosecute company matters subject criminal complaint filed usao company connection dpa usao make determination company committed criminal conduct dpa criminal conduct defined crime related companys business activities committed one executive officers directors securities fraud accounting fraud financial fraud business fraud materially affecting books records publicly filed reports company obstruction justice possible time reasonably assess impact pending criminal investigation doj may companys compliance dpa additional information respect dpa included item managements discussion analysissec consent order deferred prosecution agreement september board directors board announced companys current chief executive officer ceo general counsel would leaving respective positions effective immediately announcement took place board received considered reports companys outside counsel issues relating plavix patent litigation apotex preliminary recommendation monitor dpa monitor terminate employment individuals monitors recommendation followed investigation initiated usao conducted monitor usao corporate governance issues relating companys negotiations proposed settlement apotex company advised monitor usao investigation involve matters subject ongoing investigation antitrust division doj plavix settlement agreement time monitor made preliminary recommendation monitor usao also advised company found violation dpa unlawful conduct company employees investigation included review whether violation federal securities laws connection proposed settlement apotex terms sec consent monitor completed investigation submitted report investigation usao monitors report find violation sec consent federal securities laws connection proposed settlement monitor concluded company violated certain paragraphs dpa related governance matters violations cited monitor report relate among things communication failures including insufficient communications companys former ceo former general counsel board members senior management well failure comply certain internal company policies procedures monitor make findings respect whether company knowingly materially breached dpa make recommendations usao advised company believes matters cited monitors report fully remediated accordingly intend take action dpa respect monitors report antitrust litigation eighteen lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states since announcement march agreement apotex march lawsuits allege among things apotex settlement violates sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed consolidated class actions individual actions since july announcement modified agreement failed receive required antitrust clearance state attorneys general amended complaints include allegations regarding criminal investigation antitrust division doj november companies filed motion transfer eighteen lawsuits us district court southern district new york apotex matter similar plavixrelated patent infringement cases pending motion pending court court also considering whether stay litigation pending outcome patent infringement litigation possible time reasonably assess outcome lawsuits impact company note legal proceedings contingencies continued shareholder derivative lawsuits september certain members board current former officers company named derivative complaint steven w sampson v peter r dolan et al filed new york state supreme court also september certain members board current former officers company named derivative complaint americo marchese v peter r dolan et al filed us district court southern district new york complaints allege among things breaches fiduciary duty claims contribution indemnification relation negotiations apotex regarding plavix patent litigation among things complaints seek money damages injunctive remedies forms equitable relief possible time reasonably assess outcome lawsuits impact company plaintiff marchese voluntarily dismissed without prejudice named plaintiff sold bristolmyers squibb stock consumer fraud november companies served purported class action complaint subsequently amended include various sanofi entities captioned skilstaf inc v bristolmyers squibb company et al cv filed us district court district new jersey complaint alleges defendants misrepresented safety effectiveness plavix alone combination aspirin thirdparty payors misled causing pay plavix prescriptions insureds compared lower cost alternatives plaintiffs assert among things violations new jersey consumer fraud act plaintiffs seek compensatory punitive damages possible time reasonably assess outcome lawsuit impact company plavix litigationinternational sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex inc minister health response notice allegation noa apotex inc directed canadian patent patent covering clopidogrel bisulfate apotexs noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration patent scheduled august apotexs noa alleged patent invalid infringed march canadian federal court ottawa rejected apotexs challenge canadian plavix patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex inc order prohibition precludes approval apotexs ands patent expires unless federal courts decision reversed appeal apotex filed appeal canadian federal court appeal heard december december federal court appeal dismissed apotexs appeal upheld federal courts issuance order prohibition february apotex filed leave appeal decision supreme court canada sanofi sanofisynthelabo canada instituted prohibition action federal court canada cobalt minister health response noa cobalt directed patent canadian patent patent cobalts noa indicated filed ands clopidogrel bisulfate tablets sought notice compliance ands expiration patents cobalt alleged patent invalid patent invalid infringed case stayed pending outcome apotex appeal june korean intellectual property tribunal invalidated claims sanofis korean patent including claims directed clopidogrel pharmaceutically acceptable salts clopidogrel bisulfate sanofi appealed sanofi also commenced infringement actions generic pharmaceutical companies several launched generic clopidogrel bisulfate product korea possible time reasonably assess outcome lawsuits impact company intellectual property litigation tequin injectable form company kyorin pharmaceuticals co ltd kyorin commenced patent infringement actions march apotex sicor pharmaceuticals inc sicor inc sicor pharmaceuticals sales inc teva teva pharmaceutical industries ltd us district court southern district new york relating injectable forms antibiotic gatifloxacin kyorin holds composition matter patent company sells tequin action related apotexs sicors filing andas generic versions injectable gatifloxacin piv certifications composition matter patent expires december granted patent term extension december invalid note legal proceedings contingencies continued filing lawsuits placed stays approvals apotexs sicors generic products julyaugust unless court decision adverse company kyorin date sicor case consolidated proceeding stipulation approved us district court southern district new york august parties agreed apotex case stayed pending resolution teva sicor cases parties bound outcome litigation august court approved stipulation dismissal jointly submitted parties stipulation plaintiffs claims teva sicor dismissed without prejudice teva sicors counterclaims concerning claim us patent dismissed prejudice teva sicors remaining counterclaims dismissed without prejudice apotex case remains pending possible time reasonably assess outcome apotex lawsuit however result companys decision discontinue manufacture distribution sale tequin expected outcome apotex lawsuit material impact company erbitux yeda litigation october yeda research development company ltd yeda filed suit imclone aventis pharmaceuticals inc federal court claiming three individuals associated yeda named inventors us patent patent covers therapeutic combination egfrspecific monoclonal antibody antineoplastic agents chemotherapeutic agents use treatment cancer september following trial court issued opinion order held three researchers yeda sole inventors subject matter patent giving complete ownership patent yeda imclone appealed imclone also filed declaratory judgment action us district court southern district new york complaint alleges yeda researchers remain sole inventors patent patent invalid company party action unable predict outcome proceedings result courts decision yeda may seek damages infringement respect past erbitux sales royalties future erbitux sales yeda also right license patent others yedas license patent third parties could result product competition erbitux might otherwise occur early assess whether extent competitive impact occur quantify impact however yeda announced licensed patent amgen inc amgen amgen received fda approval market egfr product competes erbitux commercial agreement imclone company pays royalty imclone sales erbitux impacted courts decision agreement imclone company also includes provisions pursuant certain financial consequences company resulting decision would responsibility imclone addition company owns million shares imclone common stock company accounts equity method accounting carrying value per share december closing market price imclone common stock december assurance company able realize fully benefits contractual protections commercial agreement imclone financial consequences company result courts decision repligen litigation repligen corporation repligen massachusetts institute technology mit filed lawsuit us district court district massachusetts imclone claiming imclones manufacture sale erbitux infringes patent generally covers process protein production mammalian cells july court granted summary judgment favor repligen mit rejecting one imclones defenses relating patent exhaustion trial proceed issue patent infringement company party action possible time reasonably assess outcome lawsuit impact company abbott laboratories litigation february abbott laboratories filed suit imclone us district court district massachusetts case cvrgs complaint alleges imclones manufacture sale erbitux infringe us patent seeks damages alleged infringement company party action possible time reasonably assess outcome lawsuit impact company note legal proceedings contingencies continued orencia january repligen regents university michigan filed complaint company us district court eastern district texas marshall division orencia launched february complaint alleges companys thenanticipated sales orencia infringe us patent repligen since amended complaint include ongoing future sales orencia august zymogenetics inc filed complaint company us district court district delaware complaint alleges companys manufacture sales orencia infringe us patents nos trial scheduled commence april possible time reasonably assess outcome lawsuits impact company general commercial litigation clayworth litigation company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants january notice appeal respect judgment filed remains pending possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal weisz stephenson litigations company named defendant along many pharmaceutical companies action originally brought utility consumers action network consumer advocacy organization focuses privacy issues lawsuit entitled utility consumers action network behalf privacy rights clearinghouse et al v bristolmyers squibb co et al filed california state superior court san diego county july another substantially similar lawsuit rowan klein representative action behalf similarly situated persons consuming public v walgreens et al filed february court retail pharmacies company pharmaceutical companies two complaints seek equitable relief monetary damages attorneys fees based upon allegedly unfair business practices untrue misleading advertising various california statutes including california confidentiality medical information act based allegations retail stores selling consumers confidential medical information companies using consumers medical information direct marketing designed increase sale targeted drugs january company pharmaceutical defendants sought dismiss utility consumers action network case grounds californias proposition requires plaintiff must injured party order standing bring suit utility consumers action network personally injured october court entered stay utility consumers action network klein cases pending california supreme courts decision review several intermediate appellate decisions discuss applicability proposition pending cases july california supreme court entered decisions two appeals held proposition applies pending cases complaints may amended add plaintiff standing court granted plaintiffs lawsuits leave amend amended complaints containing substantially similar allegations earlier complaints filed behalf new plaintiffs purports allege personal injury lawsuit filed utility consumers action network behalf privacy rights clearinghouse entitled kimberly weisz et al v bristolmyers squibb co et al lawsuit filed rowan klein entitled roseanna stephenson behalf others similarly situated v bristolmyers squibb co et al cases preliminary stage possible time reasonably assess outcome lawsuits impact company rxusa wholesale litigation july complaint filed drug wholesaler rxusa wholesale inc us district court eastern district new york company fifteen drug manufacturers five drug wholesalers two officers defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint alleges violations federal new york antitrust laws well various laws plaintiff claims defendants allegedly engaged anticompetitive acts resulted exclusion plaintiff relevant market seeks million damages trebling relief company together manufacturer defendants filed motion dismiss case november motion pending court possible time reasonably estimate outcome lawsuit impact company note legal proceedings contingencies continued securities litigation investigations sec investigation wholesaler inventory accounting matters august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters company agreed without admitting denying liability violate certain provisions securities laws company also established million fund distributed certain company shareholders plan distribution established sec settlement resolve ongoing investigation sec activities certain former members companys management connection wholesaler inventory issues accounting matters company continuing cooperate investigation dk health care resources litigation november class action complaint filed us district court eastern district missouri company dk health care resources inc dk several current former dk directors officers complaint alleges company participated fraudulently inflating value dk stock allegedly engaging improper channelstuffing agreement dk june court granted companys motion dismiss complaint plaintiffs time appeal decision appeal lodged begin run litigation dk officers directors finally resolved possible time reasonably assess outcome lawsuit impact company starkman litigation september certain companys current former officers named purported class action starkman v bristolmyers squibb et al filed new york state supreme court alleging factual claims similar resolved federal class action us southern district new york related alleged violations federal securities laws regulations connection sales incentives wholesaler inventory levels asserting common law fraud breach fiduciary duty claims behalf certain companys stockholders october company removed case us district court southern district new york november plaintiff moved remand matter state court matter stayed supreme court march entered decision another case held holder class actions asserting securities fraud claims state law like starkman preempted federal law following oral argument court denied plaintiffs motion remand september november company plaintiff submitted stipulation dismissal without prejudice approved court pricing sales promotional practices litigation investigations company together number defendants defendant number private civil matters relating pricing practices addition company together number pharmaceutical manufacturers received subpoenas document requests various government agencies seeking records relating pricing sales marketing practices best price reporting investigations company us doj office us attorney district massachusetts reached agreement principle subject approval doj settle several investigations involving companys drug pricing sales marketing activities agreement principle provides civil resolution expected payment million agreement principle involves matters actively investigated discussed us doj us attorney district massachusetts number years including matters relating pricing certain products sold several years ago subsidiary reimbursed governmental health care programs financial relationships subsidiary noted certain customers entities certain consulting programs promotion abilify unapproved indications calculation certain medicaid rebates serzone nefazodone hydrochloride pricing certain companys products reimbursed governmental health care programs agreement contemplates states choose participate settlement would criminal charges company respect matters agreement principle also provides company enter corporate integrity agreement office inspector general us department health human services settlement contingent upon parties agreement terms final settlement agreement including terms corporate integrity agreement approval doj assurance settlement finalized states choose participate agreement principle covers matters outlined us doj us attorney district massachusetts states indicated may pursue matters outside scope expected settlement event matters could result assertion civil andor criminal claims note legal proceedings contingencies continued result agreement principle company increased reserves related investigations million bringing aggregate reserves matters million increased reserve recorded fourth quarter accordance gaap aggregate reserves reflect companys estimate expected probable loss respect matters assuming settlement finalized settlement finalized andor certain states choose participate amount reserved may reflect eventual losses furthermore open investigations issues conducted various federal state agencies well certain congressional committees company producing documents actively cooperating investigations could result assertion civil andor criminal claims possible time reasonably assess outcome investigations described additional matters us doj office us attorney district massachusetts may pursue potential impact company previously disclosed company undertook analysis methods processes calculating prices reporting governmental rebate pricing programs related us pharmaceuticals business analysis completed early based analysis company identified need revisions methodology processes used calculating reported pricing related rebate amounts implemented revised methodologies processes beginning reporting federal government agency primary responsibility rebate price reporting obligations centers medicare medicaid services cms first quarter addition using revised methodologies processes company also recalculated best price average manufacturers price required reported companys federal medicaid rebate agreement certain state agreements corresponding revised rebate liability amounts programs threeyear period upon completion analysis early company determined estimated rebate liability programs threeyear period actually less rebates paid company period accordingly fourth quarter company recorded reduction rebate liability amount estimated overpayment company submitted proposed revisions updated estimate cms review cms may take position revisions companys methodologies calculations required company believes however based current information recalculation period likely result material rebate liability however due uncertainty surrounding recoverability companys estimated overpayment arising review process described company recorded reserve amount equal estimated overpayment litigation respect private civil matters company together number pharmaceutical manufacturers defendant private class actions well suits brought attorneys general several states numerous new york counties city new york pending federal state courts actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps federal cases several state attorneys general actions suits new york counties city new york consolidated pretrial purposes us district court district massachusetts awp mdl court awp mdl certified three classes persons entities paid reimbursed seven companys physicianadministered drugs nonjury trial classes insurance companies health welfare funds massachusetts commenced november currently ongoing trial date claims class medicare part b beneficiaries nationwide yet set company company also one many defendants putative class action filed california allegedly behalf entities entitled discounted pricing pursuant section b public health services act requires prescription drug manufacturers offer discounts qualified medical providersgenerally disproportionately service poor people july order entered dismissing california case prejudice plaintiff appealed dismissal california action possible time reasonably assess outcome litigation matters described potential impact company note legal proceedings contingencies continued product liability litigation company party various product liability lawsuits involve among things hormone replacement therapy hrt products companys serzone prescription drug addition lawsuits company also faces unfiled claims involving products companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result external factors availability insurance continues restrictive cost increased significantly company evaluated risks determined cost obtaining insurance product liability losses outweighs benefits coverage protection losses became selfinsured product liability losses effective july company continue evaluate risks benefits determine insurance needs future serzone serzone antidepressant launched company may canada march us december company added black box warning serzone label warning potential risk severe hepatic events including possible liver failure need transplantation risk death within several months black box warning added package insert serzone number lawsuits including several class actions filed company plaintiffs masstort litigation allege among things company knew known hepatic risks posed serzone failed adequately warn physicians users risks addition cases filed us class actions filed canada without admitting wrongdoing liability october company entered settlement agreement respect claims us territories regarding serzone november district court conditionally certified temporary settlement class preliminarily approved settlement september court issued opinion granting final approval settlement august company agreed proceed settlement exercise backend optout right without admitting wrongdoing liability september company reached agreement principle respect claims canada regarding serzone pursuant terms proposed settlement claims dismissed litigation terminated defendants receive releases company committed paying least million funds class members may company announced following evaluation commercial potential product generic entry marketplace rapidly declining brand sales decided discontinue manufacture sale product us effective june hormone replacement therapy plaintiffs masstort litigation allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers december company defendant lawsuits filed behalf approximately plaintiffs federal state courts throughout us company expects dismissed many cases products never used initial trials hrt litigation involving primary defendant wyeth commenced federal court july pennsylvania november initial trials involve breast cancer claims company defendant cases companys hormone therapy products sold companies january august company maintains estrace anda continues manufacture products supply agreement possible time reasonably assess outcome lawsuits company party impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable note legal proceedings contingencies continued reasonably estimable december company estimated share total future costs sites approximately million recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected company paid less million excluding legal fees last five years investigation remediation matters including liabilities cercla onsite remedial obligations puerto rico air emissions civil litigation previously reported company one several defendants including many major us pharmaceutical companies purported class action suit filed superior court puerto rico february relating air emissions government owned operated wastewater treatment facility april company executed individual settlement plaintiffs amount subject certain conditions including court would decide certify case class action court deferred decision class certification pending review expert reports facilitys operations court considered expert reports hearing october thereafter facilitated settlement discussions parties claims discussions ongoing consequently class certification hearing scheduled december postponed may passaic river nj remediation natural resource damages claims september new jersey department environmental protection njdep issued administrative enforcement directive notice new jersey spill compensation control act requiring company approximately companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river directive alleges company liable historically sent bulk waste former inland chemical company facility newark nj owned mckesson corp reprocessing releases hazardous substances facility migrated newark bay continue adverse impact lower passaic river watershed subsequently epa also issued notice letter cercla numerous partiesbut including companyseeking cooperation study conditions substantially portion passaic river subject njdeps directive group parties entered consent agreement epa finance portion study epa yet determined estimated cost study consent agreement private party group committed pay roughly half million estimate subject revision future negotiation study may also lead cleanup actions directed epa army corps engineers group actively negotiating epa successful negotiations result amended consent agreement anticipation agreement company reached agreement principle mckesson corp share costs anticipated agreed portion epa study tasks company also working cooperatively group parties received njdep directive andor epa notice explore potential resolutions directive address risk collateral claims although company believe caused contributed contamination lower passaic river watershed company informed njdep willing discuss njdeps allegations company also private party group continues discuss federal agencies designated trustees natural resources affected contamination passaic river watershed possibility funding cooperative nrd study presumably would dovetail ongoing epa study ideally would joined njdep coordinate actions njdep may seek directive late njdep issued supplemental directive filed suit one site parties seeking compel implementation interim measures unclear whether njdep take additional actions site parties andor whether litigation arise response new claims extent liability company may face either njdep epa respect future claims federal trustees mckesson corp responsible parties yet determined north brunswick nj board education remediation claims october company contacted north brunswick nj board education boe regarding discovery industrial waste materials allegedly including materials er squibb sons expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work work plan approved njdep evaluating need conduct response actions remediate contain potentially impacted ground water due financial constraints late boe asked company contribute funds interim basis assure uninterrupted performance necessary site work company actively monitoring cleanup project including costs discussing boe township terms cooperative funding agreement allocation process municipal records indicate township operated landfill site company investigating historic use site including activities company may responsible date neither boe township asserted claims company note legal proceedings contingencies continued njdep air permitnew brunswick nj facility december company njdep entered administrative consent order aco concerning alleged violations new jersey air pollution control act implementing regulations companys new brunswick facility pursuant aco company agreed submit permit application creating facilitywide emissions cap pay small administrative fine obligations satisfied early subsequently february aco amended provide company would install new cogeneration turbine new brunswick facility december would obtain applicable air permits december company obtained required operating permit september purchased new cogeneration turbine cost approximately million installed turbine december compliance aco company fulfilled terms conditions aco february received notice termination aco njdep concludes matter mead johnson facilitynsps issue october company commenced voluntary environmental audit mead johnson facility mt vernon indiana determine compliance epas new source performance standards nsps applicable operation incinerator december company disclosed possible violations nsps requirement currently process modifying operations fall within exemption requirements date neither epa indiana department environmental management pursued penalties potential violations however company could potentially subject civil penalties past noncompliance nsps december epa responded selfdisclosure stated intend pursue enforcement action issues time possible however indiana department environmental management could future pursue civil penalties past noncompliance nsps ods regulatory compliance epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozonedepleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements company performed voluntary corporatewide audit facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities addition matters covered companys audit report letter epa epa previously sent companys wholly owned subsidiary mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june result identified potential violations evansville facility company currently discussions epa resolve potential violations discovered audit identified result epa request information evansville facility epa determines evansville facility facilities violation applicable ods requirements company could subject penalties andor required convert replace refrigeration equipment use nonods approved substitutes mact compliancepuerto rico facilities barceloneta humacao march company commenced voluntary environmental audit barceloneta humacao puerto rico facilities determine compliance epas regulations regarding maximum achievable control technology requirements emissions hazardous air pollutants pharmaceuticals production pharmaceutical mact company submitted epa audit report humacao facility june barceloneta facility july disclosed potential violations pharmaceutical mact requirements facilities company epa currently discussions regarding resolution matter note legal proceedings contingencies continued proceedings sec germany investigation october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry formal secs inquiry encompasses matters currently investigation german prosecutor munich germany company understands inquiry investigation concern potential violations foreign corrupt practices act german law respectively company cooperating sec german authorities company established accrual represents minimum expected probable losses respect investigation german prosecutor possible time reasonably assess outcome investigations impact company bari italy investigation previously disclosed january company notified prosecutor bari region italy bari prosecutor company investigation result activities two employees region investigation involves company well number doctors pharmacists pharmaceutical companies sales representatives main allegation parties engaged plan defraud national health service bari prosecutor also alleges companies lacked appropriate compliance controls andor processes procedures control activities sales representatives bari prosecutor requested suspend operations pharmaceutical companies investigation appoint judicial administrator preliminary measures pending february company bari prosecutor reached agreement principle settle matter agreement yet finalized company would pay administrative fine amount material company note subsequent events january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca plc astrazeneca develop commercialize two investigational compounds studied treatment type diabetes company received upfront payments million astrazeneca addition company receive milestone payments astrazeneca upon successful achievement various regulatory sales related stages companies agreed upon initial development plans two compounds majority development costs paid astrazeneca subsequent development costs generally shared equally note selected quarterly financial data unaudited first second third fourth dollars millions except per share data quarter quarter quarter quarter year net sales gross margin earningsloss continuing operations net earningsloss earnings per common share basic earningsloss continuing operations discontinued operations net net earningsloss diluted earningsloss continuing operations discontinued operations net net earningsloss dividends declared per common share cash cash equivalents marketable securities net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities includes net litigation charges million million first fourth quarters respectively net litigation income million million second third quarters respectively first third fourth quarters include litigation insurance recoveries million million million respectively first second third fourth quarters include restructuring million million million million respectively first third fourth quarters include upfront milestone payments million million million respectively first quarter includes million gain sale product asset first second third fourth quarters include million million million million respectively accelerated depreciation asset impairment contract termination fourth quarter includes debt retirement costs million fourth quarter includes million claim damages earnings per share quarters may add amounts year period computed discrete basis includes litigation charges million million million first second fourth quarters respectively second third quarters include litigation insurance recoveries million million respectively first second third fourth quarters include restructuring items million million million million respectively first fourth quarters include upfront payments licensing agreements million million respectively first second quarters include million million respectively gain sale equity investments first second third quarters include million million million respectively loss sale fixed assets second quarter includes debt retirement costs million fourth quarter includes million deferred income net costs resulting termination collaborative agreement merck muraglitazar third quarter includes gain sale consumer medicines business million note selected quarterly financial data unaudited continued common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year three months ended december result net loss basic diluted loss per share equal million weightedaverage shares issuable well million interest expense net tax conversion convertible debt included diluted earnings per share calculation dilutive report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheet bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows year ended audit also included financial statement schedule listed index item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows year ended conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements company adopted statement financial accounting standards sfas r sharebased payment effective january sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december also audited accordance standards public company accounting oversight board united states effectiveness companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion managements assessment effectiveness companys internal control financial reporting unqualified opinion effectiveness companys internal control financial reporting deloitte touche llp deloitte touche llp parsippany new jersey february report independent registered public accounting firm board directors stockholders bristolmyers squibb company opinion consolidated balance sheet december related consolidated statements earnings comprehensive income retained earnings cash flows two years period ended december present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows two years period ended december conformity accounting principles generally accepted united states america addition opinion financial statement schedule two years period ended december presents fairly material respects information set forth therein read conjunction related consolidated financial statements financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp pricewaterhousecoopers llp philadelphia pa march item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule e based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report form k issued report managements assessment effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information none report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited managements assessment included managements report internal control financial reporting appearing item bristolmyers squibb company subsidiaries company maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment company maintained effective internal control financial reporting december fairly stated material respects based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule included explanatory paragraph regarding companys adoption statement financial accounting standards sfas r sharebased payment effective january sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r effective december deloitte touche llp deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item